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Abstract 
Cara Bernadette Eldridge 
The effect of replication impediments on differentiation 
In this thesis I set out to answer the question ‘is differentiation robust to replication 
impediments?’. Prior work in the group has focussed on the epigenetic impact of replication 
impediments in the terminally differentiated DT40 chicken cell line. I wanted to find out 
whether these impediments could impact the fundamental biological process of embryonic 
development. In this work the BOBSC human induced pluripotent stem cell line was 
differentiated to definitive endoderm while replication was perturbed using DNA damaging 
agents, low dose hydroxyurea and G-quadruplex secondary structure stabilisation.  
DNA damage was induced both in the undifferentiated state and during differentiation. When 
damage was induced during differentiation, greater levels of cell death were seen and there was 
a larger increase in cells in G2/M phase of the cell cycle compared with treatment in the 
undifferentiated state. The efficiency of differentiation was observed to negatively correlate 
with the dose of DNA damaging agent. 
During unperturbed differentiation, the levels of DNA damage response proteins, including 
p53, were found to decrease. However, when DNA damage was induced during differentiation 
the level of p53 increased. In order to understand whether the upregulation of p53 was 
preventing differentiation, TP53-/- cells were differentiated in the presence of DNA damaging 
agents. These cells were found to differentiate as efficiently as wildtype untreated cells. This 
indicates that p53 prevents differentiation in the presence of DNA damage, termed here a 
‘differentiation checkpoint’. 
The level of γH2A.X was found to be markedly increased 50 hours into unperturbed 
differentiation. This correlates with the point at which the cells transition from being epithelial 
to mesenchymal. The role of this rise is not known but may correspond to massive 
transcriptional changes that occur during this transition. 
G-quadruplex-binding ligands were also shown to alter the course of differentiation, either by 
a p53-dependent mechanism or by a separate, possibly G-quadruplex specific, mechanism. This 
also occurred in REV1-/- cells, a specialised polymerase known to play a role in G-quadruplex-
processing.  
This work has led to the conclusion that replication impediments are able to alter the course of 
definitive endoderm differentiation in human induced pluripotent stem cells. 
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Chapter 1. Introduction 
The aim of this project was to understand whether replication impediments could alter 
differentiation. This was particularly novel as all work performed in the group previously had 
utilised a terminally differentiated chicken cell line. Throughout this thesis embryonic stem 
cells and induced pluripotent stem cells were differentiated in the presence of replication 
impediments.  
1.1 Embryonic stem cells and induced pluripotent stem cells 
Both human and mouse embryonic stem cells have been studied in great detail due to their value 
in medicine, their ability to generate genetic knockout mouse cell lines, and for insight into 
development. Induced pluripotent stem cells have been and will be incredibly important in 
regenerative medicine. For this reason, they were considered an ideal system to study in this 
thesis. 
 
1.1.1 Mouse embryonic stem cells 
The culture and differentiation of mouse embryonic stem cells (mESCs) has greatly impacted 
molecular biology and this made the system a valuable tool for use in this project. During 
development the zygote becomes the morula and then the blastocyst, prior to implantation and 
lineage specification. mESCs are derived from the inner cell mass (ICM) of an E3.75-4.75  
mouse blastocyst (Boroviak et al., 2014) in the preimplantation epiblast (Evans and Kaufman, 
1981; Martin, 1981). The first mESCs cultured in vitro were shown to be capable of 
differentiating in vitro as well as forming tumours in an in vivo context (ibid). These cells are 
able to replicate indefinitely without losing cell fate, as well as differentiate into the three 
somatic lineages and germ cells (ibid). They are therefore able to form chimaeras contributing 
to all lineages after in vitro cell culture once returned to the epiblast (ibid). These cells have 
been instrumental in the production of genetically engineered mice, more recently using the 
CRISPR/Cas9 technology (Jinek et al., 2012), and have allowed us to model many diseases 
including cancer (reviewed by Zhang et al., 2011a). 
 
1.1.1.1 Generation of mESCs in culture 
The first embryonic stem cells with a normal karyotype were generated in 1981 using the mouse 
background 129 SvE (Evans and Kaufman, 1981). However, the generation from other mice 
was not as straightforward, possibly due to differences in the genetic background (Gardner and 
Brook, 1997). Furthermore, aside from in human cells, ES cells were not generated from other 
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animals until 2008 when rat stem cells were generated in culture upon an optimisation of culture 
conditions, discussed later (Buehr et al., 2008; Li et al., 2008). This also allowed isolation in 
two other mouse strains C57/BL6 (Kiyonari et al., 2010) and NOD (Nichols et al., 2009). 
Interestingly, the majority of mES cell lines created are of male XY genotype; this is postulated 
to be due to the process of X chromosome inactivation and those cells with XX genotype can 
result in deletions of an X chromosome (Rastan and Robertson, 1985).  
 
As these cells were not common to all organisms, it was a concern that they were an in vitro 
artefact that had no biological relevance. There are two reasons why these cells may be easier 
to generate in rodents. Firstly, rodents form an egg cylinder (Copp, 1979): after the blastocyst 
is formed, the epiblast cells become organised into cup-shaped epithelium by apoptosis of the 
internal epiblast cells and this may facilitate isolation of these cells (Coucouvanis and Martin, 
1999). The other concern that is specific to these cells is that rodents are able to enter a state of 
facultative diapause during differentiation: this state is very specific to their development and 
is not thought to be shared with primates (reviewed by Paria et al., 2002). This allows 
embryonic development to enter a state of dormancy prior to implantation to cope with external 
conditions, for example when a mother is still weaning pups from a previous litter. It can also 
be induced in an experimental context by lowering levels of oestrogen in the mouse, again 
enhancing the likelihood of capturing this cell state (Paria et al., 1998). 
  
1.1.1.2 Signalling pathways maintaining the pluripotent state 
The initial mESCs were cultured with mouse embryonic fibroblasts (MEFs), later discovered 
to produce leukaemia inhibitory factor (LIF) (Smith et al., 1988; Williams et al., 1988). LIF 
acts through STAT3, which is a transcription factor that inhibits differentiation pathways and 
promotes cell viability (Boeuf et al., 1997; Smith, 2001). LIF binds to the glycoprotein 130 
(gp130) cell surface receptor, activating the JAK/STAT3 pathway. This results in 
phosphorylation of STAT3, causing translocation from the cytoplasm to the nucleus where it 
binds target DNA. In conventional mESC cultures grown in serum, BMP4 (bone morphogenic 
protein) binds to BMPR1 and BMPR2 membrane proteins, causing activation of the 
ERK/MAPK and SMAD signalling pathways and results in SMAD proteins, translocating into 
the nucleus and activating Id (inducer of differentiation) genes (Figure 1) (Ying et al., 2003). 
The combination of LIF and BMP cause upregulation of pluripotency genes and this 
combination of factors allows serum-free culture of mESCs (Ying et al., 2003). However, 
cultures are frequently maintained in serum and LIF and these tend to be heterogeneous in their 
gene expression of a number of pluripotency genes including Zfp42, Dppa3, Nanog, Esrrb and 
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Klf4: this was not therefore an optimum culturing procedure (van den Berg et al., 2008; 
Chambers et al., 2007; Hayashi et al., 2008; Niwa et al., 2009; Toyooka et al., 2008). 
 
FGF4 stimulation of the ERK/MAPK signalling pathway primes mESCs for lineage 
specification, and therefore differentiation (Kunath et al., 2007; Stavridis et al., 2007): the 
combination of LIF and BMP restrict but do not block this pathway. Inhibition of glycogen 
synthase kinase 3 (GSK3) stimulates WNT signalling, causing -CATENIN to relocate to the 
nucleus, removing inhibition of specific transcription factors and activation of the pluripotency 
network (Figure 1) (Wray and Hartmann, 2012).  Inhibition of the MAPK pathway along with 
inhibition of GSK3 can be done using two small molecule inhibitors, known as 2i: MEK by 
PD0325901 and GSK3 by CHIR99021 (Silva and Smith, 2008). This combination is sufficient 
to keep cells in the naïve pluripotent state with full pluripotency, and this revolutionised culture 
of these cells (Silva and Smith, 2008). While mESCs can be maintained in serum conditions, 
these populations are often heterogeneous in morphology and gene expression (Hayashi et al., 
2008). However, using the 2i system, growing cells on gelatin coated plates with LIF, the 
dependence on serum and feeder cells are removed as well as the heterogeneity (Ying et al., 
2008).  
 
 
Figure 1. mESCs grown on 2i are more homogenous in nature (left diagram) in comparison to those grown in 
serum (right). PD0325901 works by inhibiting MEK and stopping MAPK signalling. CHIR00921 inhibits GSK3 
and causes β-catenin to build up where it activates its targets in the nucleus. Diagram reproduced from Marks and 
Stunnenberg, 2014. 
 
1.1.1.3 Gene expression profiles of mESCs 
Work from the group of Austin Smith has shown that over a quarter of expressed genes show 
at least two-fold differences in expression between 2i and serum culture conditions (Marks et 
al., 2012). However, the expression profile of these cells can be altered simply by switching the 
culture conditions, so these changes are reversible. Importantly, lineage specification genes 
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remain downregulated in cells cultured in 2i conditions. Most genes considered to be critical 
for pluripotency are expressed similarly between 2i and serum cultured mES cells, including 
Pou5f1, Sox2, Nanog, Zfp42, Klf2 and Klf4 (Marks et al., 2012). The OCT4, SOX2, NANOG 
trio share binding sites in the genome and are key to controlling expression of pluripotency 
genes, including themselves. Highly expressed pluripotency transcripts in naïve mES cells also 
include Dppa3, Tbx3, Gbx2 and Nodal (Guo et al., 2009). 
 
Heterogeneity in stem cell populations can be monitored in much greater detail than the initial 
experiments using single-cell RNA sequencing. This allows separation on the individual cell 
level of transcriptomes, and has been used in human and mouse ESCs as well as induced 
pluripotent stem cells (Kolodziejczyk et al., 2015; Nguyen et al., 2018), for example to show 
differences in naïve and primed human ES cells (Messmer et al., 2019). 
 
1.1.2 Epigenetic state of mESCs 
The chromatin in the nucleus holds epigenetic information as well as the genetic code. The 
epigenetic information is encoded in histone modifications, DNA methylation and non-coding 
RNA. Epigenetic details are stored in the histones around which the DNA is wrapped, the 
histone modifications and particular histone variants can broadly lead to euchromatic and 
heterochromatic regions in the genome. Methylation of the DNA itself, mostly at CpG sites, 
also causes a change in chromatin structure and alters gene expression. Both of these codes 
have been shown to play a role in maintenance of the ground state, and specification to 
differentiate (Sim et al., 2017; Zhang et al., 2012; Zheng et al., 2016). 
 
1.1.2.1 Histone modifications in mESCs 
Histones are composed of an H32H42 tetramer and two H2AH2B dimers in which the DNA is 
wrapped around to form a nucleosome (Arents et al., 1991). These histones can be modified, 
often on the N-terminal histone tail, to alter the packing of DNA. Modifications include 
methylation, phosphorylation, sumoylation, ubiquitylation and acetylation. Historically, 
histone post-translational modifications (PTMs) were considered to be active and associated 
with euchromatin, for example acetylation, or repressive and linked to heterochromatin 
formation, such as methylation. This is now known not to be the case and it is clear that there 
is also cross-talk between marks and dependency upon the location in the genome as to the 
outcome of the mark (reviewed by Bannister and Kouzarides, 2011).  
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Histone modifications were initially thought to be key to transcriptional activation in mES cells. 
Bivalent promoters carrying both the transcriptional activation mark histone 3 lysine 4 
trimethylation (H3K4me3) and the repressive mark histone 3 lysine 27 trimethylation 
(H3K27me3) have attracted much attention due to the idea that these promoters are poised for 
up or downregulation (Azuara et al., 2006; Bernstein et al., 2006). These bivalent regions have 
been shown to be high in mES cells cultured in serum but much lower in those cultured in 2i 
(Marks et al., 2012). The H3K27me3 mark is laid down by polycomb repressive complex 2 
(PRC2) and it is this mark that is reduced at promoters of cells grown in 2i compared to those 
in serum, although the global level is similar (Marks et al., 2012). The H3K4me3 peaks are 
similar in their frequency and intensity across the genome in serum and 2i cultured cells. Since 
cells cultured in both ways have a high potential to differentiate, this suggests that bivalent 
promoters do not exist to poise the cell for differentiation as initially proposed.  
 
RNA polymerase II (Pol II) proximal pausing in collaboration with histone marks has also been 
identified as a mechanism to control gene expression. Levels of Pol II at the transcription start 
site (TSS) were higher in 2i cells compared to serum cells (Marks et al., 2012). This mechanism 
may act to control gene expression quickly, for example in lineage specification, instead of 
using bivalent chromatin. 
 
1.1.2.2 DNA methylation in mESCs 
DNA methylation is a mark that occurs by covalent transfer of a methyl group to the C5 of a 
cytosine at CpG sites: this transfer is catalysed by DNA methyltransferases (DNMTs). This 
modification can change the expression of a region of DNA: methylation over the promoter 
region is generally thought to repress expression of that gene. This modification is known to be 
required for normal mammalian development, including the process of X-chromosome 
inactivation and repression of transposable elements (Jones and Takai, 2001). 
 
DNMT3A and DNMT3B primarily set up these modifications and DNMT1 is responsible for 
maintaining them on the DNA (Okano et al., 1999; Robert et al., 2003). The removal of these 
marks is catalysed by the TET enzymes, specifically TET1 and TET2 in mES cells. They 
catalyse the oxidation of 5-methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC) and 
finally to unmethylated cytosine (Ficz et al., 2011). This methylation machinery is required for 
lineage specification and mice lacking these DNMTs do not develop normally, highlighting 
their importance (Siegfried and Cedar, 1997; Smith and Meissner, 2013). p53 is thought to play 
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a role in the control of the DNA methylation (Tovy et al., 2017) and this will be discussed 
further in the DNA damage response section 1.3. 
 
There is also known to be a relationship between the DNA methylation and the histone 
modifications. This has been shown to occur by proteins known to bind to methylated DNA, 
such as KAISO, MECP2 and MBD1, which then recruit complexes containing histone 
deacetylases (HDACs) and histone methyltransferases (reviewed by Bird, 2002). Thereby the 
histone modifications are altered due to the DNA methylation. 
 
The E3.5 ICM of developing mice has a very low level of DNA methylation, around 20% of 
CpG islands (Smith et al., 2012). There is a significant difference in the level of DNA 
methylation between mESCs grown in serum and 2i: serum mESCs are hypermethylated to 
around 80% whereas those grown on 2i more accurately represent the E3.5 stage in the embryo, 
having very little DNA methylation (Stadler et al., 2011). Within ten days of switching the 
culture medium, cells grown on 2i or serum can interconvert between the states in morphology, 
transcriptome and DNA methylation (Habibi et al., 2013; Marks et al., 2012). 
 
In 2i cells, the DNA methylation occurs in specific euchromatic regions of the genome, and 
these locations are marked with the histone modification H3K9me3 (Habibi et al., 2013). This 
mark is thought to be written and sustained by DNMT1, a de novo DNA methyltransferase, 
which is recruited to these regions by UHRF1, and in turn binds to H3K9me3 which is enriched 
at imprinted control regions and intracisternal A-particle elements (Rothbart et al., 2012). 
 
1.1.3 Cell cycle in mES cells 
The cell cycle of mES cells is very fast, measured to be between 10 and 14 hours, with around 
65 percent of cells being in S phase at any one time (Pauklin et al., 2011). Only around 15 
percent of cells are in G1 phase and it has been suggested that the G1 phase of cells cultured in 
2i is shorter than that for cells cultured in serum (Malashicheva et al., 2012). Interestingly, these 
mES cells do not have a G1/S phase checkpoint, mentioned in more detail with hESCs. This is 
thought to be due to the lack of Cyclin D, hyperphosphorylation of the retinoblastoma protein 
and unresponsiveness to CDK4 (Savatier et al., 1996). It is likely that this governs naïve 
pluripotency. It has been suggested that this short G1 phase causes constitutive replication stress 
and these cells have upregulated mechanisms to deal with this (Ahuja et al., 2016). Replication 
stress is defined as the slowing or stalling of replication fork progression, this is discussed in 
more detail in the DNA damage response section 1.3. However, more recent work has shown 
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that mES cells cultured in the LIF 2i state have differing cell cycle properties compared to cells 
grown in serum (ter Huurne et al., 2017). These cells are thought to have an active G1 
checkpoint due to hypophosphorylation of Rb and an increased G1 cell cycle phase. Therefore, 
this cell cycle distribution may not be required for naïve pluripotency. 
 
1.1.4 Epiblast stem cells 
After implantation, mESCs cannot be derived from the blastocyst. However, a different cell 
type can be isolated from E5.5-7.5 mice: post-implantation epiblast-derived cells (EpiSCs) 
(Tesar et al., 2007). This state no longer represents naïve pluripotency but a state of primed 
pluripotency in which the cells differ from mESCs in terms of their morphology, growth factor 
requirements, gene expression profiles, level of DNA methylation and X chromosome 
activation (Nichols and Smith, 2009). Female mES cells have gone through the process of X 
chromosome inactivation by the EpiSC stage.  
 
1.1.4.1 Derivation of EpiSCs 
EpiSCs have been derived from the post-implantation epiblast of mice by culturing with Activin 
and FGF but without LIF (Tesar et al., 2007). While these cells can be maintained in the primed 
state indefinitely, they are not able to contribute to blastocyst chimeras but are able to generate 
teratomas with differentiated cell types (Guo et al., 2009; Tesar et al., 2007). These cells are 
able to efficiently differentiate in vitro showing that they have a wide differentiation potential 
(Tesar et al., 2007). 
 
1.1.4.2 Signalling pathways controlling EpiSCs 
The signalling pathways maintaining pluripotency in EpiSCs have been shown to be 
functionally distinct from that of ESCs. mESCs use LIF to signal through the gp130/LIF 
receptor, described above, to maintain pluripotency (Boeuf et al., 1997). However, in 
EpiSCs, blocking STAT3 phosphorylation at tyrosine-705 using a JAK inhibitor supported 
the undifferentiated state, showing that this mechanism is not the same in EpiSCs (Tesar et 
al., 2007). Inhibition of type I Activin receptor-like kinases 4, 5 and 7 showed that the 
Activin/Nodal pathway is instead required for maintaining the pluripotent state in EpiSCs. 
Inhibition of this pathway promoted differentiation of EpiSCs towards neuroectodermal fates 
(Tesar et al., 2007). This dependence on Activin/Nodal and SMAD2/3 signalling is similar 
to the pathways controlling pluripotency in human embryonic stem cells, discussed in 
Section 1.1.5. 
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1.1.4.3 Gene expression profiles of EpiSCs 
Pou5f1, Sox2 and Nanog have been shown to be expressed at equivalent levels in naïve and 
primed mES cells (Tesar et al., 2007). However, a number of transcripts have been shown to 
have decreased expression on the transition to EpiSCs including Pecam1, Tbx3, Dppa3, Zfp42 
and Gbx2, allowing monitoring of this change of state. EpiSCs also exhibit increased expression 
of transcripts associated with the epiblast and lineage specification genes including Otx2, 
Eomes Foxa2, T, Gata6, Sox17, Fgf5 and Cer1 (Guo et al., 2009; Tesar et al., 2007). Therefore, 
this change can be tracked in cell culture conditions. 
 
1.1.4.4 Chromatin state of EpiSCs  
After implantation of the embryo, at the transition from naïve to primed mESCs in culture, a 
major wave of DNA methylation occurs such that there is an increase to around 70% 
methylation at E6.5 (Smith et al., 2012). This is thought to play a role in lineage specification 
as DNA methylation has been shown to occur at promoters of pluripotency factors (Thiagarajan 
et al., 2014). Bisulfite sequencing data has shown that the methylation profiles of 2i cells very 
closely represent E3.5 hypomethylation whereas serum cells mimic the hypermethylation of 
the E6.5 state (Smith et al., 2012). Less is known about the histone modifications in the EpiSC 
state but H3K9me3 is thought to act in concert with DNA methylation in silencing in these cells 
(Tosolini et al., 2018). 
 
1.1.4.5 Differentiation of mESCs to mEpiSCs  
mESCs cultured in the 2i state can be differentiated in vitro to EpiSCs, by removal of LIF and 
2i and the addition of FGF and Activin, these cells are often referred to as epiblast-like cells 
(EpiLC) (Guo et al., 2009). These differentiated cells imitate the E6.5 mouse epiblast from the 
post-implantation embryo. In these cells one X chromosome is inactivated in XX karyotypes, 
they have lost the ability to produce germ cells and there is a change in the expression of 
transcription factors and cell surface markers, discussed above. This EpiSC mouse state is more 
representative of the human ESC state suggesting that human ESCs are in a primed state of 
pluripotency. While the transition from the naïve to primed state is relatively straightforward, 
it is irreversible and the reversal requires reprogramming (Guo et al., 2009). This transition has 
been suggested to be more of a state change and not differentiation as such (Vallier 
unpublished). 
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1.1.5 Human embryonic stem cells and induced pluripotent stem cells 
The first human ESCs (hESCs) derived in 1998 portrayed the desired characteristics of a 
primate ES cell: cultivation from the preimplantation or peri-implantation embryo, prolonged 
proliferation in the undifferentiated state and the ability to form of all three embryonic germ 
layers even after lengthy culture (Thomson et al., 1998). These hESCs were derived from 
human embryos generated for IVF, after approval. The cells were cultured to the blastocyst 
stage and the ICMs were removed. They were initially cultured on a layer of mouse embryonic 
fibroblasts (MEFs) but were able to be transferred to coated plates without a feeder layer. 
 
Three of the cultured cell lines had XY karyotype and the other two had XX karyotype, all were 
able to be frozen and thawed. The H9 XX cell line was kept in culture for 32 passages and 
maintained a normal genotype over this time, is still commonly used in cell culture and was 
used in this project (Thomson et al., 1998). The cell lines produced had high levels of telomerase 
expression and expressed the cell surface markers stage-specific embryonic antigen SSEA-3, 
SSEA-4, TRA-1-60, TRA-1-81 and alkaline phosphatase that characterise undifferentiated 
nonhuman primate ESCs (Thomson et al., 1995).  
 
The Niakan group received approval to continue human embryonic development for longer than 
ever before, a maximum of 14 days after development, and to use CRISPR/Cas9 in human 
embryos. This came with the aim of understanding the processes required during human 
development and the differences between this and mouse development. However, the definitive 
confirmation of an ESC requires the knowledge that these cells are able to contribute to the 
germ line, using chimeras. Clearly this function is not possible to test in human cells as it was 
in the mouse, due to ethical reasons, so this rigorous definition cannot be applied. While these 
cells have been termed embryonic stem cells, they are different from mESCs in their cell culture 
requirements, morphology and expression profile. hESCs and mouse EpiSCs share a 
dependence on Activin/Nodal signalling, flattened morphology and a limited capacity for 
colonising preimplantation embryos (James et al., 2006). This suggests that these isolated cells 
represent a later stage of differentiation, analogous with EpiSCs, and this corresponds with the 
last pluripotent stage before gastrulation (Brons et al., 2007; Greber et al., 2010; Tesar et al., 
2007). This, again, highlights the fact that true embryonic stems cells may be a feature specific 
to rodents. 
 
Instead of monitoring the ability to form chimeras in the cells, these cells were tested for their 
propensity to produce teratomas, as was previously the method in mESCs. All of the derived 
10 
 
hES cell lines produced teratomas after injection into severe combined immunodeficient beige 
(SCID/beige) mice. The cells also differentiated in vitro when grown without a layer of mouse 
embryonic fibroblasts with and without LIF (Thomson et al., 1998).  
 
The degree of similarity of these stem cells to the cells they originate from in the embryo is 
much lower than that of the mouse, raising questions about the culture of these cells. Significant 
changes in the global DNA methylation was seen between the in vitro and in vivo cells (Guo et 
al., 2014; Smith et al., 2014). 
 
The similarity of different hES cell lines to one another has been heavily debated, as well as the 
differences inflicted using different culture conditions. Different human ES cells have varying 
propensities of over 100 fold to differentiate towards different lineages (Osafune et al., 2008). 
The HUES 8 cell line is more inclined towards pancreatic differentiation whereas HUES 3 is 
best for cardiomyocyte differentiation (Osafune et al., 2008). These differences were suggested 
to be due to epigenetic changes in these cell lines, as the genetic changes could not account for 
this (Ibid). These differences are clearly very important in differentiation protocols but will also 
impact the significance of research on some of these specific cell types. 
 
1.1.5.1 Gene expression and signalling in hESCs 
Regulatory pathways are poorly understood in hES cells compared to mES cells, but these cells 
are thought to resemble the EpiSC state in mice (Brons et al., 2007; Tesar et al., 2007). As in 
mESCs, the trio of pluripotency factors OCT4, SOX2 and NANOG control pluripotency (Wang 
et al., 2012). However, there are a range of homologs of key transcriptional regulators in mESCs 
such as TBX3 and ESRRB which are not expressed in hESCs, whereas other factors shown to 
be dispensable in the mouse system, PRDM14, FOXO1 and LSD1 have been identified to 
regulate hES cell pluripotency (Adamo et al., 2011; Chia et al., 2010; Zhang et al., 2011b). 
However, large scale transcriptome analysis has suggested that 75% of the genes expressed in 
mESCs were also expressed in hESCs (Hirst et al., 2006). Clearly the mouse and human ES 
cells are very different in the context of the regulation by their signalling pathways and care 
should be taken when comparing the two systems. 
 
The epigenetics of hESCs have been studied in much less detail than mESCs. However, the role 
that epigenetic changes play during the differentiation have been identified in greater detail. 
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1.1.5.2 Reprogramming 
The ability to reprogram a cell of any fate into an embryonic stem cell has clearly been an 
attractive topic due to the potential to solve numerous medical problems, as well as for 
biological insight. The notion of reprogramming was shown to be correct in John Gurdon’s 
landmark experiments in Xenopus laevis (Gurdon, 1962). The concept of ‘reprogramming 
factors’ was discussed with the Myod experiments in mice whereby mouse embryonic 
fibroblasts were programmed to myoblasts on addition of this cDNA (Davis et al., 1987) and 
the cloning of Dolly the sheep showed this could occur in mammals (Campbell et al., 1996).  
 
Initial experiments to reprogram mouse and human fibroblasts to induced pluripotent stem cells 
(iPSCs) occurred using viral overexpression of transcription factors (Park et al., 2008; 
Takahashi and Yamanaka, 2006; Takahashi et al., 2007; Yu et al., 2007). These methods used 
retroviral transduction of Pou5f1, Sox2, Klf4 and c-Myc into mouse embryonic fibroblasts or 
tail-tip fibroblasts (Takahashi and Yamanaka, 2006). There have been many optimisations to 
this method to increase the efficiency and to generate ‘footprint free’ methods, such as using 
lentiviral vectors, using the cre-lox system to remove the sequences and changing the 
stoichiometry of the reprogramming factors. While optimisation of these methods continues, it 
is important to note that these cells may maintain the characteristics of their initial cell type to 
an extent, and this may be important during differentiation. 
 
While miPSCs are used frequently, they are not discussed in further detail here as they were 
not used in this project. 
 
1.1.5.3 hiPSCs 
Human induced pluripotent stem cells (hiPSCs) are often used in cell culture as they have huge 
medical potential, especially in cell replacement therapy. These cells are able to overcome a 
number of issues with hESCs including ethical issues, availability of these cells and host 
rejection. The similarity of these cells to hESCs as well as to each other is highly debated. It 
has been shown that different iPS cell lines have a more diverse genetic background, epigenetic 
signature and differences in reprogramming (Kim et al., 2010; Polo et al., 2010; Rouhani et al., 
2014). The differences in reprogramming may be due to the reprogramming process not being 
complete, as there are many reprogramming practices with differing efficiencies (Osafune et 
al., 2008). However, since there are still so many differences between the cells referred to as 
hESCs, it is hard to determine whether the differences seen within hiPSCs are greater and 
importantly which cell type more closely recapitulates the cell state in the embryo. 
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The BOBSC-T6/8_b1 (BOBSC) hiPSCs (Yusa et al., 2011) have been used by the Sanger 
Centre to generate a large library of genetic knockouts using the CRISPR/Cas9 technique, in 
which there are currently 194 targeted genes (June 2019) (www.sanger.ac.uk/htgt/lims2) 
(Sanger Centre COMSIG knockout unpublished). Due to the availability of this knockout 
library, these cells were used throughout this project. 
 
1.1.6 hiPSC and hESC differentiation 
1.1.6.1 Differentiation in cell culture 
Human ES and iPS cell lines are able to generate all three lineages after gastrulation, as 
discussed previously, but as more methods are created it is becoming possible to differentiate 
cells into many differentiated cell types with the possible outcome of forming organs: this 
includes forming ‘mini brains’ from cerebral organoids (Lancaster et al., 2013). Protocols for 
generating the three lineages have improved greatly over time and it is possible to differentiate 
cells to definitive endoderm with over 90 percent efficiency. This was the protocol used 
throughout this project. Mapping transcription factor binding dynamics of lineage specification 
genes has helped to understand the role of DNA methylation in differentiation (Tsankov et al., 
2015) whereas studies focussing on histone marks have revealed the importance of modifiers 
including HDAC1 during gastrulation (Dovey et al., 2010). 
 
1.1.6.2 Definitive endoderm differentiation 
Embryonic stem cells can develop into the three lineages: endoderm, mesoderm and 
neuroectoderm (Figure 2). Definitive endoderm (DE) differentiation has been heavily studied 
due to its clinical significance in generating whole organs such as the pancreas and liver. 
Although the protocols allow generation of this cell type with relatively high efficiency and the 
transcriptomics of this protocol are well understood, a full understanding of the underlying 
pathways is yet to be elucidated (Chia et al., 2019; Teo et al., 2011, 2012). 
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Figure 2. A simplified schematic to show lineage specification in ESCs. 
 
Cells are induced to differentiate using Activin/Nodal signalling, activation of FGF and BMP4 
signalling, activation of WNT signalling and inhibition of P13K. This is performed using three 
recombinant proteins, Activin A, FGF2 and BMP4, and inhibitors of PI3K and GSK3 (Teo et 
al., 2011). Pluripotent cells differentiate into the primitive streak stage, they then undergo the 
epithelial mesenchymal transition (EMT) before becoming specified to definitive endoderm. 
Transition through the EMT causes a dramatic change in cell morphology, visible down a 
microscope, as well as a switch from the expression of E-cadherin to N-cadherin (Teo et al., 
2011). This transition is very important in cancer and has been studied most widely in this 
context. 
 
In a similar manner to mouse embryonic stem cells, the trio of transcription factors OCT4, 
SOX2 and NANOG control pluripotency in hES cells. The expression of these genes also 
regulates the end of pluripotency and the onset of differentiation. When the cells are 
differentiating, SOX2 is downregulated within the first 24 hours, NANOG by 48 hours and 
POU5F1 in 72 hours due to its late downregulation by the definitive endoderm marker SOX17. 
Two primitive streak (PS) genes known to be expressed in the gastrulating mouse embryo, 
EOMES and GSC, have these three transcription factors bound cooperatively to them but, 
although EOMES is required for human endoderm differentiation, GSC is entirely dispensable 
(Boyer et al., 2005).  
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EOMES is expressed from around eight hours in differentiating cells, followed by MIXL1, T 
and GSC from twelve hours. Therefore, there is a significant amount of overlap between the 
expression of pluripotency genes and markers of DE. EOMES is thought to be a key cell fate 
coordinator at this time in differentiation and is its expression is regulated directly by OCT4, 
SOX2 and NANOG. OCT4 and SOX2 inhibit expression but NANOG upregulates EOMES on 
the induction of specific differentiation cues. To ensure commitment to differentiation, EOMES 
is able to downregulate POU5F1, SOX2 and NANOG (Figure 3). It is also suggested that BMP4 
may play a role in directly inhibiting POU5F1 and SOX2 in order to commit to differentiation 
(Teo et al., 2011). 
 
 
 
Figure 3. A simplified schematic to show the control 
of gene expression during differentiation to 
definitive endoderm from the pluripotent state. 
EOMES is upregulated, leading to downregulation 
of pluripotency factors and an upregulation of 
definitive endoderm specific genes, including 
SOX17.                                       
 
 
 
 
EOMES is a key transcription factor thought to push differentiation towards endoderm and 
prevent the differentiation to mesoderm. This factor has been shown, in complex with 
SMAD2/3, to bind to a large number of genes involved in differentiation to both the endodermal 
and mesodermal lineage. Being upregulated early, EOMES is a key protein to activate primitive 
streak genes including itself, MIXL1, T, GSC, TBX6, FGF8, SNAI1, SPRY2, SPRY4, WNT3, 
WNT3A and NODAL. It is also thought to switch on a number of definitive endoderm genes: 
SOX17, CXCR4, LHX1, FOXA1, FOXA2 and FOXA3. It binds to and inhibits a selection of 
mesoderm specification genes: MEOX1, TBX6, KDR, FOXC1, ISL1, PDGFRA. However, 
despite EOMES playing a central role at this point in development, its knockdown did not affect 
the EMT that the cells undergo during differentiation from the primitive streak (Teo et al., 
2011). 
 
Specification of definitive endoderm is marked with the co-expression of SOX17 and FOXA2. 
Differentiation also causes a change in the cell cycle of these cells. They move from having 
over 60 percent of cells in S phase at one time to the majority of cells being in G1 phase, 
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indicative of a more differentiated cell type. These features can be validated using flow 
cytometry to monitor the efficiency of differentiation, discussed in Results I. 
 
However, studies on differentiation have shown that the efficiency of differentiation is not only 
altered by the culture conditions used to differentiate the cells, but also the confluence of the 
cells, which is important when comparing differentiation efficiencies of different cell types 
(Graffmann et al., 2018; Kempf et al., 2016). This is shown to affect the outcome only in the 
first 24 hours of differentiation, suggesting it is key for lineage specification. 
 
DMSO has also been shown to alter the normal pathway of differentiation, discussed in greater 
detail in the Results I (Czysz et al., 2015; Pal et al., 2012). This finding is important because 
DMSO is thought to be able to remove DNA secondary structures, possibly causing the 
alteration of the differentiation pathway (Kang et al., 2005; Winship, 1989). 
 
1.1.6.3 Mesoderm differentiation 
The differentiation to mesoderm is also a key pathway to understand for clinical medicine. The 
paraxial mesoderm goes on to become the kidney, whereas the lateral plate mesoderm forms 
heart and blood vessels. Mesoderm differentiation begins in a similar manner to endoderm 
differentiation due to the shared early cell type, mesendoderm. The protocols for differentiation 
to mesoderm are varied and relatively complicated, they have not been used at all in this thesis. 
However, one group reported an efficient protocol for this differentiation using the GSK3i 
CHIR99021, which was shown to increase mesendoderm gene expression, including T and 
MIXL and then markers of intermediate mesoderm PAX2 and LHX1 (Lam et al., 2014). The 
GSK3i addition suggests that this pathway requires a prolonged activation of the WNT pathway 
for mesoderm differentiation, this is on the contrary to definitive endoderm specification where 
the pathway is downregulated after 24 hours. 
 
1.1.6.4 Neuroectoderm differentiation 
The Studer group has established a method to derive neuroectoderm cells using two small 
molecule inhibitors, LDN193189 and SB431542, that inhibit the BMP and TGFβ signalling 
pathways respectively (Tchieu et al., 2017). These two inhibitors are known as dual SMAD 
inhibitors and cause a cell fate specification to neuroectoderm as marked by the expression of 
PAX6 and SOX1. The efficiency can be further increased by addition of a WNT pathway 
activator. Further understanding of this pathway will be incredibly useful in forming neural 
cells in culture for regenerative medicine. 
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1.1.6.5 Cell cycle control of differentiation 
Numerous experiments have been performed to show that the cell cycle is intrinsically 
important in controlling pluripotency as well as lineage specification. hES and mES cells have 
a short G1 phase, thought to be due to the lack of a G1 checkpoint inferred by the resistance to 
DNA damage (Neganova et al., 2011). This is discussed in greater detail during the DNA 
damage section. This short G1 phase increases in length throughout differentiation, suggesting 
that differentiation alters regulation of the cell cycle (Calder et al., 2013).  
 
The propensity of hES cells to differentiate into the different lineages was analysed in Ludovic 
Vallier’s group and it was found that cells are only able to differentiate into certain cell types 
at certain points in the cell cycle (Pauklin and Vallier, 2013). They see that only cells in early 
G1 can differentiate towards endoderm, whereas cells commit to neuroectoderm in late G1 
phase. They show that this is controlled by Cyclin D which activates CDK4/6 leading to 
phosphorylation of SMAD proteins. The phosphorylation prevents SMAD movement into the 
nucleus in late G1 phase, thereby preventing endoderm differentiation and allowing the 
specification to neuroectoderm. Further work has shown that Cyclin D1 is highly expressed in 
late G1 where it recruits transcriptional corepressors of endoderm specification genes and 
coactivators of neuroectoderm genes (Pauklin et al., 2016). 
 
A separate study from the Vallier group has shown that loss of pluripotency, which they name 
pluripotent state dissolution (PSD), is also dependent on the location of the cell in the cell cycle 
(Gonzales et al., 2015). They show that S and G2 cell cycle phases act to restrict PSD whereas 
in G1, when these pathways are absent, PSD could occur. ATM mediated p53 and Cyclin B1 
activation can cause S/G2 arrest and this can block the cells in a pluripotent state. This very 
clearly shows that the activity of cell cycle controlling proteins are able to control cell fate 
decisions. 
 
1.2 DNA secondary structures 
While DNA is often considered to be a stable, double stranded structure holding the genetic 
information, it is also known to form many different secondary structures in vivo (reviewed by 
Bochman et al., 2012). These structures can cause problems for the DNA polymerase during 
replication, as well as the RNA polymerase in transcription. There are many non-B-forms of 
DNA that can form in vitro and are thought to occur in vivo. These structures include simple 
hairpins and cruciforms which form in inverted or mirror repeat sequences, triplex DNA that 
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can form in polypurine DNA stretches including (CAG)n, Z-DNA, R-loops which require RNA 
and DNA binding, and G-quadruplexes (G4s). The in vitro prediction of the locations of these 
structures often occurs at points of known instability in vivo (Burrow et al., 2010). For the 
purpose of this thesis I will focus on the G4 structure. 
 
1.2.1 The G-quadruplex structure 
1.2.1.1 Formation of the G-quadruplex 
G4s are able to form in stretches of DNA rich in guanine bases. Four guanines Hoogsteen base 
pair to form a G-quartet (Gellert et al., 1962), stabilised by a central monovalent cation such as 
K+ or Na+. These G-quartets stack through π-π interactions to form the G-quadruplex (Sundquist 
and Klug, 1989; Williamson et al., 1989). These G4s can be tetramolecular, bimolecular or 
unimolecular, formed using a single strand of DNA, as is most significant in the context of 
DNA replication (Figure 4). The G4 structure formation occurs preferentially on single stranded 
DNA, such as during transcription and replication. 
 
 
 
 
 
Figure 4. The canonical G4 requires four runs of three guanines on one strand of DNA to fold into a unimolecular 
G4. Each planar stack is formed of a G-quartet containing four guanines and a central metal ion to stabilise the 
structure. Adapted from Lerner et al., 2019; Šviković and Sale, 2017. 
1.2.1.2 Biological significance of G4s 
The role, if any, that these structures played in vivo was and still is heavily debated (Maizels 
and Gray, 2013; Murat and Balasubramanian, 2014; Rhodes and Lipps, 2015; Tarsounas and 
Tijsterman, 2013). However, the initial evidence for the significance of these structures was 
shown when G-rich sequences, seen in telomeres, gene promoters and immunoglobulin switch 
regions, could form G4s and they proposed that self-recognition of these motifs could attach 
the four chromatids during meiosis (Sen and Gilbert, 1988). These structures have since also 
been shown to be enriched in ribsomal DNA, transcription start sites and mitotic and meiotic 
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DSB sites (Capra et al., 2010; Eddy and Maizels, 2006; Hershman et al., 2008; Huppert and 
Balasubramanian, 2005; Nakken et al., 2009). These sequences have also been found to be 
conserved between yeast and human genomes (Capra et al., 2010). Since these structures are 
enriched at key locations in the genome it has been suggested that they play a number of 
biological roles in these cells. 
 
Telomeric repeats have high numbers of G4 structures due to the repeat sequence (AGGGTT) 
acting as a canonical G4 (Huppert and Balasubramanian, 2005). Therefore G4s are predicted to 
form in the telomeres of many species. In vitro studies have shown that the telomere associated 
proteins, TEBPα and β in ciliates and Rap1 in Saccharomyces cerevisiae, promote G4 formation 
(Fang and Cech, 1993; Giraldo and Rhodes, 1994; Paeschke et al., 2005; Sundquist and Klug, 
1989). These structures have also been linked to specification of DNA replication origins in 
vertebrates (Besnard et al., 2012; Cayrou et al., 2012; Valton et al., 2014). 
G4s are also thought to play a role in the regulation of transcription through a number of means. 
For example, the c-MYC locus is commonly used in the discussion of G4s as it has been highly 
studied. It is of added interest due to its role in cancer. This locus contains the nuclease 
hypersenstive element III1 downstream of the MYC promoter which controls the majority of 
transcription from this locus. In this element there is a G4 motif that has been shown to form a 
G4 in vitro (Simonsson et al., 1998). Mutagenesis of this region to prevent the formation of a 
G4 show that this is no longer able to repress transcription of this region (Siddiqui-Jain et al., 
2002). Therefore, in this context, the G4 is shown to act as a transcriptional repressor. 
Numerous tumour supressor and proto-oncogenes besides MYC have been shown to contain 
DNA G4s, as well as RNA G4s, discussed later, and this may be key for their regulation (Welsh 
et al., 2013). 
 
The myosin D (MyoD) protein family of transcription factors has been highly studied for its 
role in regulating transcription through G4s. These proteins bind to the promoters of muscle-
specific genes to regulate muscle development. In vitro studies have shown that MYOD 
homodimers bind to G4s enriched in muscle specific genes. However, MYOD-MYOE 
heterodimers do not bind to these G4s and instead bind to an E-box in the promoters of these 
genes and upregulate transcription (Shklover et al., 2010; Yafe et al., 2008). 
 
The HRAS promoter had been shown to contain two regions of DNA which are each able to 
fold into a G4 (Cogoi et al., 2014). Importantly, these have been shown to be bound to two zinc-
finger transcription factors MAZ and Sp1. The authors have suggested that the MAZ protein is 
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able to bind and then unwind these G4 structures. This knowledge was used to generate 
anticancer molecules used to prevent transcription of HRAS (Cogoi et al., 2014). 
 
The evolutionary significance of G4 forming sequences is debated due to the number of 
organisms with A/T-rich genomes, including Plasmodium falciparum and Dictyostelium 
discoideum (Szafranski et al., 2005). While direct evidence of the biological role of G4s in vivo 
is not vast, they are known to form potent replication blocks and this has great impacts for gene 
expression which is discussed next. Regardless of their role, these structures are able to form 
and are therefore able to cause problems during replication and transcription. 
 
1.2.1.3 G4 prediction tools 
Estimations suggest that there are around 700,000 sequences in the human genome that can 
form G4s but this estimation is highly dependent on the stringency of the algorithm, as many 
G4s that exist do not conform to the cannonical sequence ((Huppert and Balasubramanian, 
2005; Sahakyan et al., 2017; Todd et al., 2005). 
 
The ‘Quadparser’ algorithm was developed by Shankar Balasubramanian’s group and simply 
allowed a search of DNA sequences of the nature (G≥3N1-7)4 (Huppert and Balasubramanian, 
2005). This motif was predicted to form in physiological conditions and was therefore 
suggested to be a good initial predicter (Hazel et al., 2004). However, the canonical (G≥3N1-7)4 
sequence has been long known to not include a number of G4 structures shown to form (Patel 
and Hosur, 1999). Biophysical studies have also shown large differences in the thermal stability 
between different G4s (Hazel et al., 2004).  
 
Another predictive tool, quadruplex-forming G-rich sequence (QGRS) mapper, was generated 
using a looser G4 definition: (G≥2Nn)4 (D’Antonio and Bagga., 2004). This allows you to input 
a sequence of DNA and outputs a list of potential G4s ranked with a G-score. This G-score 
informs the user of the likelihood of a structure forming in the DNA based on the number of G-
quartets stacked, the length of loops and the symmetry of the structure. 
 
Eddy and Maizels used a ‘sliding window’ technique to calculate the potential of a G4 forming 
(Eddy and Maizels, 2006). This strategy calculated the likelihood of G4 formation based on the 
density of guanines within a region of the DNA; the score received is independent of the length 
of the sequence. 
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While giving a quick look at the possible G4 potential, these methods were not the most reliable 
as the prediction tools were extrapolated from a small data set. Some of the more recent 
predication methods are likely to give more biologically relevant answers. These allow 
combinations of longer loops, mismatches, bulges, location of cytosines and structural features: 
these included Pgsfinder, Quadron and G4-hunter (Beaudoin et al., 2014; Bedrat et al., 2016; 
Hon et al., 2017; Mukundan and Phan, 2013; Sahakyan et al., 2017). These approaches have 
been tested on much larger datasets and have improved predictions, especially of non-canonical 
G4s. Furthermore, groups have attempted to create lists of genes containing G4s (Zhang et al., 
2008).  
1.2.1.4 Evidence that G4s form in vivo 
The G4 structure has been visualised using antibodies suggested to be specific to G4s, although 
the specificity of this is debated. Visualisation of DNA G4s in the ciliate Stylonychia lemmae 
was achieved using antibodies specific to the telomeric repeat of this organism (Schaffitzel et 
al., 2001). This provided early evidence that these structures existed in the cell. The BG4 
antibody was generated using phage display and used to visualise G4s in DNA using 
immunofluoresence (Biffi et al., 2013). This study also showed an increase in these structures 
after the addition of a G4-binding ligand, suggesting that they do stabilise these structures in 
vivo and that the antibody shows some degree of specificity. However, the monoclonal antibody 
1H6 which was initially thought to recognise G4s was shown to cross-react with thymidine-
rich single stranded DNA, highlighting the problems with using these techniques (Kazemier et 
al., 2017). 
 
1.2.1.5 G4 prevelance in the mitochondrial genome 
Most of the work on G4s has been done using nuclear DNA, however it is becoming clear that 
mitochondrial DNA (mtDNA) also contains these structures. Around 90 potential locations for 
G4 formation have been found in the mtDNA . These are biased to the heavy strand due to the 
high guanine content (Dong et al., 2014; Zybaĭlov et al., 2013). It has also been shown that a 
G4 is involved in controlling the switch between transcription and replication (Agaronyan et 
al., 2015). Specific ligands have also been developed to target the mitochondrial genome 
(Huang et al., 2015). These G4s are not the focus of this thesis, but it is worth noting as many 
perturbations generated by G4 ligands are likely to cause problems in the mitochondria too. 
 
1.2.1.6 RNA G-quadruplexes  
While much of the initial work on G4s focussed on the DNA G4s, there has been subsequent 
analysis of RNA G4s which are also thought to have significant biological impact. These 
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structures were thought to have similar propensities to form, and similar properties. However, 
the chemical differences between DNA and RNA have revealed changes by using biophysical 
measurements. RNA has an extra 2’-OH group which was shown to allow additional 
intramolecular interactions in the loop regions and therefore enhances the stability of these 
structures compared to DNA G4s (Zhang et al., 2010). RNA G4s also prefer parallel G4 folding, 
compared to DNA which is able to fold into parallel, antiparallel and mixed structures (Zhang 
et al., 2010). However, it is also important to remember that RNA is much more likely to form 
a number of other secondary structures, compared to DNA, due to its single stranded nature. 
These considerations are likely to alter the probability of RNA folding into a G4. 
 
As for DNA G4s, RNA G4s are thought to play a key role in a number of processes (Bugaut 
and Balasubramanian, 2012; Fay et al., 2017). One such role is in translation whereby a G4 in 
the 5’ or 3’ UTR, as well as in the coding sequence, has been seen to prevent efficient translation 
(Arora and Suess, 2011; Crenshaw et al., 2015; Endoh et al., 2013; Kumari et al., 2007). These 
G4s have also been shown to alter splicing codon choice (Burley et al., 2017; Marcel et al.), 
RNA localisation (Subramanian et al., 2011) and act as the termination structure in ρ-
independent mitochondrial transcription termination (Wanrooij et al., 2010). RNA G4s also 
have a stronger binding affinity to Polycomb repressive complex 2 (PRC2) than an unstructured 
G-rich motif or duplex RNA, suggesting a role for these structures in epigenetic control (Wang 
et al., 2017). These RNA G4s have also been visualised in cells using BG4, as discussed 
previously, using a ligand to stabilise the structure (Biffi et al., 2014). 
 
Non-coding RNA G4s have also been shown to form in tRNAs encoded in the nuclear and 
mitochondrial genome. Some work has shown that the G4 structure is required for the 
degradation of these non-coding structures produced in the mitochondria (Pietras et al., 2018). 
Another group has shown that cytoplasmic tRNAs are cleaved during the stress response to 
produce fragments, and these assemble into intermolecular G4s which are suggested to play a 
further role in the stress response (Lyons et al., 2017). 
 
While the aims set out in this thesis are to understand how replication impediments alter 
differentiation in a DNA replication context, the ability of RNA to form G4s is likely to impact 
the experiments and should be considered when examining the results. 
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1.2.2 G4-processing enzymes 
The existence of  G4 structures poses the problem of replicating these stretches of DNA by 
replicative polymerases (Woodford et al., 1994). Interestingly, the unwinding of the DNA 
duplex lends itself to the formation of G4s on both strands but not equally. Replication of the 
leading strand of DNA is known to be continuous whereas lagging strand synthesis occurs via 
formation of Okasaki fragments and occurs discontinuously. The nature of lagging strand 
replication was thought to lend itself to G4 formation due to the increased length of time of it 
being single-stranded (Cheung et al., 2002; Ding et al., 2004). However, the lagging strand is 
thought to be coated in RPA which prevents the formation of these G4s (Safa et al., 2016). 
Evidence now suggests that G4s are able to form on the leading strand during DNA replication, 
shown in the BU1 assay discussed later (Schiavone et al., 2016). 
 
This means that the process of DNA replication can enhance the formation of G4s on the DNA, 
and this can also occur during transcription. Increasing the length of time of the DNA being 
single stranded, for example by slowing replication, can also increase the chance of a possible 
G4 forming. 
 
Certain helicases, primase and polymerases have been implicated in the replication of the G4. 
In vitro the majority of human helicases tested are able to unwind G4 structures, and those that 
do are often associated with a disease phenotype such as the RecQ helicases WRN and BLM, 
and FANCJ (Huber et al., 2002; London et al., 2008; Mohaghegh et al., 2001; Ribeyre et al., 
2009; Sanders, 2010). However, these disease phenotypes are not clearly linked to G4-
processing defects. Mutations in the human FANCJ protein are associated with Fanconi 
anaemia and these patients show a phenotype suggesting a lack of ability to replicate G-rich 
regions of the DNA: their DNA shows deletions of these G-rich regions (London et al., 
2008). In a similar manner to the FANCJ mutations in human patients, mutations in the 
Caenorhabditis elegans DOG-1 helicase, a relation of FANCJ, can cause large scale 
deletions in G-rich sequences (Cheung et al., 2002; Kruisselbrink et al., 2008). These types 
of studies highlight the importance of proper processing of these G4 structures, and the 
requirement of specific helicases in this process. 
 
1.2.3 Maintenance of epigenetic marks through DNA replication 
While it is vitally important for the cell to perfectly replicate its DNA across generations in 
order to maintain fidelity, it is also important that epigenetic marks transferred such that gene 
expression state is not lost. The structure of DNA suggested a simple, elegant model as to its 
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replication (Watson and Crick, 1953), but replication of marked nucleosomes on the DNA did 
not lend itself to a straightforward explanation. As discussed in the earlier sections, histone 
modifications and DNA methylation, both forms of epigenetic information, play key roles in 
embryonic development. During replication the histone marks associated with a genomic region 
must be returned to this region and this has been shown to be correct using sequencing methods 
(Reverón-Gómez et al., 2018). The replicative helicase removes the histones from the DNA and 
these are then randomly distributed to each of the leading and lagging DNA strands by the 
histone chaperones ASF1 and CAF1 (De Koning et al., 2007). In order to maintain the number 
of histones on each DNA strand, new, unmodified histones are added with these recycled 
histones and modifications are transferred from the old to new histones to maintain the 
epigenetic information (Bannister et al., 2001; Hansen et al., 2008; Lachner et al., 2001; 
Margueron and Reinberg, 2010). This process must be performed in a timely fashion to 
maintain the coordination between DNA synthesis and the histone marks associated with these 
regions.  
 
Much of the published work looking at the replication of G4s and its effect on epigentic 
instability has been done in the DT40 cell line, a chicken B cell line derived from leukosis virus 
induced bursal lymphoma (Baba et al., 1985), initally used for its ease of genetic manipulation 
(Buerstedde and Takeda, 1991). This cell line has an easily observable phenotype which arises 
as a result of a G4 sequence 3.5kb from the transcription start site (TSS) of the BU-1 locus 
(Sarkies et al., 2012). 
 
The BU1 gene encodes a cell surface receptor that is uniformly highly expressed in wildtype 
DT40 cells and can be monitored using flow cytometry. However, clonal expansion of these 
cells shows expression of the BU-1 locus decreases in a stochastic manner at every replication 
cycle in cells either stabilised with G4-binding ligands, containing genetic knockouts of 
processing enzymes or experiencing nucleotide pool depletion. The general proposed 
mechanism for this is a blockage of the DNA replication fork at the G4 secondary structure and 
restart downstream. This causes a loss of the histone modifications associated with this tract of 
DNA as new, unmarked histones are deposited (Figure 5). Monitoring of this phenomenon is 
discussed in the next section. 
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Figure 5. When DNA replication is uncoupled from the deposition of the original histones, the chromatin structure 
can change and alter gene expression. This uncoupling can be caused by a number of factors including DNA 
damage, secondary structures and replication stress, shown with the yellow star, in this instance a G4. Adapted 
from Sarkies et al., 2010. 
 
1.2.3.1 Using the BU1 assay to detect G4-dependent epigenetic instability 
Epigenetic instability is defined here as a loss of chromatin marks in a region of DNA, often 
resulting in changes in gene expression. This has been studied in our group in great detail, 
initially at the ρ-globin locus and then the BU-1 locus of DT40 cells (Sarkies et al., 2010, 2012; 
Schiavone et al., 2014).  
 
Epigenetic instability occurs due to uncoupling that is thought to occur because the replicative 
DNA helicase moves through the G4 structure whereas the polymerase gets stuck. This has 
been suggested to leave a ssDNA gap where the G4 forms. This replication process leaves gaps 
in the leading strand of DNA. The replication of these gaps occurs later, meaning that parental 
histones can no longer be transferred to the daughter DNA strand and naïve, unmarked histones 
are deposited such that the original histone markings are lost, which leads to changes in gene 
expression (Figure 5). While the BU-1 locus has proved to be a good system to analyse the role 
of G4s in inducing epigenetic instability, this phenomen is capable of happening at any location 
where the helicase and polymerase are uncoupled. This can include a slowed rate of DNA 
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synthesis (Papadopoulou et al., 2015), described later using low dose hydroxyurea, DNA 
damage, genetic knockout of factors involved in processing of secondary structures and 
stabilising secondary structures on the DNA, as discussed using G4-binding ligands. Using 
these model systems, G4-processing enzymes have been implicated in processing genomic G4s, 
acting in concert at both the 5’ and 3’ ends of the structure. 
 
REV1 is a Y family DNA polymerase known to play a role in translesion synthesis occuring 
after DNA damage, in order to maintain replication fork progression (Edmunds et al., 2008; 
Jansen et al., 2009). In cells lacking REV1, postreplicative gap filling occurs in gaps of 400-
3000 base pairs, around 20 kilobases behind the replication fork (Lehmann, 1972; Lopes et al., 
2006). This distance allows an uncoupling of genetic and epigenetic marks at specific DNA 
secondary structures to be seen in these REV1 deficient cells. This is due to the gap filling being 
uncoupled from bulk DNA replication and therefore the loss of histones associated with this 
region as they are displaced when the replicative helicase unwinds the DNA. At the β-globin 
locus in DT40 cells this is seen through the derepression of ρ-globin (Sarkies et al., 2010). This 
work showed that the REV1 polymerase played a role in the processing of secondary structures, 
namely G4s, a previously unexpected role. 
 
Further work has focussed on the BU-1 locus in DT40, introduced in Section 1.2.1.3, as this 
offers a powerful system to enable the study of epigenetic instability. The BU-1 locus contains 
a putative G4 between exons two and three on the leading strand, around 3.5 kilobases 
downstream of the TSS (Figure 6) (Sarkies et al., 2012). The BU1 protein is ubiquitously 
expressed on the surface of DT40 cells and can be monitored using permeabilised flow 
cytometry. When there is an uncoupling of DNA synthesis and deposition of recycled histones, 
as seen in REV1-/- cells, the epigenetic information is lost and expression of BU1 is lost in a 
stochastic manner at each replication cycle, this is associated with a loss of H3K4me3 and 
H3K9/12ac (Sarkies et al., 2012; Schiavone et al., 2014). Using this elegant assay, FANCJ, 
WRN/BLM (in a redundant manner) and the primase polymerase PRIMPOL have been shown 
to also play a role in G4-processing during DNA replication (Sarkies et al., 2012; Schiavone et 
al., 2016). FANCJ and WRN and BLM helicases and REV1, PrimPol, Pol  and Pol  
polymerases have been shown to play a role in G4-processing in a number of other studies 
(Bétous et al., 2009; Crabbe et al., 2004; Huber et al., 2006; Rey et al., 2009; Wu et al., 2008). 
Interestingly, there is some evidence to suggest that these polymerases have preference for the 
type of G4 they replicate such that REV1 is more able to process G4s containing longer loops, 
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whereas PRIMPOL is involved in priming after shorter G4s with a higher melting temperature 
(Schiavone et al., 2014, 2016). 
 
Figure 6. The structure of the BU-1 
locus in DT40, taken from Sarkies et 
al., 2012. The putative G4 is in the 
second intron, towards exon three, 
with the sequence shown. 
 
 
 
1.2.4 G4-stabilising ligands 
The prospect of targeting these G4 structures has led to a significant focus on the development 
of ligands to bind and stabilise these structures in the DNA and RNA: these are referred to as 
G4-binding ligands. An initial reason for targeting was to block the action of telomerase on 
telomere elongation, for example in cancer cells, by using a G4-binding ligand to stabilise the 
structure in these repeats (Mergny et al., 2002; Neidle and Parkinson, 2002; Oganesian and 
Bryan, 2007; Patel et al., 2007). 
 
While there are a vast range of G4-binding ligands which bind to subsets of these structures 
with varying affinities, the features of these small molecules are similar. As mentioned 
previously, G4s have a large π-surface therefore, in order to increase the π-π interactions, most 
of the small molecules that bind to G4s also have large π-systems. The ligands also tend to be 
positively charged in order to bind to the negatively charged DNA, but this is non-specific. Due 
to this lack of specificity many ligands will also bind to DNA not containing G4s in a less 
specific manner, hence causing problems in cell systems where there are much greater quantites 
of duplex DNA compared to G4s. Ligands are thought to be able to bind to G4s through tetrad-
stacking or binding to loop or groove regions, suggesting further specificity that could be used 
for medical targeting of G4s (Kimura et al., 2007; Le et al., 2015). In order to measure the 
binding of ligands to G4s a number of biophyscial techniques have been used including surface 
plasmon resonance (SPR) (Redman, 2007). 
 
A vast array of G4-binding ligands have been used, both from natural sources, and those 
rationally generated to bind and stabilise G4s. These ligands are closely related to one another: 
TMPyP4, Telomestatin, Pyridistatin (PDS), PhenDC3, N-Methyl Mesoporphyrin IX (NMM), 
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and PIPER (Figure 7). In this thesis NMM, PDS and PhenDC3 were used to stabilise G4 
structures. 
 
 
Figure 7. Structures of six commonly used G4-binding ligands. The structures share large delocalised regions in 
aromatic rings and mostly sit on top of the G-quartet stacks to increase the π-π bonding. 
 
NMM was initially developed as a DNA aptamer and was later found to be selective for G4s 
over ssDNA, dsDNA, dsRNA, RNA-DNA hybrids, Z-DNA, triplex and Holliday junctions (Li 
et al., 1996; Nicoludis et al., 2012). A later developed drug, PDS, was rationally designed based 
on previously known G4-binding ligands: it contains a planar electron system but is more 
flexible to make it suited to binding more structures. PDS was shown to stabilise telomeric 
DNA and alter the shelterin complex, thus inducing a DDR (Rodriguez et al., 2008). It has also 
been shown to cause transcription and replication-dependent damage by binding specifically to 
G4s as measured by γH2AX foci (Rodriguez et al., 2012). PhenDC3 is a member of the 
bisquinolinium family that has been shown to bind G4s with high selectivity and specificity by 
overlapping the G-quartet in a crescent shape (De Cian et al., 2007; Moruno-Manchon et al., 
2017; Rigo et al., 2016). PhenDC3 has also not been linked to DNA damage response like PDS. 
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Each of these three drugs was shown to induce BU1 instability in the DT40 system and was 
therefore appropriate for trial in this thesis, with varying success as discussed in the results 
chapters. None of these drugs have the perfect properties for use in cell systems due to size, 
toxicity and specificity and a new drug was developed in an attempt to combat these issues 
(Guilbaud et al., 2017). While this is also discussed in the results chapters, it was not appropriate 
to use in either human or mouse system. 
 
1.2.5 Hydroxyurea induced nucleotide pool depletion 
Replication stress induced by nucleotide pool imbalance, for example using the addition of 
hydroxyurea (HU), can lead to a decrease in the DNA polymerase speed leading to a local 
uncoupling of the polymerase and DNA helicase (Byun et al., 2005; Pacek and Walter, 2004; 
Papadopoulou et al., 2015), as mentioned in the BU1 assay. HU induces ribonucleotide 
reductase (RNR)-inhibition and a depletion of dNTPs. This uncoupling leads to formation of 
regions of ssDNA and usually activation of DDR checkpoints (Byun et al., 2005; Pacek and 
Walter, 2004). Using the BU1 assay, it was shown that chronic, low doses of HU gave rise to 
stochastic loss of expression of BU1. First the loss of the active chromatin marks H3K4me3 
and H3K9/14ac and then the appearance of the repressive mark H3K9me3 and the DNA 
damage marker γH2A.X (Papadopoulou et al., 2015). 
 
1.3 The DNA damage response 
Replication impediments cannot be discussed without focus on the DNA damage response 
(DDR), and its importance in all cells including during differentiation. Thousands of lesions are 
formed in the DNA in every human cell each day as a result of endogenous and exogenous 
damage as well as errors during DNA replication (Lindahl and Barnes, 2000), as discussed in 
reference to G4s. These structures must be repaired to enable processivity of the replication and 
transcription machinery, as well as to allow faithful transmission of genetic information to the 
next generation. Cancer is a fundamental example of the result of this process going wrong. 
There are many forms of environmental DNA damage humans expose themselves to including 
ultraviolet (UV) light, being commonly known to cause skin cancer in humans, and tobacco, 
which can cause lung cancer. 
 
In order to deal with these various forms of DNA damage, cells have evolved the DDR whereby 
cells are able to detect damage, signal that they are damaged and repair the damage to the 
greatest extent possible at the time. DNA damage arises in the DNA in a range of forms due to 
29 
 
the range of DNA damaging agents, and the type of damage necessitates the type of repair 
required.   
 
1.3.1 The DDR in somatic cells 
1.3.1.1 DNA repair pathways 
There are three pathways that can be used to repair DNA damage on one strand of the DNA. 
Base-excision repair (BER) allows the removal of a non-helix distorting, damaged base from 
the DNA throughout the cell cycle. The base is recognised by a DNA glycosylase that removes 
the base, leaving an AP site which is cleaved by an AP endonuclease. The single stranded gap 
can be filled in using long (two to ten nucleotides) or short patch (single nucleotide) repair with 
a polymerase and ligase (reviewed by David et al., 2007; Hoeijmakers, 2001). On the other 
hand, nucleotide excision repair (NER) is able to recognise helix-distorting lesions and acts via 
two pathways, transcription-coupled NER and global-genome NER (reviewed by Hoeijmakers, 
2001). These pathways act in a similar manner to BER but require the excision a larger region 
of DNA, 22-30 nucleotides. Mismatch repair (MMR) detects mismatches of bases in the DNA 
as well as insertions and deletions and repairs the bases (reviewed by Jiricny, 2006). 
 
When a double strand break ensues, there are two key mechanisms controlling the repair 
processes: non-homologous end-joining (NHEJ) and homologous recombination (HR) 
(reviewed by Lieber, 2008; San Filippo et al., 2008). These two strategies compensate for one 
another but offer the cell differing levels of accuracy and therefore are employed to different 
levels in each cell type. The phase of the cell cycle also controls the choice of pathway in the 
cell. Due to the higher accuracy of HR, this is most frequently used in stem cells in order to 
maintain fidelity. 
 
In standard NHEJ, the Ku70/Ku80 heterodimer recognises DSBs in the DNA and activates 
DNA-PKcs. When classic NHEJ is not active there are two other pathways that can be used: 
microhomology-mediated end-joining (MMEJ) and alternative end-joining (AEJ) but these are 
always error-prone (McVey and Lee, 2008). These pathways are active throughout the cell 
cycle as they do not require a homologous DNA template. This is on the contrary to HR, which 
requires a sister-chromatid and therefore can only occur in S and G2 phases of the cell cycle. 
HR starts with the creation of ssDNA using the MRN complex, and then the DNA invades the 
undamaged template using RAD51, BRCA1 and BRCA2 (San Filippo et al., 2008). HR can 
also be used to repair interstrand crosslinks with the help of the Fanconi Anaemia pathway 
(Kennedy and D’Andrea, 2005). 
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1.3.1.2 Types of DNA damage 
While there are many forms of DNA damage that cause distinct lesions in the DNA and 
therefore recruit different repair factors and cause the activation of different pathways, the main 
forms of DNA damage dealt with in this thesis are those induced with G4-binding ligands, UV 
irradiation, methyl methanesulfonate (MMS) and hydroxyurea. As discussed previously, some 
G4 ligands have been shown to induce DNA damage in the form of DSBs, possibly at the 
location of the G4s they bind (Rodriguez et al., 2012), but this is not thought to be a general 
feature of these ligands.  
 
Ultraviolet damage induces two mutagenic, cytotoxic lesions in the DNA: cyclobutane-
pyrimidine dimers (CPDs) and 6-4 photoproducts (6-4PPs) (Yagura et al., 2011). Most UV 
damage is repaired using the NER mechanism described above. Two human diseases with 
mutations in the NER pathway, Xeroderma pigmentosum (XP) and Cockayne’s syndrome (CS), 
display increased sensitivity to UV light (Cockayne, 1946; Hebra F, Fagge CH, 1874).  
 
MMS is an alkylating agent which modifies guanine, adenine and cytosine to 7-methylguanine, 
1-methyladenine, 3-methyladenine and 3-methylcytosine respectively. The modified guanine 
causes base mispairing whereas adenine induces replication blocks (Beranek, 1990). The 
damage induced by MMS is repaired using the BER pathway, described above, and the action 
of DNA alkyltransferases (Lindahl and Wood, 1999).   
 
HU was also used in a manner to induce chronic replication stress but is also able to induce 
DNA damage in cells. HU acts as an inhibitor of RNR, thereby exerting its effects on nucleotide 
pool depletion (Shao et al., 2004). However, it is now thought to induce damage including base 
oxidation and depurination (Sakano et al., 2001). These are important considerations when 
using the drug in biological systems, especially as it is used in the treatment of many diseases 
and as a chemotherapeutic agent. 
 
1.3.2 Checkpoint activation after DNA damage 
In order for the cell to process and deal with DNA damage, it must activate the DNA damage 
checkpoint in order to induce a DDR and repair the damage. It is essential for the cell to control 
this checkpoint to maintain the genetic identity of the cell, and to switch it off when the repair 
has occurred so as to allow the cell to re-enter the cell cycle. These control pathways are 
incredibly important as seen by the number of human diseases associated with mutations in 
DDR genes (Ciccia and Elledge, 2010). This pathway acts to reduce CDK activity in order to 
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slow down or inhibit cell cycle progression at the G1/S, S and G2/M checkpoints in the cell 
cycle. It also regulates DNA repair, and when the level of damage is too high, senescence or 
apoptosis (Kruse and Gu, 2009). The DDR is also suggested to induce cellular differentiation 
as a mechanism to protect the organism, probably to protect from the cancer stem cell 
phenotype. 
 
Three members of the phosphatidylinositol-3-kinase-like kinase family control these signalling 
pathways, ATM, ATR and DNA-PK, and they phosphorylate vast numbers of proteins to induce 
a response (Matsuoka et al., 2007). These proteins act in concert with the checkpoint protein 
kinases that they activate, CHK1, CHK2 and MK2 (Liu et al., 2000; Matsuoka et al., 1998; 
Reinhardt et al., 2007) (Figure 8).  
 
Figure 8. The canonical roles of ATM and ATR 
kinases in the DNA damage response. Double 
strand breaks activate ATM causing its 
phosphorylation, it is subsequently able to 
phosphorylate and activate a number of 
downstream proteins causing the cell cycle to be 
halted. 
 
 
ATM is recruited to DSBs whereas ATR acts on a larger range of damage that cause ssDNA 
coated with the single stranded DNA binding protein RPA (Zou and Elledge, 2003). ATM is 
recruited to DSBs by the MRN complex (Lee and Paull, 2005; Uziel et al., 2003) and 
phosphorylates a range of proteins, including H2A.X, CHK2, BRCA1 and p53 in order to 
induce a response (Banin et al., 1998; Canman et al., 1998). The phosphorylation of H2A.X 
occurs minutes after damage and rapidly spreads over hundreds of kilobases of DNA, this helps 
to recruit DNA repair proteins and chromatin remodellers (Meier et al., 2007; Savic et al., 
2009). Both ATR and ATM appear to be required for DSB repair, suggesting they have non-
redundant functions (Brown and Baltimore, 2003; Wang et al., 2004). 
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ATM is not an essential protein in mice or humans but ATR is, as shown by embryonic lethality 
in mice and attempted knockouts in human cell lines (Brown and Baltimore, 2000, 2003; Cortez 
et al., 2001; de Klein et al., 2000). It is suggested that ATR may protect the genome constantly 
during DNA synthesis through the regulation of nucleotide levels, origin firing, fork 
progression and control of movement through the cell cycle (Byun et al., 2005; Lopes et al., 
2006). ATM and ATR kinases show significant crosstalk in the DDR, for example ATR is also 
able to phosphorylate H2A.X and recruit ATM (Ward and Chen, 2001), and ATM is able to be 
phosphorylated by ATR directly, inducing its activation (Stiff et al., 2006). 
 
1.3.3 The DNA damage response in differentiation 
The work in this thesis examines the role of the DDR in pluripotent cells and during 
differentiation. While this process has not been studied exhaustively in this context, there is 
literature suggesting that proteins regulating the DDR may play a role in normal differentiation 
(Fujita et al., 2008; Oka et al., 2019; Sherman et al., 2011; Weiss and Ito, 2015). There is also 
significant evidence that stem cells process damage in a different way to somatic cells 
(Cervantes et al., 2002)(reviewed by Vitale et al., 2017), as would be expected from the nature 
of this cell type. Maintaining cells in an undifferentiated state after DNA damage has occurred 
is often preferred due to the higher level of DNA damage repair factors and increased 
homologous recombination (Momcilovic et al., 2010; Tichy et al., 2010). The importance of 
DDR factors during differentiation is discussed below. 
 
1.3.3.1 Histone variants required during differentiation 
There are a number of non-canonical histone variants that are used only in certain cases in the 
cell. The phosphorylation of histone variant H2A.X has been implicated in stem cell self-
renewal in mESCs and miPSCs, however it is not clear whether this is also the case in human 
cells (Turinetto et al., 2012). These γH2A.X foci did not correlate with any DDR factors such 
as 53BP1 and RPA, and decreased on differentiation (Banáth et al., 2009). Previous groups 
have highlighted H2A.X during the EMT (Singh et al., 2015; Weyemi et al., 2016a). Singh et 
al describe H2A.X phosphorylation, by ATM kinase on the canonical serine-139, and how this 
is required to induce HMGA2 transcription. H2A.X has the interesting property that its 
phosphorylation acts to destabilise the nucleosome and impair the H1 histone from binding (Li 
et al., 2010). This is important for the binding of HMGA proteins described in this paper as this 
family competes with H1 for binding to linker DNA, also loosening the chromatin (Catez et al., 
2004; Kishi et al., 2012). In a separate study, Weyemi et al show that loss of H2A.X in the 
MCF10A and HCT116 cell line activates the EMT program (Weyemi et al., 2016a, 2016b). 
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Taking these two results together suggests that unphosphorylated H2A.X maintains the cells in 
an epithelial state. While H2A.X mice are viable, they display a number of abnormalities 
including growth retardation and immune deficiency, as well as male mice being infertile 
(Celeste et al., 2002). 
 
The proposed phosphorylation of histone H2A.X at the EMT is associated with mass 
transcriptional activation caused by transcription factors binding and mediating this transition 
(Singh et al., 2015). However, recent data from the Rosenberg group focusing on Escherichia 
coli has shown that transcription factor binding is a sufficient block to induce replication fork 
stalling and reversal, leading to DNA damage at these transcription factor binding sites (Xia et 
al., 2019). The tight interplay between H2A.X controlled gene expression and DNA damage 
makes it hard to decipher whether this phosphorylation is able to induce transcription or whether 
transcription factor binding induces phosphorylation by activating the DDR or a non-canonical 
pathway. 
 
As discussed previously, H2A.X plays a role in the DDR and can be phosphorylated at serine-
139 by ATM, ATR or DNA-PK upon checkpoint activation. This could suggest that checkpoint 
activation, the EMT and chromatin modifications are linked in some manner. 
 
H2A.Z, encoded by H2AFZ in humans, has been shown to act as a regulator of the epithelial 
mesenchymal transition (Domaschenz et al., 2017), discussed in reference to definitive 
endoderm differentiation. Mice deficient in this protein die early in development, suggesting 
this is needed during embryonic development (Faast et al., 2001). Many histone variants have 
been shown to be required in differentiation, H3.3 has been shown to be needed for maintenance 
of the pluripotent state in ESCs (reviewed by Meshorer and Misteli, 2006). It is also interesting 
to note that ‘poised’ gene promoters, thought to be particularly important in embryonic 
differentiation, are often nucleosome-free or marked with unstable nucleosomes H3.3 and 
H2A.Z (Jin et al., 2009).  
 
1.3.3.2 The role of p53, p63 and p73 in differentiation 
p53, p63 and p73 are members of a family of transcription factors, first discovered for acting 
as tumour suppressors and controlling cellular stress, known to play key roles in the 
undifferentiated state, initiation of differentiation and EMT. The p53 protein acts to sense and 
respond to damage by inducing cell cycle arrest or apoptosis through transcription of multiple 
transcripts, downstream of the checkpoint kinases (Lane, 1992). While this family of proteins 
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have a high level of sequence similarity, especially in the DNA binding domain, they are not 
totally redundant. Genetic knockouts of Trp53 in mice and TP53 in human cell lines are viable, 
suggesting that this protein is not required in differentiation (Donehower, 1996). On the 
contrary, Xenopus embryos depleted of p53 cannot complete gastrulation (Wallingford et al., 
1997). These differences may be explained at least in part by the availability of family members 
to take over as no triple knockout in mice or human has been reported. 
 
In somatic cells, the level of p53 is kept low and this is controlled by the E3-ubiquitin ligase 
MDM2 (Oliner et al., 1992). MDM2 null mice do not survive development in the embryo, 
suggesting the importance of the tight control of p53 levels during development, and these mice 
can be rescued by genetic knockout of Trp53 (Jones et al., 1995; de Oca Luna et al., 1995). This 
suggests that p53 must be downregulated during development. The canonical DDR causes 
phosphorylation of p53 on serine-15, in human cells, usually by ATM kinase (Banin et al., 
1998; Canman et al., 1998; Khanna. et al., 1998). However, there are a vast number of PTMs 
associated with p53 controlling its activity (reviewed by Gu and Zhu, 2012). 
 
The total level of p53 protein in the embryo, and in mES cells, has been shown to be high, 
whereas that of p63 and p73 vary depending on the culture conditions (Lin et al., 2005; Lutzker 
and Levine, 1996; Shigeta et al., 2013). Recent work has shown that the p53 family is important 
for coordination of signalling pathways controlling mesendoderm differentiation by performing 
triple knockouts in both mouse and human ES cells (Wang et al., 2017). They show that the 
decision for a cell to differentiate down the mesendoderm pathway is controlled by the p53 
family: the p53 family activates specification genes by inducing expression of genes including 
Wnt3 and Fzd1. WNT goes on to activate TCF3 which, with SMAD 2/3, binds to enhancers of 
mesendoderm genes and activates their transcription, thus controlling the exit from 
pluripotency. This clearly shows that the p53 family are required, if redundantly, in embryonic 
development. Interestingly, this group show that many of the genes upregulated by p53 in 
mESC differentiation are also transcripts associated with the DDR, including p21 (Wang et al., 
2017). 
 
This connection between Wnt signalling and p53 has been previously shown in mESCs, and 
has been related to the role of p53 in responding to DNA damage (Lee et al., 2010). 
Phosphorylation of p53 at serine-315 has also been implicated in the control of Nanog 
expression in mESCs, in order to induce differentiation pathways after DNA damage (Lin et 
al., 2005). 
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p53 has been shown to play a role in the control of the EMT: the data suggested that p53 binds 
to the promoter of miR-200c and miR-183 activating their transcription and controlling 
expression of EMT specific genes (Chang et al., 2011). They also show that overexpression of 
TP53 reverts the mesenchymal phenotype to epithelial. Therefore, p53 is needed to initiate the 
EMT program but evidence suggests that it is then downregulated by MDM2 to allow 
completion of this transition (Araki et al., 2010). Another study suggested a more direct 
interaction in the EMT: TWIST1 binds the p53 C-terminus and this allows MDM2 degradation 
of p53 (Piccinin et al., 2012). Therefore, p53 is upregulated in the ground state but is 
downregulated during the EMT such that it should decrease throughout endoderm 
differentiation after its initiation. It is important to note that in these instances it is the total level 
of p53 protein, and not the post-translational modifications that change. 
 
Interestingly, the TP53 transcript has been shown to contain an RNA G-quadruplex (Marcel et 
al., 2011; Wanrooij et al., 2010). The authors suggest that the G4 sequence in intron three of 
TP53, controls splicing choice and therefore the particular p53 isoform produced. Similarly, 
NRAS and BCL-X contain RNA G4s (Burley et al., 2017; Kumari et al., 2007). 
 
Finally, p53 has also been shown to be vital in controlling the methylation state of mES cells 
in the naïve ground state (Tovy et al., 2017). They show that p53 deficient mES cells do not 
maintain the hypomethylation required of the ground state due to the control of DNMT3A, 
DNMT3B, TET1 and TET2 enzymes by p53. The lack of p53 causes an imbalance of the 5mC 
and 5hmC marks, increasing the methylation in mES cells and increasing heterogeneity DNA 
methylation (Tovy et al., 2017). 
 
1.3.3.3 The role of caspases in differentiation 
Recent work has suggested that cellular differentiation and cell death share many features, 
suggesting a common pathway in cardiac differentiation (Ghiasi et al., 2018). Differentiation 
to a number of cell types including skeletal muscle cells, erythrocytes and Drosophila sperm 
has been shown to induce caspase activity (Arama et al., 2003; Fernando et al., 2002; Zermati 
et al., 2001). This study by Ghiasi et al shows an increase in reactive oxygen species (ROS), 
p53 and APAF-1 cell death protein during differentiation. They also describe membrane 
potential loss, PARP-1 cleavage and  cytochrome c release, all indicative of a cell death 
response (Ghiasi et al., 2018). Each of these features occur in apoptosis but during cardiac 
differentiation they occur to lower, reversible levels. They suggest that the timing and intensity 
of these processes are likely to determine whether cell death or differentiation is the outcome. 
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Other studies have suggested that although ROS increase during differentiation, the ability for 
cells to deal with this damage is decreased, therefore the ability for cells to process damage may 
decrease during differentiation (reviewed by Hirano and Tamae, 2012). 
 
1.3.4 The importance of DDR proteins during development 
Genetic knockout of CHEK1 (Liu et al., 2000), ATR (de Klein et al., 2000), BRCA1, BRCA2 
and RAD51 (Lim and Hasty, 1996) often leads to embryonic lethality in mice. Whereas genetic 
knockout of TP53 (Donehower, 1996), ATM (Barlow et al., 1996) and CDKN1A (Martín-
Caballero et al., 2001) lead to spontaneous tumour formation. While this does not immediately 
link these DDR proteins to being essential during development, it does suggest that they could 
play a role in unchallenged differentiation. Interestingly, the Rad51 knockout mouse develops 
further upon additional knockout of Trp53 suggesting that these proteins need to be kept in 
check during differentiation (Lim and Hasty, 1996). 
 
Finally, the DSBs have been shown to control the expression of neuronal early-response genes 
(Madabhushi et al., 2015). This activity-dependent DSB formation is suggested to be induced 
by Topoisomerase IIβ relieving topological constraints. This highlights the importance of the 
DDR on gene expression and the interplay of these fields. 
 
1.3.5 Replication stress in development 
1.3.5.1 Ultrafine anaphase bridges 
Regions in the genome which are hard to replicate can cause the generation of ultrafine 
anaphase bridges (UFBs). These UFBs need to be resolved for correct chromosome segregation 
at cell division and this occurs using the protein PICH (Biebricher et al., 2013). They normally 
form at locations of repetition in the DNA, such as rRNA, telomeres and centromeres, or fragile 
sites (Nielsen and Hickson, 2016). Unpublished work by Kamikawa and Tsubouchi looking at 
UFBs in mES cells showed that there were actually fewer in these ES cells, suggesting again 
that these cells are able to deal with fast replication accurately. Mouse knockouts of Pich show 
that it is embryonic lethal, meaning that the removal of these structures occurs frequently in ES 
cells and it is necessary for them to be removed (Eliene Albers et al., 2018). 
 
1.3.5.2 DNA origin firing 
Due to the rapid cycling of embryonic stem cells they must have tightly regulated control of 
DNA replication. Origin licencing is under tight control in ES cells to help maintain 
pluripotency. In human ES cells the G1 phase of the cell cycle is very quick compared to 
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somatic cells, around 2.5 hours, and this has been suggested to maintain pluripotency (Kareta 
et al., 2015; Soufi and Dalton, 2016). G1 phase is also when cells respond to differentiation 
cues, therefore ES cells must integrate numerous signals quickly at this point (Gonzales et al., 
2015). A study on the licensing factor MCM loading onto DNA has shown that rapid loading 
is needed for pluripotency and prevents differentiation (Matson et al., 2017). 
 
MCM2-7 complexes are loaded onto chromatin in excess and these excess complexes normally 
do not get fired and are therefore called dormant origins (Ge et al., 2007). However, during 
replication stress these provide a backup for the cell. These dormant origins are considered to 
play a role in defence against this stress in ES cells as many more of these are recruited (Ge et 
al., 2015). 
 
1.3.5.3 Replication fork speed changes during differentiation 
Throughout cellular differentiation many aspects of DNA replication are altered including 
changes to origin choice and timing. However, it has also been found that the global fork speed 
increases dramatically on erythroid differentiation (Hwang et al., 2016). The authors show that 
this switch is mediated by CDK activity and this causes an increase in fork speed and a decrease 
in the length of S phase. 
1.4 Aims 
The aim of this thesis was to be able to understand whether replication impediments could 
impact differentiation from embryonic stem cells. Previous work in the group has shown that 
replication impediments can perturb the deposition of histone marks onto the appropriate 
regions of the DNA and this causes changes to gene expression. However, since all of this work 
so far has been performed in the terminally differentiated chicken DT40 cell line it is important 
to show whether this model is consistent with other systems, especially cellular differentiation. 
 
Embryonic differentiation is an incredibly important process and it is kept in check by a large 
number of mechanisms in very varied pathways. Therefore, it could be that the cell has multiple 
mechanisms for dealing with replication stress and that this same phenomenon is not seen 
during the differentiation of ES cells. However, it is compelling to suggest that there may be a 
role due to the many changes occurring, especially epigenetically in the control of gene 
expression, during this process. 
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Initially I set up systems to differentiate both mES and human iPS cells. These differentiation 
protocols were chosen due to a combination of high efficiency, knowledge of the pathways 
controlling differentiation, defined protocols and a sufficient number of cell cycles to reveal 
this replication dependent phenomenon. After validation of the systems I focussed on the hiPSC 
model of differentiation to definitive endoderm which yielded a high differentiation efficiency. 
I mainly monitored the differentiation efficiency using permeabilised flow cytometry which 
gave a clear readout of differentiation on a single-cell basis. 
 
In order to perturb replication, I used ligands that stabilise a specific secondary structure in the 
DNA, the G-quadruplex, DNA damage inducing agents, nucleotide pool depletion and iPSCs 
with genetic knockouts of enzymes known to help in the processing of G-quadruplexes in the 
DNA. 
 
Throughout this thesis I have shown that each of these individual factors was able to alter the 
differentiation to definitive endoderm. Each altered the differentiation efficiency, level of cell 
death, and activation of DDR factors to varying extents. I observed very different responses in 
the undifferentiated state compared to during differentiation when replication was altered. 
These changes were probed in further detail using RNA sequencing to enable a greater 
understanding of the pathways affected. 
 
DNA damage in the form of UV irradiation or MMS treatment decreased the efficiency of 
differentiation while showing a block in G2/M phase of the cell cycle: the efficiency of 
differentiation negatively correlated with the dose of DNA damaging agent. Interestingly, the 
analysis of inflicting damage throughout differentiation led me to understand that changes to 
the levels of proteins in the DNA damage response occur during differentiation. When DNA 
damaging agents were added, the levels of p53 increased resulting in increased cell death and 
a lower efficiency of differentiation. 
 
I have also shown that G-quadruplex-binding ligands were able to alter the course of 
differentiation, either by a p53-dependent mechanism or by a separate, possibly G-quadruplex 
specific, mechanism. This also occurred in REV1 knockout cells, a polymerase known to play 
a role in G-quadruplex processing. G-quadruplex stabilisation during differentiation prevented 
definitive endoderm specification. I also suggest that the G4 ligand Pyridostatin inhibits 
differentiation in a manner specific to inducing DNA damage, and that this is not the case with 
an alternative ligand, PhenDC3. 
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Chapter 2. Materials and Methods 
2.1 Cell Culture 
2.1.1 Mouse embryonic stem cell culture 
2.1.1.1 Basic cell culture 
The cells used were a kind gift from Edith Heard who had analysed X-chromosome inactivation 
during embryogenesis by differentiating these cells from the ground state to the epiblast stem 
cell stage (EpiSC) (Schulz et al., 2014). PGK12.1 cells were cultured in DMEM medium 
supplemented with 15% decomplemented ES -FBS (Gibco), 0.1 mM -2-mercaptoethanol 
(Sigma), 1000 U/mL mouse leukaemia inhibitory factor (LIF) (Miltenyi) and PenStrep. E14 
cells were maintained in Glasgow medium supplemented with 15% decomplemented ES-FBS 
(Gibco), 0.1 mM -2-mercaptoethanol (Sigma), 1000 U/ mL mouse leukaemia inhibitory factor 
(LIF) (Miltenyi), 0.1 mM MEM non-essential amino acids (Gibco), 1 mM sodium pyruvate 
(Gibco), 2mM Glutamax and PenStrep. Cells were grown in an incubator (37C, 5% CO2) on 
24 well or six-well plates (Costar) coated in 0.1% gelatin (Sigma) in 2 – 4 mL medium and 
passaged every two-three days. Cells were washed with 1 mL PBS before splitting and then 
incubated at 37C (5 min) with 1 mL ES-trypsin. Cells were resuspended in medium and plated. 
Cell medium was replaced every day.  
 
2.1.1.2 Two inhibitor culture 
Cells were adapted to LIF and 2i culture medium over a number of passages by changing the 
medium and splitting using accutase (Gibco) instead of trypsin. Medium consisted of N2B27 
supplemented with 1000 U/mL LIF, 3 µM GSK3 inhibitor CHIR99021 (Tocris) and 1 µM MEK 
inhibitor PD0325901 (Syn Kinase). N2B27 medium contained 50% Neurobasal medium 
(Gibco), 50% DMEM/F12 (Gibco) supplemented with 2 mM Glutamax (Gibco), 0.1 mM β-2-
mercaptoethanol, NDiff Neuro2 supplement (Millipore) and B27 serum free supplement 
(Gibco). 
 
2.1.1.3 Differentiation 
In order to induce differentiation, mES cells cultured on LIF and 2i were passaged onto plates 
coated in Fibronectin (10 µg/mL) in N2B27 media supplemented with 10 ng/mL FGF2 (R&D) 
and 20 ng/mL Activin A (R&D). Initial cell density was around 8×104 cells/cm2. 
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2.1.1.4 Freezing and thawing 
Frozen cells were thawed in the bead bath until just a small ice crystal was left and then added 
to 10 mL warm serum containing LIF medium. Cells were centrifuged (290 g, 5 min), 
supernatant was removed, and cells were resuspended in 5 mL medium. Cells were plated as 
serial dilutions onto precoated gelatin-coated 24 well plates and put into the incubator. Cells 
were frozen from 24 well plates by removing cell culture medium, washing with PBS and 
adding 350 µL ES-trypsin. Cells were put into the incubator until all clumps were single cells 
(2-5 min) and checked under the microscope. Cells were resuspended and added to 150 µL 
medium without LIF and transferred to a cryovial, 500 µL 2X freezing medium (90% ES-
FBS/10% DMSO) was added and the cells were frozen slowly at -80⁰C using Mr. Frosty™ 
freezing container. After eight hours the cells were transferred to the liquid nitrogen for long 
term storage. 
 
2.1.1.5 Mycoplasma testing preparation 
Mycoplasma testing was performed once a month by the LMB mycoplasma testing service in 
all mouse and human cell lines. Mouse lines were grown without antibiotic for three days before 
testing. One mL of spent cell culture media that had not been changed for at least 24 hours was 
removed from three wells of each cell line, placed in a 15 mL tube and centrifuged (200 g, 5 
min). One mL of supernatant per sample was placed in a sterile Eppendorf® and stored at 4C 
until testing. Cells remained mycoplasma negative throughout the project. 
 
2.1.2 Human induced pluripotent stem cell culture 
2.1.2.1 Basic cell culture 
The BOBSC cells (Yusa et al., 2011) were obtained from the Sanger Centre. Knockout BOBSC 
lines were generated as part of the COMSIG (Causes of Mutational SIGnatures) project, funded 
by the Wellcome Trust, using a CRISPR/Cas9 strategy in which one allele was disrupted by 
gene targeting and the other by error-prone repair (Table 1). All cells, including knockouts, 
were cultured in Essential 8™ or Essential 8™ Flex medium on six-well plates coated in 
Vitronectin-XF (Stem Cell) kept at 37⁰C, 5% CO2 unless otherwise stated. Cells were passaged 
1:10 every three or four days depending on confluency. Cell media was aspirated and one mL 
of 0.5 mM EDTA (Thermo Fisher Scientific) was washed over the cells. The cells were left at 
room temperature in fresh EDTA for five minutes before the EDTA was removed and the cells 
were blasted with media to remove them from the plate before being transferred to a new plate. 
Cells were maintained as small clumps. 
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Cell line Code Barcode Targeting 
Wildtype BOBSC T6/8 B1 BOBSC-T6/8_B1 n/a 
REV1 KO HUFP0046_1_A_B06 1095802743 Exon 12 
WRN KO HUFP0034_1_A_E06 1095778295 Exon 12 
PRIMPOL KO HUFP0046_1_A_C02 1095802750 Exon 5 
TP53 KO HUFP0007_3_A_H04 1095765195 Exon 6 
ATM KO HUFP0029_1_B_A12 1095717002 Exon 7 
Table 1. hiPS cell lines used throughout the project, the knockout cell lines were generated by the Sanger Centre 
COMSIG project. Specific targeting information can be found in: 
https://www.sanger.ac.uk/htgt/lims2/public_reports/well_genotyping_info_search. 
 
2.1.2.2 Endoderm differentiation   
Cells were passaged 1:8 onto vitronectin coated six-well plates one day prior to setting up 
endoderm differentiation. On day one of differentiation, cell media was changed to CDM-PVA 
supplemented with 100 ng/mL Activin A (R&D), 80 ng/mL FGF2 (R&D), 10 ng/mL BMP4 
(R&D), 10 µM PI3K inhibitor LY294003 (Promega) and 3 µM GSK3i CHIR99021 (Tocris) 
(initially Selleckchem, but this was found to be unreliable). On day two, cell medium was 
replaced with CDM-PVA supplemented with Activin A, FGF2, BMP4 and LY294003 as above. 
CDM-PVA consisted of 50% Ham’s F-12 (Gibco) and 50% IMDM (Gibco) supplemented with 
1 g/L PVA (Sigma), 1 mM concentrated Lipids (Life technologies), 0.5 mM Thioglycerol 
(Sigma), 15 µg/mL Transferrin (Roche) and 7 µg/mL Insulin (Roche). The PVA solution was 
first made up in MPW by heating to 90⁰C whilst stirring. The stirring was continued overnight, 
while cooling, to ensure the powder was dissolved. On day three, the media was replaced with 
RPMI+ supplemented with 100 ng/mL Activin A and 80 ng/mL FGF2. RPMI was 
supplemented with 1 mM NEM-NEEA (Gibco) and B27 supplement. Recombinant proteins 
were added at concentrations stated in the main text: Cerberus 1 (R&D), Lefty-A (R&D). 
 
2.1.2.3 Neuroectoderm differentiation 
Cells were set up for neuroectoderm differentiation in a similar manner to definitive endoderm 
differentiation, cell media was changed every day. On day one and two cells were cultured in 
CDM-PVA, as above, supplemented in FGF2 (20 ng/mL), CHIR99021 (3 µM), LDN-193189 
(0.1 µM) (EZSolution Source Bioscience) (Selleckchem was used initially but yielded poor 
results) and SB431542 (10 µM) (Tocris). From day three to six, cells were cultured in N2B27 
medium, as before, with 10 µM SB431542. From day seven onwards, cells were kept in N2B27 
until analysis. 
 
42 
 
2.1.2.4 Freezing and thawing 
hiPSCs were thawed as above for mESCs but resuspended in 3 mL Essential 8™ medium and 
plated on precoated vitronectin six-well plates at 1 mL per plate. One well of cells was frozen 
by removing medium, washing with EDTA and adding 1 mL EDTA (5 min, RT). EDTA was 
aspirated, clumps of cells were resuspended in 500 µL DMEM medium and 500 µL 2X freezing 
medium was added as in mES cells. Cells were frozen in Mr. Frosty™ and then transferred to 
liquid nitrogen. 
 
2.1.3 Human embryonic stem cell culture 
The H9 hES cells were provided by the lab of Madeline Lancaster (MRC LMB). They were 
cultured, frozen, thawed and differentiated as above for BOBSC cells. 
 
2.1.4 Treatment of cells 
2.1.4.1 G-quadruplex-binding ligands 
When cells were cultured in the presence of G4 ligands, the ligands were thawed, vortexed due 
to their poor solubility and added to medium. This ligand-containing medium was vortexed 
again before being added to cells. If the cells were to be kept in ligands for over a week the 
medium was filtered to prevent contamination. 
 
2.1.4.2 DNA damaging agents 
DNA damaging agents were added as for ligands, but in the case of MMS it was first diluted 
1000X in cell medium and vortexed before being added to cells at the correct concentration. 
 
2.1.4.3 UV irradiation 
The UV-C source was turned on 30 min prior to use to stabilise. Bulb output was assessed with 
a calibrated UV-C meter (UVP Inc) and length of time for a given dose was calculated (0.5-20 
J/cm2). Cells media was removed and replaced with 1 mL PBS per well. The lid of the plate 
was removed, and cells were transferred to the UV box, the shutter was opened for the time 
required at that given dose and then shut. Cell media was replaced, and cells were returned to 
the incubator. This was only performed in six-well plates. 
 
2.1.4.4 Cell counting 
Both mouse and human cells were counted using the Countess Cell Counter (Thermo Fisher) 
‘ES’ cell program to analyse the viability and number of cells. 
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2.1.4.5 Dead cell removal 
Dead cells were removed from non-adherent samples using the MACS dead cell removal kit 
(Miltenyi Biotec). Cells were centrifuged (300 g, 5 min), resuspended in 100 µL microbeads 
and incubated (RT, 15 min). The MACS columns were put into the magnetic rack and 500 µL 
binding buffer was run through the column. Once most of the buffer had eluted, a new 15 mL 
falcon tube was placed under the column. 500 µL binding buffer was added to the cells and 
magnetic beads and this was added to the column. The flow through was collected in the falcon 
tube and the column was washed three times with 500 µL binding buffer to collect the last cells. 
Binding buffer (500 µL) was added to the column and flushed with the plunger, and the eluate 
was thrown away. The tube containing the alive cells was spun down (300 g, 5 min) and 
collected for permeabilised flow cytometry, Section 2.3. 
 
2.2 Western blotting 
2.2.1 Protein extraction 
Medium from one well of a six-well plate was aspirated and one millilitre of single cell 
dissociation buffer (Gibco) was added (37⁰C, 10 min). Cells were transferred to an Eppendorf®, 
centrifuged (1500 g, 4 min) and aspirated, leaving the cell pellet. Cells were washed twice in 
500 µL PBS and then resuspended in 100 µL roughly per 1×106 cells RIPA buffer (Cell 
Signalling) containing cOmplete™ protease inhibitor (Roche) and phosphatase inhibitor Halt™ 
(Thermo Scientific) 1X. Tubes containing cells and buffer were rotated slowly (4⁰C, 1 h) and 
then transferred to a cold centrifuge (16,000 g, 4⁰C). The supernatant (protein) was transferred 
to a clean tube, care was taken not to disturb the DNA pellet at the bottom. 5X Laemmli buffer 
(Sigma) was added and the protein was boiled (95⁰C, 5 min). Protein was stored at -20⁰C until 
use. 
 
2.2.2 SDS-PAGE gel electrophoresis 
2.2.2.1 Bis-Tris gel 
Protein was thawed on ice until liquid and was then run on a NuPAGE® Bis-Tris 4-12% precast 
gel (Thermo Fisher) unless stated otherwise. The gel was set up and 1X MOPS buffer (50 mM 
MOPS, 50 mM Tris, 0.1% SDS, 1 mM EDTA, pH 7.7) was added (300 mL) to fill the central 
well and half of the remaining tank. 10 µL PageRuler™ prestained protein ladder (Thermo 
Fisher) was added to one well per gel and 20 µL of each protein sample was added to the 
remaining wells. The gel was electrophoresised (120 V, 2 h) until the 10 kDa marker had almost 
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reached the bottom of the gel. The gel was removed from the casing and put into DI water until 
the transfer. 
 
2.2.2.2 Tris-Acetate gel 
Tris-Acetate gels were run when the proteins were to be transferred using a wet transfer system. 
The system was set up as above but using a NuPAGE® 3-8% tris acetate gel and run in 
NuPAGE® 1% tris acetate SDS running buffer. The gel was either run as above or for ATM 
(40 V, 4⁰C, overnight). 
 
2.2.3 Protein transfer 
2.2.3.1 Semi-dry transfer 
Semi-dry transfers were performed using the iBlot® 2 system (Thermo Fisher) using iBlot® 2 
transfer stacks. Gels were put into the transfer cassette on top of the nitrocellulose membrane 
followed by two pieces of wet Whatman™ paper, bubbles were removed, and the top stack 
added. The iBlot® was sealed and proteins were transferred (25 V, 7 min) to the nitrocellulose 
membrane. The membrane was put into deionised water, cut to size and stained with Ponceau 
S (15 s, RT, rotating). The membrane was washed twice and blocked. 
 
2.2.3.2 Wet transfer 
Wet transfer was only performed for proteins that did not give a signal using the semi-dry 
system, including phospho-p53 and ATM. The XCell II™ Blot Module was used for the 
transfer process and performed in NuPAGE® Transfer Buffer containing 10% methanol. The 
system was set up as in in the manual, with a nitrocellulose membrane for transfer and proteins 
were transferred (25 V, 2 h, 4⁰C). 
 
2.2.4 Western blotting 
2.2.4.1 Blocking 
The membrane was blocked in 5% milk (Marvel) in 1X TBST (150 mM NaCl, Tris HCl pH7.4 
10 mM, 0.1% tween) (1 h, RT, rotating). The membrane was then probed with antibodies. 
 
2.2.4.2 Antibody staining 
Primary antibodies were added as stated in Table 2 below. Membranes were incubated with 
primary antibody overnight, rotating at 4C unless otherwise stated. The membrane was washed 
three times for 5-15 minutes while rotating at room temperature with 1X TBST. The membrane 
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was then blotted with secondary antibody (1 h, RT, rotating). All secondary antibodies were 
HRP-conjugated (Dako P0447-9) used at 1:5000 dilution. The secondary antibody was washed 
as for the primary antibody and then the HRP was visualised. 
 
2.2.4.3 Visualisation 
The membrane was transferred to a clean piece of plastic and 3 mL HRP substrate (Millipore 
Luminata Crescendo) was added for five minutes then removed and the membrane was 
transferred to a cassette. The blot was revealed in the dark room for five seconds to 15 minutes, 
depending on the strength of the protein band, and then processed on a film developer. Standard 
protein sizes were marked on and bands were compared to expected sizes. 
 
Protein epitope Dilution Catalogue 
no. 
Manufacturer Species 
H2A.X (ser139) JBW301 1:5000 05-636  Merck 
Millipore 
Mouse 
p53 (DO-1) 1:1000 Ab1101 Abcam Mouse 
p-p53 Ser15 1:1000 9284 CST Mouse 
PC10 1:5000 SC-56 Santa Cruz Mouse 
TUBULIN (B512) 1:10000 T6074 Sigma Mouse 
-ACTIN 1:20000 Ab8227 Abcam Mouse 
pCHK1 Ser345 (133D3) 1:1000 113D3 CST Rabbit 
CHK1 1:1000 Ab40866 Abcam Mouse 
pRPA32 (S33) 1:1000 A300-246A Bethyl Rabbit 
RPA32 1:2000 A300-244A Bethyl Rabbit 
H2A.X total 1:1000  2595S CST Rabbit 
MDM2 (SMP14) 1:200 SC-965 Santa Cruz Mouse 
pCHK2 1:1000 2661 CST Rabbit 
CHK2 1:50000 Ab109413 Abcam Rabbit 
ATM 1:5000 Ab17995 Abcam Rabbit 
Table 2. A list of all primary antibodies used for western blotting. 
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2.3 Flow cytometry 
All cells were sorted for collection on the Beckman Coulter MoFlo by Maria Daly and the 
Flow Cytometry team at the LMB. Unless stated otherwise, flow cytometry was performed on 
the BD LSRFortessa, which is equipped with 405 nm, 488 nm, 561 nm and 640 nm lasers. 
Cells were monitored for GFP or antibody staining, combined with DAPI and analysed using 
FlowJo®, LLC. Where possible 100,000 cells were analysed. 
 
2.3.1 GFP monitoring 
In the GFP-tagged mESCs, cells were analysed for GFP in the LIF, 2i and EpiLC states. Cells 
were washed with PBS and incubated with ES-trypsin at 37⁰C until the cells were in a single 
cell suspension. The cells were transferred to a 15 mL falcon tube with 5 mL warm cell culture 
medium, centrifuged (300 g, 5 min), washed with 5 mL PBS and spun down again. The cell 
pellet was resuspended in 500 µL warm medium and transferred to flow cytometry tubes 
(Sarstedt) to be analysed for GFP. 
 
2.3.2 Permeabilised flow cytometry 
Around 1×106 cells were collected to be analysed by permeabilised flow cytometry for each 
condition. Cell media was aspirated and one millilitre of Cell Dissociation Buffer (Thermo 
Fisher Scientific) was added for ten minutes at 37⁰C. The cells were collected, transferred to an 
Eppendorf® and centrifuged (1500 g, 4 min). The cell pellet was fixed in 200 µL 1% PFA for 
human cells or 4% PFA for mESCs (10 min, RT) and centrifuged (1500 g, 4 min). The pellet 
was resuspended in 200 µL of 90% PBS/10% DMSO and kept at -80⁰C until preparation for 
flow cytometry. 
 
Fixed cells were thawed at room temperature for ten minutes, spun down (1500 g, 4 min), 
aspirated and resuspended in 200 L 1XBD Perm/Wash buffer. Half of the volume of a 
positive control sample was transferred into a new tube for the IgG control, all tubes centrifuged 
(1500 g, 4 min), and resuspended in 100 L BD buffer. Cells were permeabilised and blocked 
(15 min, RT) and spun down for antibody staining: either primary followed by secondary or 
conjugated antibody staining (see below). Mouse cells were permeabilised in 0.1% PBS-tween 
(20 min, RT) and then blocked in 0.1% BSA/10% normal goat serum/0.3 M glycine (1 h, RT) 
prior to antibody staining (see below). 
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2.3.2.1 Primary and secondary antibody staining 
Cells were resuspended in 100 L anti--H2A.X antibody (1:500) (Merck Millipore 05-636) 
(ab2893 and ab11174 Abcam rabbit antibodies were also used when combining staining with 
other mouse antibody combinations) (4C, overnight) or IgG control without antibody. Cells 
were spun down (1500 g, 4 min), washed in BD buffer twice and resuspended in secondary 
antibody (1:200) (1 h, RT, dark). Cells were spun down and washed, as above, and resuspended 
in 400 L PBS/BSA 0.5% with 1 g DAPI per sample. Cells were transferred to flow cytometry 
tubes and covered from light until analysis on the BD LSRFortessa. 
 
A number of other antibodies were used in a similar manner as shown in Table 3 below; all 
primary antibodies were used at 1:500 and all secondaries (Invitrogen Alexa Fluor) at 1:200 
unless otherwise stated. 
 
Protein Primary Antibody Secondary Antibody 
H2A.X 
(ser139) 
Merck Millipore 05-636 Ms 
Abcam ab2893 Rb 
Abcam ab11174 Rb 
Alexa Fluor 488 A10680 Gt  Ms 
Alexa Fluor 594 A21207 Dk  Rb 
Alexa Fluor 594 A21207 Dk  Rb 
H2A.X Cell Signaling (CST) 2595 Rb Alexa Fluor 594 A21207 Dk  Rb 
p53 Santa Cruz DO-1 sc-126 Ms Alexa Fluor 488 A10680 Gt  Ms 
REX1 Abcam ab28141 Rb Alexa Fluor 568 A11011 Gt  Rb 
DNMT3A Abcam ab13888 Ms Alexa Fluor 647 A21234 Gt  Ms 
pRPA32 (S33) Bethyl A300-246A Rb Alexa Fluor 594 A21207 Dk  Rb 
Table 3. A list of primary and secondary antibodies used in combination for permeabilised flow cytometry. 
 
2.3.2.2 Conjugated antibody staining 
Cells were resuspended in 100 L BD buffer containing 4 L conjugated antibody, or 
appropriate isotype control, per reaction and incubated in the dark (1 h, RT). Cells were washed 
once in BD buffer, spun down (1500 g, 4 min) and resuspended in 400 L PBS/BSA 0.5% with 
1 g DAPI per sample. Cells were transferred to flow cytometry tubes and analysed as above. 
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Protein Conjugated Primary Antibody 
SOX17 BD Pharmingen 562205 Alexa Fluor 488 Ms 
EOMES Invitrogen 50-4877-42 eBioscience eFluor 660 Ms 
p53 Santa Cruz P53 DO-1 sc-126-PE PE conjugated  
PAX-6 BD PharmingenAlexa Fluor 647 Ms 562249 
SOX1 BD Pharmingen 561549 PerCP-Cy5.5 Ms  
Table 4. A list of conjugated antibodies used for permeabilised flow cytometry. 
2.3.3 Cell death staining 
In order to determine whether cells, that had lost adherence to culture plates, were apoptotic, 
necrotic or still alive, cells were stained using the FITC Annexin V Apoptosis Detection Kit 
with 7-AAD (Biolegend®). Cell supernatant or adherent cells were collected, transferred to a 
falcon tube and spun down (300 g, 4 min). Cells were washed twice in Cell Staining Buffer and 
then resuspended in 100 µL Annexin V Binding Buffer per well of a six-well plate. The cells 
were added to a flow cytometry tube, 5 µL FITC Annexin V and 5 µL 7-AAD was added. Cells 
were vortexed and incubated in the dark (RT, 15 min). 400 µL Annexin V Binding Buffer was 
added to each tube and the cells were analysed using flow cytometry. 
 
2.3.4 Live cell sorting 
Mouse ES cells were sorted for live cells expressing GFP by Maria Daly and the MRC LMB 
flow cytometry team. Cells were washed with PBS, trypsin was added (37⁰C, 2-5 min) until 
single cells could be seen. Cells were added to 5 mL warm culture medium, spun down (290 g, 
7 min), washed in PBS and spun down again. Cells were resuspended in 1 mL warm medium 
and 1 mL PI solution (15 µg/mL PI in 2.5% FBS/PBS). The solution was transferred through a 
strainer to remove clumps into a sorting tube and taken to be sorted for GFP positive, PI 
negative populations. 
2.4 Cell cycle Analysis 
2.4.1 EdU visualisation 
2.4.1.1 EdU Click-iT® kit 
The kit was prepared as stated in the EdU Click-iT® protocol but the EdU was made up in 
MPW instead of DMSO. 
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2.4.1.2 EdU staining 
Cells at around 30% confluency had 25 µM EdU per well of a six-well plate (or adjusted 
accordingly) added to cell culture medium and incubated for one hour at 37⁰C. The cells were 
then collected and fixed with 1% PFA as above in the permeabilised flow cytometry Section 
2.3.2. 
 
2.4.1.3 Click-iT® reaction 
Cells were thawed at room temperature until liquid, spun down (1500 g, 4 min) and resuspended 
in 100 µL BD buffer (above). Cells were centrifuged again and resuspended in 100 µL BD 
buffer (RT, 15 min) to permeabilise and block. The cells were spun down and resuspended in 
125 µL Click-iT® reaction buffer as in the kit (containing CuSO4 and fluorescent azide) for 30 
minutes in the dark at room temperature. The cells were then centrifuged, and the pellet 
resuspended in 1.5 µg RNaseA, 1 µg DAPI in BD buffer per condition and left (RT, 30 min or 
overnight, 4⁰C) until the cells were analysed by flow cytometry. Cells could also be stained for 
permeabilised flow cytometry before being resuspended in the final buffer. 
 
2.4.2 Cell division mapping 
To trace the number of cell cycles that had occurred, the CellTrace™ Violet Cell Proliferation 
Kit (Invitrogen™) was used.  
 
2.4.2.1 Set up of CellTrace™ 
20 µL of DMSO was added to the tube of fluorophore and this was added to 20 mL of warm 
PBS to make a 5 µM solution. Cell media was removed from each well of a six-well plate and 
cells were incubated with 1.5 mL of solution per well (37⁰C, 20 min). The cells were washed 
twice with warm media and then returned to the incubator until analysis. Control cells were 
collected just after setting up to compare the initial fluorescence. 
 
2.4.2.2 Visualisation  
Cells were collected as with permeabilised flow cytometry and stored until analysis in order to 
analyse multiple timepoints and conditions at once. Cells could be permeabilised to combine 
with any permeabilised flow cytometry staining and then analysed using flow cytometry. 
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2.4.2.3 Analysis 
Cells should lose half of the fluorescence for each cell division as this is proportional to the 
amount of dye in each cell. Therefore, comparing the fluorescence of the cells collected at the 
start and end of differentiation allowed the number of cell divisions to be quantified using 
Equation 1.  
𝑁 =
log (
𝐶𝑜
𝐶𝑡)
log 2
 
Equation 1. The formula for the number of cell divisions (N) in a CellTrace™ experiment where C0 is the 
fluorescence at time 0 and Ct is the fluorescence after N cell divisions. 
 
2.4.3 Quantification using FlowJo® software 
Cells collected for permeabilised flow cytometry were stained with DAPI to analyse the DNA 
content of the cells using the violet V-450 laser. The population of cells in each phase of the 
cell cycle was quantified using the ‘Cell Cycle’ function in the FlowJo® flow cytometry 
analysis software. This gives a crude representation of the percentage of cells in G1, S or G2/M 
phase.  
 
2.4.4 Cellular synchronisation 
Cells were blocked in prometaphase using 200 ng/mL nocodazole (Sigma) for 16 hours. Cells 
were released by washing once with DPBS and twice with warm medium. Cells were then either 
differentiated or kept in the undifferentiated state. 
 
2.5 RNA analysis 
2.5.1 RNA extraction 
Before RNA extraction, pipettes and bench space were cleaned with RNaseZAP® (Thermo 
Fischer) to remove any RNase contamination and filter tips were used throughout the extraction 
process. RNA extraction was performed using the RNeasy® Qiagen RNA extraction kit. 
Medium was aspirated from adherent cells and replaced with 600 µL RLT buffer containing β-
mercaptoethanol. Cells were resuspended in buffer and transferred to sterile Eppendorf® tubes. 
At this stage cells could be kept at -80⁰C or extracted for RNA immediately. Extraction was 
performed as stated in the protocol but without the initial spin to remove debris. RNA was 
eluted into 30 µL nuclease free water and 1 µL was analysed on the nanodrop to check the RNA 
concentration and for contamination with DNA or protein. RNA was stored at -80⁰C. 
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2.5.2 Reverse transcription  
RNA was reverse transcribed to DNA using Qiagen QuantiTect® reverse transcription kit using 
800 ng RNA. The initial gDNA wipeout was performed (42⁰C, 2 min) and the reverse 
transcription (42⁰C, 25 min). cDNA was stored at -20⁰C for up to 48 hours before quantitative 
(qPCR) was performed. 
 
2.5.3 Quantitative PCR 
2.5.3.1 Primer design 
Primers for qPCR were designed using the Primer3web software with an amplicon size of 100-
180bp and an optimum melting temperature of 60C for control, pluripotency, mESC and 
EpiLC transcripts as well as hiPS cell differentiation transcripts. Where possible, primers were 
designed to amplify across intronic regions to prevent gDNA contamination, biasing the results. 
Primer sequences are shown in Table 5, Table 6 and Table 7. 
 
2.5.3.2 Primer validation 
Primers were validated using qPCR amplification across a range of cDNA dilutions: 1:4, 1:16, 
1:64, 1:256 and a no template control. The qPCR mastermix was made up of 50% SYBR® 
Green Mastermix (Applied Biosystems), 10 µM forward (Fwd) and 10 µM reverse (Rv) primer 
and 10% diluted cDNA in DEPC. Reactions were set up on a 96 or 384-well optical plate in 20 
µL volumes in triplicate and sealed with optical film. The plate was spun down (3220 g, 1 min) 
and run on a ViiA7™ real-time system for 45 cycles (hold stage: 50⁰C, 2 min and 95⁰C, 10 min 
and PCR stage: 95⁰C, 15 s and 60⁰C, 1 min). The melt curve was analysed for each primer pair 
to check the amplification and the efficiency of the primers was calculated using Equation 2 
below; if the efficiency was between 90-105 then the primers were able to be used in 
experiments. 
 
𝑬𝒇𝒇𝒊𝒄𝒊𝒆𝒏𝒄𝒚 =  1 + 2
−1
𝑑𝑦 𝑑𝑥⁄  × 100               90-105% 
𝑹𝟐  𝟎. 𝟗𝟖 
Equation 2. Used to determine the efficiency of a set of qPCR primers. If the efficiency was between 90 and 105% 
and the R2 value above 0.98 then the primers could be used to quantify gene expression. 
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2.5.3.3 Primers for qPCR 
The primers used in mouse and human cell lines are shown in Table 5, Table 6 and Table 7. 
 
Transcript Fwd Primer: 5’-3’ Rv Primer: 5’-3’ 
β-actin CTT TGC AGC TCC TTC GTT GC CGA TGG AGG GGA ATA CAG CC 
Gapdh GCA TCT TCT TGT GCA GTG CC ATG AAG GGG TCG TTG ATG TGG C 
Oct4/Pou5f1 AGC ACG AGT GGA AAG CAA CT TCT GCA GGG CTT TCA TGT CC 
Nanog TTC TTG CTT ACA AGG GTC TGC AGA GGA AGG GCG AGG AGA 
Sox2 GCG GAG TGG AAA CTT TTG TCC GGG AAG CGT GTA CTT ATC CTT CT 
Gbx2 GCT TTC TCT GCG GCC GAA AAG CTC TCC TCC TTG CCC TT 
Rex1/Zfp42 TGG GTA CGA GTG GCA GTT TC CCA CGT GTC CCA GCT CTT AG 
Stella/Dppa3 GAC CCA ATG AAG GAC CCT GAA GCT TGA CAC CGG GGT TTA G 
T/Brachyury CTC TCT CTC CCC TCC ACA CA ACT GCA GCA TGG ACA GAC AA 
Nodal TCA AGC CTG TTG GGC TCT ACT GTC AAA CGT GAA AGT CCA GTT CT 
Fgf5 ACG AGG AGT TTT CAG CAA CA CCA CTC TCG GCC TGT CTT TT 
Table 5. A list of qPCR primers to amplify mouse transcripts during EpiLC differentiation. 
 
Transcript Fwd Primer: 5’-3’ Rv Primer: 5’-3’ 
PBGD GGA GCCA TGT CTG GTA ACG G CCA CGC GAA TCA CTC TCA TCT 
GAPDH TCA CCA GGG CTG CTT TTA ACT GAC GGT GCC ATG GAA TTT GC 
-ACTIN CGC GAG AAG ATG ACC CAG AT ATC ACG ATG CCA GTG GTA CG 
HPRT1 AGG CTT TGG ACG GCC TCT GGA A CGA ATG ACA CCG TAC TCC TCA TAG AAG CT 
POU5F1 AGT GAG AGG CAA CCT GGA GA ACA CTC GGA CCA CAT CCT TC 
SOX2 TGG ACA GTT ACG CGC ACA T CGA GTA GGA CAT GCT GTA GGT 
NANOG CAT GAG TGT GGA TCC AGC TTG CCT GAA TAA GCA GAT CCA TGG 
FOXH1 GAT CGC CTT GGT GAT TCAG TTC CAG CCC TCG TAG TCTT C 
MIXL1 GGT ACC CCG ACA TCC ACT TG TAA TCT CCG GCC TAG CCA AA 
NODAL TGA GCC AAC AAG AGG ATC TG TGG AAA ATC TCA ATG GCA AG 
EOMES ATC ATT ACG AAA CAG GGC AGG C CGG GGT TGG TAT TTG TGT AAG G 
GSC GAG GAG AAA GTG GAG GTC TGG TT CTC TGA TGA GGA CCG CTT CTG 
T  TGC TTC CCT GAG ACC CAG TT GAT CAC TTC TTT CCT TTG CAT CAA G 
SOX17 CGC ACG GAA TTT GAA CAG TA GGA TCA GGG ACC TGT CAC AC 
Table 6. A list of qPCR primers used to analyse the BOBSC differentiation to definitive endoderm. 
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Transcript Fwd Primer: 5’-3’ Rv Primer: 5’-3’ 
GAPDH TCA CCA GGG CTG CTT TTA ACT GAC GGT GCC ATG GAA TTT GC 
-ACTIN CGC GAG AAG ATG ACC CAG AT ATC ACG ATG CCA GTG GTA CG 
REV1 CGT GGC TTG GAT AGA CCA ACG TTT ACC CTT CAT GCC AGT 
WRN CCA GCA CCC AAT GAA GAG CA GCC ATG ACA GCA ACA TTA TCT CT 
PRIMPOL GAG CAA AGC AGT CCT GAC CT GTA ACC TCC AAA GCC ACA CG 
Table 7. A list of qPCR primers used to verify COMSIG BOBSC knockout cell lines. 
 
2.5.3.4 RNA expression quantification 
Once the primers had been validated as efficient, cDNA from cells cultured in each condition 
was diluted 1:5 and the reaction was set up as above for primer validation. Once the CT values 
had been obtained, gene expression was normalised to the geometric mean of the control genes, 
using the GEOMEAN function on Excel, and a relative expression value produced. 
 
2.6 Next generation sequencing 
2.6.1 RNA sequencing 
2.6.1.1 RNA extraction 
RNA was extracted as in Section 2.3.1 and then quantified using the nanodrop to verify that the 
concentration was high enough to use and that there was no protein or DNA contamination. 
RNA was collected from separate samples on the same day to minimise variation in culture 
conditions, while this makes it easier to analyse this leads to some caveats in understanding the 
significance of specific numbers of genes, the broad picture should be the same. 
 
2.6.1.2 RNA quality analysis 
To check the quality of RNA it was run on an Agilent RNA Pico 6000 chip using an Agilent 
2100 Bioanalyzer. The RIN score was deduced and RNA with a score above seven was used to 
generate RNA libraries. 
 
2.6.1.3 RNA library preparation 
750 ng of RNA was diluted into 50 µL DEPC water and kept on ice. RNA libraries were 
prepared using the NEBNextUltraII RNA library preparation kit (E7770) and PolyA tail 
isolation with eight PCR cycles and the NEBNext Oligos 1-24 and then stored at -20⁰C until 
analysis. 
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2.6.1.4 RNA library quality assessment 
One µg of each prepared library was run on an Agilent 2100 Bioanalyzer High Sensitivity DNA 
chip and the electrogram was analysed for shape of the graph and the average size of each 
library (bp): the library was checked for primer (~80 bp) and adapter (~128 bp) contamination 
and any libraries with high content were re-purified. Once the libraries were of high enough 
quality they were quantified. 
 
2.6.1.5 Library quantification 
Libraries were quantified using the KAPA Library Quantification Kit Illumina®. Libraries were 
serial diluted to 1:100,000 and 1:1,000,000 in 10 mM Tris-HCl pH 8.0 and quantified in 
triplicate as stated in the protocol using the Rox-low buffer for the ViiA7 qPCR system. Melt-
curves for the libraries were also analysed to assess the quality of the libraries. Average CTs 
were transferred to the KAPA quantification excel spreadsheet with standard values and the 
concentration of each library was calculated.  
 
2.6.1.6 Library pooling 
After quantification, libraries created with different NEBNext Oligos were pooled to a total 
concentration of 20 nM in 10 mM Tris-HCl pH 8.0. Between 12 and 18 libraries were pooled 
for each sequencing lane in order to give at least 100,000 reads per library. The pooled library 
was run on a High Sensitivity DNA chip, as above, and the average size of the library calculated 
before sending to sequencing. 20 µL of pooled library was handed to CRUK Genomics Core 
and sequenced on a HiSeq4000 machine with single end reads.  
 
2.6.2 Chromatin immunoprecipitation (ChIP) sequencing 
Protocol for ChIP taken from Davide Schiavone, former member of the Sale lab. 
 
2.6.2.1 Cell collection and crosslinking 
hiPS cells were cultured in 15 cm dishes for ChIP and DT40 cells used as a ‘spike-in control’ 
were cultured by Benedicte Recolin in the lab and treated with 2 mM HU for 16 hours before 
collection. When the cells were ready to be collected, one dish of cells was counted and on the 
other six dishes the medium was removed and replaced with 20 mL DPBS. Plates were taken 
to the fume hood, 600 µL formaldehyde (final concentration of 1%) (Santa Cruz) was added 
and plates were incubated (RT, rotating, 10 min). To quench the reaction 2 mL of 2 M glycine 
was added (0.2 M final concentration) (RT, rotating, 5 min) and the cells were cooled in plates 
(10 min, 4⁰C). Cells were scraped off the plates, transferred to 50 mL falcon tubes and spun 
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down (400 g, 5 min, 4⁰C). Formaldehyde-containing medium was disposed of appropriately 
and the cell pellet was washed with 10 mL cold PBS. Cells were spun down (400 g, 5 min, RT) 
and the washing was repeated. The PBS was removed, the cell pellet was snap frozen in liquid 
nitrogen and kept at -80⁰C until cell lysis was performed. 
 
2.6.2.2 Cell lysis 
Cells were thawed on ice, resuspended in 10 mL of ChIP lysis buffer (10 mM tris pH 7.5, 10 
mM NaCl, 3 mM MgCl2, 0.5% NP40, 0.5 mM PMSF), incubated (RT, 5 min) and spun down 
(200 g, 5 min). This was repeated twice, and the cells were either snap frozen as above or 
continued to be sonicated. 
 
2.6.2.3 Sonication 
Cells were resuspended in sonication buffer (1% SDS, 10 mM EDTA, 50 mM tris pH 8, 1X 
PIC, 0.5 mM PMSF) at 40,000 cells/µL and then kept on ice for 30 minutes with occasional 
vortexing until sonication. Cells were aliquoted into 1.5 mL tubes with 400-600 µL in each 
tube, and the same volume in each tube per sonication. Cells were sonicated using the Bioruptor 
using 30 cycles (30 s on / 30 s off, high power, 4⁰C). Cells were removed from the Bioruptor, 
100 L was transferred to a new tube to analyse sonication efficiency and the remainder was 
snap frozen in liquid nitrogen. 
 
2.6.2.4 Analysis of sonication efficiency 
100 µL MPW, 8 µL of 5 M NaCl and 2 µL 10 mg/mL RNase A were added to each of the 
sheared chromatin samples to analyse the sonication efficiency. The cells were vortexed and 
incubated with shaking overnight (65⁰C, 300 rpm). Tubes were briefly centrifuged, 10 µL of 10 
mg/mL Proteinase K was added and the cells were incubated (42⁰C, 1.5 h). The samples were 
then electrophoresed with loading dye on an 1.5% agarose gel (90 V, 1.5 h) with 1 Kb plus 
DNA ladder (Thermo Fisher). The DNA fragment size was analysed and checked for 500 bp 
fragments. 
 
2.6.2.5 Immunoprecipitation 
Chromatin was thawed, diluted in 3 mL dilution solution (1.1% triton X-100, 1.2 mM EDTA, 
16.7 mM tris pH 8, 167 mM NaCl, 1X PIC, 0.5 mM PMSF) and the human chromatin was 
spiked with 1:10 DT40 chromatin. 50 µL was removed and stored at -20⁰C for total input 
sequencing. The diluted chromatin was aliquoted at 1 mL per 1.5 mL tube and 2 g of antibody 
was added: H3 (Abcam ab1791) or γH2A.X (Abcam ab2893). The tubes were sealed with 
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parafilm and kept at 4⁰C rotating overnight. Protein G magnetic beads were added to the tube 
with a cut pipette tip (30 L/tube). Tubes were sealed in parafilm and incubated with tumbling 
(4⁰C, 1-2 h). The beads were separated on a magnetic rack and the liquid was removed. 750 L 
wash buffer one (0.1% SDS, 1% triton X-100, 2 mM EDTA, 20 mM tris pH 8 and 150 mM 
NaCl) was added per tube and the tubes were inverted 25 times to disperse the beads. The beads 
were separated on the magnetic rack as before, 750 L wash buffer two was added (0.1% SDS, 
1% triton X-100, 2 mM EDTA, 20 mM tris pH 8 and 500 mM NaCl) and the tubes were inverted 
25 times to disperse the beads as before. This was repeated with wash buffer three (1 mM 
EDTA, 10 mM tris pH 8, 1% NP-40, 1% sodium deoxycholate and 0.25 M LiCl) and wash 
buffer four (10 mM tris pH 8 and 1 mM EDTA). A short centrifuge was performed to remove 
the remaining liquid and the total inputs were thawed. Elution buffer (100 mM NaHCO3 and 
1% SDS) was added, at 150 L per sample or 100 L for inputs. RNaseA (20 g) was added 
to each sample and they were incubated in the thermomixer (1000 rpm, 65⁰C, overnight). The 
samples were removed from the thermocycler and treated with Proteinase K, as before, then 
incubated at 42⁰C for one hour. 
 
2.6.2.6 Phenol-chloroform extraction 
The extraction was performed in a fume hood. 150 L MPW followed by 300 L phenol-
chloroform was added to each tube, the tubes were shaken and spun down (16,000 g, 5 min, 
RT). The top, aqueous phase was transferred to a new tube (DNA lo bind), 300 L MPW was 
added, the tubes were shaken and spun down as before. Chloroform (550 L) was added to each 
tube, and the tubes were shaken and spun down again. The top phase was transferred to a new 
tube (DNA lo bind), 300 L MPW was added, shaken and spun down as before. The top phase 
was transferred to a new tube with 2 L glycogen and 0.5 M NaCl. One volume of isopropanol 
was slowly added to the top of the tube and the tubes were transferred to sealed Eppendorf® 
racks where the DNA precipitated (overnight, -20⁰C). The tubes were spun (16,000 g, 1 h, 4⁰C), 
the supernatant was removed and 150 L 70% ethanol was added. The tubes were centrifuged 
(16000 g, 2 min, 4⁰C), the supernatant was removed, and this was repeated. All ethanol was 
removed, the pellet was dried (5 min, RT) and resuspended in 10 L EB (Qiagen). 
 
2.6.2.7 Qubit fluorometric dsDNA quantification (Thermo Fisher) 
A working solution was made (199 µL dsDNS HS buffer, 1 µL Qubit dsDNA solution) for the 
number of samples to be tested. The standards were then prepared in Qubit dsDNA tubes (190 
µL working solution with 10 µL standard one or two) with the samples (199 µL working 
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solution, 1 µL sample) and these were vortexed and left at room temperature for three minutes. 
The standards were then read in the machine, followed by the samples which then had their 
concentration recorded. DNA libraries were then prepared. 
 
2.6.2.8 DNA library preparation 
DNA libraries were made using the NEBNext® Ultra™ II library prep kit (E7645) using 1 ng 
of starting DNA. Libraries were prepared as stated in the kit instruction manual using eleven 
cycles of PCR enrichment. The libraries were checked using the bioanalyzer, quantified using 
the KAPA system and sent for sequencing as explained in 2.4.1.4-6. 
 
2.7 Data analysis  
2.7.1 Analysis of sequencing data quality 
To assess the quality of the data sequences were analysed with FastQC v0.11.5 
(http://www.bioinformatics.babraham.ac.uk/projects/fastqc/). The FastQC report was checked 
for the per base sequence quality, per tile sequence quality, per sequence quality score, per base 
sequence content, per sequence GC content, per base N content, sequence length distribution, 
sequence duplication levels, overrepresented sequences, adapter content and K-mer content. If 
these were within the acceptable range for either RNAseq or ChIPseq data then the data was 
analysed further by the PNAC Bioinformatician at the MRC LMB, Alastair Crisp. Data was 
trimmed for adaptor sequences with a minimum quality threshold of 30 using TrimGalore 
v0.4.4 (https://github.com/FelixKrueger/TrimGalore). 
 
2.7.2 Performing differential expression analysis  
Trimmed reads were aligned to the Human genome version GRCh38.87 using TopHat v2.1.0 
(https://genomebiology.biomedcentral.com/articles/10.1186/gb-2013-14-4-r36), reads were 
quantified per genomic region and differential expression was calculated using Cufflinks v2.2.1 
(https://www.nature.com/articles/nbt.2450). Separately, a principle component analysis plot 
(PCA) for each experiment was produced using the TopHat alignment and DESeq2 v1.18.1 
(Love et al., 2014) and the similarity of each triplicate checked before further analysis. CuffDiff 
was used to calculate differential expression analyses, using a student’s t test and assuming a 
normal distribution T=(E[log(y)])/(Var[log(y)) where E is expression, Var is variance and y is 
the ratio of the normalized counts between the two conditions. The FDR was set to 0.05. Further 
analysis will compare the results of the Cufflinks and DESeq2 pipelines. 
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2.7.3 Analysing sequencing data 
All further analysis was performed by myself. Triplicate samples for each experiment were 
loaded into the PEAT analysis tool (https://github.com/lmb-seq/PEAT), generated by Alastair 
Crisp and Paula Freire Pritchett at the MRC LMB, for further analysis.  
 
Data was checked for differentially expressed genes and read counts, GO terms (gProfile) and 
TF binding sites (TRANSFAC geneXplain), and plots could be generated. Probability testing 
of enrichment analysis was performed using Benjamini Hochberg multiple testing.  
 
Significantly differentially expressed genes were taken to be transcripts that had a FPKM of  ≥ 
1 in each sample and a log2 fold change of one between samples. 
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Chapter 3. Results I: Setting up an in vitro 
system to study differentiation 
3.1  Mouse embryonic stem cells 
On initiating the project, I elected to use mouse embryonic stem cells (mESCs) to explore two 
different changes of state in cell culture. The two mouse ES cell lines used were the well-
established male E14 and female PGK12.1 lines (Hooper et al., 1987; Norris et al., 1994). Both 
are feeder-free, leukaemia inhibitory factor (LIF) dependent cell lines that can be cultured 
without feeders on gelatin-coated dishes. 
 
3.1.1 Culturing mESCs: the ‘gold standard’ 
Mouse ES cells can be maintained in either of the serum and LIF or 2i and LIF states although 
their gene expression profiles, epigenetic marks and morphology are remarkably different 
between the two. The interconversion between these two states is possible by switching the 
media in just a few passages. The transition between these states was monitored throughout the 
chapter, along with the transition to epiblast-like cells. 
 
3.1.2 Transition from mES cells to epiblast-like stem cells 
Prior to differentiating the mESCs, cells were grown in LIF and 2i containing culture medium 
for a few passages. Transferring the cells from serum to 2i was straightforward but the 
passaging of cells required optimisation to ensure the cells re-adhered after each passage. This 
could be helped by using specific culture dishes (Corning™ Costar™). Once mES cells were 
adapted to this state, they were differentiated to epiblast-like cells (EpiLC); this transition 
mimics the transition from the preimplantation embryo, mES cells, to the post-implantation 
embryo, EpiSCs. In this process, the cells transition from naïve pluripotency to primed 
pluripotency whereby one X-chromosome is inactivated in female cells and the cells become 
dependent upon Activin A and FGF2 (Nichols and Smith, 2009). Cells were cultured on 
fibronectin and N2B27 medium was supplemented with Activin A and FGF2 for at least three 
days prior to assessing the cells for loss of mES cell markers and gain of EpiLC gene expression: 
this transition took around five to six cell cycles and therefore would allow a replication-
dependent phenomenon to be shown. The transition between the two states was reversible 
within the first 24 hours, after which the cells lost the mES cell state markers and were 
committed to differentiation. Preliminary experiments showed that the viability of the cells, as 
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examined by the cell counter, was lower than expected. The number of cells plated before 
initiating differentiation was increased to over 1.6x105 cells per well of a six-well plate and this 
increased the cell viability to above 90 percent from 70 percent originally.  
 
3.1.3 Analysing differentiation efficiency of mESCs using qPCR 
Gene expression changes occurring during this transition were monitored using quantitative 
PCR (qPCR) which allows quantification of the mRNA levels of specific transcripts in the bulk 
population of cells over this period. Although the core trio of pluripotency genes, Pou5f1, Sox2 
and Nanog, remain expressed at relatively high levels from mESCs to EpiLCs, there are several 
genes that become downregulated on differentiation to the epiblast-like state (Guo et al., 2009). 
These genes include Zfp42, Esrrb, Dppa3 and Klf4; they are key transcripts to probe using 
qPCR to validate the system. As well as using the genes that will turn off over the course of a 
successful differentiation, it is important to look at genes that are switched on during this 
process. This gives a deeper knowledge into the direction of the differentiation, suggesting 
whether the cells simply lose pluripotency or whether they become specified down the EpiLC 
pathway. There are a number of genes that are upregulated at this transition including Nodal, 
brachury (T), Fgf5 and goosecoid (Gsc) (Guo et al., 2009). 
 
qPCR primers were designed for a selection of genes that would be differentially regulated 
during the differentiation: the primers needed to produce a 100-180 bp sequence when 
amplified. Where possible, this was designed over an intron such that only cDNA and not 
gDNA would be amplified. Housekeeping control genes were also picked to normalise the 
results to, however considering the nature of the differentiation some common ‘control’ genes 
were likely to alter significantly over this process. 
 
Preliminary results showed that the differentiation protocol was efficient: viewing cells down 
the microscope showed that the morphology was altered dramatically from forming small round 
colonies to producing individual cells with a flatter nature. RNA was collected in the mES and 
EpiL cell states and converted to cDNA before being quantified using qPCR (Figure 9). qPCR 
data showed that gene expression patterns had robustly changed in the direction expected during 
the differentiation for all genes apart from Nodal which showed no difference between the two 
states. However, one clear problem was that the two normalising genes initially being used, β-
actin and Gapdh, gave slightly different relative readouts, suggesting that these transcripts may 
also change expression during differentiation (Figure 9a and b). Gapdh was used to normalise 
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gene expression in all further experiments due to gene expression remaining most constant in 
the literature during mES cell differentiation (Murphy and Polak, 2002). 
 
Figure 9. qPCR data showing the 
differentiation of mESCs to EpiLCs. (a) 
E14 mES cells were cultured in 2i medium 
(E14 2i) before being differentiated to 
EpiLCs (E14 EpiLC), RNA was extracted 
in each stage and qPCR was performed. 
Gene expression was normalized to Gapdh. 
Mean±SD are plotted of three technical 
replicated of n=4 biological replicates. 
Multiple t tests used to calculated p<0.05 
marked with *. (b) as (a) but normalising to 
βactin n=2. (c) using PGK12.1 cells n=1 
biological replicates, error bars show 
technical replicates in this instance. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The PGK12.1 mES cells did not differentiate as efficiently as the E14 cells, as seen by the level 
of cell death and qPCR data (Figure 9c). Most experiments, especially those involving 
differentiation, were only performed in E14 cells in order to give the most reliable data. Most 
published experiments use only male cell lines and this may be in part due to the slower 
differentiation and altered gene expression profile of female cells containing two X-
chromosomes, due to the process of X-inactivation (Rastan and Robertson, 1985; Schulz et al., 
2014).  
(a) 
(b) 
(c) 
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3.1.4 DNA replication impediments during differentiation 
Having set up a system to study embryonic differentiation, the aim of the project was to assess 
whether problems during DNA replication could alter the course of differentiation. While there 
are numerous ways to cause replication impediment formation, I began by looking at G-
quadruplexes (G4s). There were two means by which I planned to do this: culturing cells with 
G4-binding ligands which are able to bind to transient G4s and stabilise them in the genome 
(De Cian et al., 2007; Guilbaud et al., 2017; Li et al., 1996; Rodriguez et al., 2012) and by 
producing genetic knockouts of enzymes known to be involved in processing G4s, likely 
increasing the persistence of the structures at the replication fork: Rev1-/-, Brip1-/- (Fancj) and 
Primpol-/- (Sarkies et al., 2012; Schiavone et al., 2014, 2016).  
 
3.1.4.1 G-quadruplex-binding ligands 
Initially, two G4-binding ligands were chosen to assess whether stabilising G4 secondary 
structures in the genome could alter the efficiency of differentiation: Pyridostatin (PDS) and 
PDC12. PDS was tested because it is frequently used in G4 experiments, has been well 
documented in the literature and has a high affinity for a broad range of G4s (Rodriguez et al., 
2008). However, it is also thought to induce DNA damage and therefore its effects on the cells 
may be broader than simply stabilising G4s (Rodriguez et al., 2012). PDC12 was used as it had 
been developed by the Balasubrumanian group as a PDS derivative and its in vivo G4 
stabilisation activity had been analysed by our lab (Guilbaud et al., 2017). It was shown to 
induce less toxicity and DNA damage in cells compared to previous G4 ligands, allowing them 
to be cultured for longer periods of time (Guilbaud et al., 2017; Rodriguez et al., 2012). 
However, as discussed later, there were numerous issues related to using this drug in mES cells, 
namely that it required much higher concentrations to induce an effect and was highly insoluble 
in DMSO, which in turn could lead to adverse effects on differentiation. I hypothesised that 
using these two ligands in parallel would allow us to gain insight into which effects may be 
specific to G4s. However, they may well bind to structurally different G4 structures: this is 
discussed in greater detail throughout the thesis. 
 
A range of concentrations of both drugs were tested on the cells to assess the toxicity to the 
mESCs and this was compared to the literature (Guilbaud et al., 2017).  PDC12 and DMSO 
were added to E14 and PGK12.1 cells cultured in the 2i state to analyse how these treatments 
affected the viability and doubling time of the cells at a range of concentrations after six days: 
0.3125 to 40 M (Figure 10). This shows that the cells exhibited similar viability and doubling 
times across the range of DMSO and PDC12 concentrations tested in the 2i state. PDS 
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concentrations were kept between 0.5 and 4 µM for all experiments but there was significant 
batch to batch variation in the drug, such that inducing the same effect often required slightly 
varying concentrations. The concentrations of PDC12 were initially kept between 10 and 20 
µM, which had been shown to exert a significant effect on the endogenous G4 in the BU-1 
locus, but were then increased up to 80 µM as minimal effects were induced. These 
concentrations meant the addition of large volumes of DMSO which, despite having little effect 
in DT40 cells (Guilbaud et al., 2017), were likely to affect differentiation to an extent itself; 
this will be discussed in greater detail with reference to the hiPS cell differentiation. Another 
issue that became noticeable with the PDC12 ligand was that it formed crystals ≥ 10 µM in all 
conditions tested. These crystals were large, and it was clear that the true concentration of drug 
in the media was significantly lower due to this crystallisation. The crystals could be removed 
by filtration but this did not overcome the concentration reduction. Although the following 
experiments were completed with both PDS and PDC12 in parallel, only the results with PDS 
will be discussed further due to the inconsistencies with PDC12 at high concentrations, and 
therefore large DMSO volumes, required to give a G4 specific effect. Another G4 ligand, NMM 
was used during the project when it was clear that the PDC12 was unreliable, and this is 
discussed throughout the chapter (Nicoludis et al., 2012). This ligand was used at concentrations 
between 0.5 and 4 µM, similarly to PDS, at a level that did not induce significant toxicity. 
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Figure 10. E14 and PGK12.1 mES cells were cultured in 2i medium for six days with either DMSO as a vehicle 
control or the G4 ligand PDC12 at concentrations from 0.312 to 40 µM. The number of live cells were counted 
using PI staining and this allowed the doubling time and the percentage of dead cells to be quantified. 
 
The setup of different experiments with the G4 ligands was able to address key questions 
(Figure 11):  
1. Can maintenance of the ground state be perturbed by G4 ligands and can this alter 
differentiation?  
2. Can perturbing the ground state and differentiation with G4 ligands alter the 
differentiation process?  
3. Can G4 ligands alter the differentiation process directly?  
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Figure 11. Schematic to show different targeting of the ligands in the undifferentiated state and during 
differentiation. (1) assessing whether culturing with ligands in the ground state can impair the ground state 
maintenance and the propensity to differentiate (2) assessing whether ligands in the ground state and during 
differentiation, impact differentiation (3) addition of ligands at the onset of differentiation to understand whether 
this can perturb differentiation. 
 
 
Can maintenance of the ground state be perturbed by G4 ligands? 
The initial experiment addressed whether maintaining the cells in the presence of G4 ligands in 
the 2i state could alter the expression of pluripotency markers. E14 and PGK12.1 cells cultured 
in the presence of ligands for three weeks were collected and RNA was extracted for qPCR 
analysis (Figure 12). It was clear that PDS treatment in both E14 and PGK12.1 cells, as well as 
NMM in the E14 cells, resulted in a decrease in pluripotency marker genes including Gbx2 and 
Zfp42. This suggested that either these drugs were able to alter the expression of pluripotency 
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genes in the ground state and this could alter the viability of the cells or they could alter the 
viability which could change the expression of pluripotency factors. However, whether these 
ligands were inducing a replication-dependent G4 effect could not be ascertained with this data. 
 
Figure 12. qPCR data normalised to Gapdh for pluripotency genes in mESCs cultured in 2i medium with and 
without the addition of G4 ligands for three weeks (a) E14 cells with 2 µM PDS (b) PGK12.1 cells with 2 µM 
PDS (c) E14 cells cultured with 2 µM NMM. Mean is plotted with error bars showing the standard deviation of 
technical triplicates and * denotes significance p<0.05 using multiple t testing.  
 
Can perturbing the ground state with G4 ligands alter the differentiation process? 
The next experiment aimed to probe whether altering the ground state using G4 ligands could 
change the efficiency of differentiation to EpiLCs. E14 mESCs were cultured with PDS for 
three weeks and then washed to remove the drug prior to differentiating the cells without the 
ligand. Cells were collected eight days after the induction of differentiation to EpiLCs, with and 
without PDS, and RNA was extracted for qPCR (Figure 13). This initial result suggested that 
culturing the cells in the ground state with the ligand altered the differentiation efficiency very 
little, however this experiment was performed using a low concentration of PDS, 0.5 µM, due 
to toxicity at high concentrations using this batch.  
 
 
 
 
 
(a) 
(b) 
(c) 
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Figure 13. qPCR data for pluripotency 
and EpiLC transcripts in E14 mESCs 
cultured with or without 0.5 µM PDS in 
the 2i state for three weeks before 
washing out the ligand and 
differentiating without PDS. Error bars 
are the standard deviation of technical 
triplicates. * denotes significance of 
p<0.05 using multiple t testing. 
 
 
 
Can G4 ligands in the ground state and during differentiation alter the differentiation 
process? 
The next experiment cultured the cells with ligand in the mESC state and then also 
differentiated the cells in the presence of the ligand. Cells were cultured with the ligand for 
three weeks and then differentiated in the presence of 2 µM PDS, RNA was collected after four 
days and qPCR was performed (Figure 14). The presence of PDS in the E14 cells did not 
significantly prevent upregulation of markers of EpiLCs. However, these treated cells did not 
show a significant decrease in mESC gene expression compared to untreated cells including 
Nanog, Zfp42, Gbx2 and Dppa3. This suggested that these cells may be remaining in a more 
pluripotent state and not differentiating. Together these experiments showed that G4-binding 
ligands were able to alter the pluripotent state and the efficiency of the differentiation process. 
However, since the qPCR experiments were performed only once the significance of this results 
cannot be confirmed using this method. The alkaline phosphatase assay could have also been 
used to analyse the cell state of the mES cells to confirm adequate differentiation. 
 
Figure 14. qPCR data normalised 
to Gapdh showing E14 cells 
grown in the undifferentiated state 
with 2 µM PDS for three weeks 
and then differentiated in the 
presence of the drug for four days. 
Error bars are the standard 
deviation of technical triplicates. * 
denotes significance of p<0.05 
using multiple t testing. 
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3.1.5 Single-cell analysis of differentiation efficiency 
While performing these qPCR experiments it was clear that there was not going to be a clear-
cut answer to the initial question: G4-binding ligands would not fully prevent differentiation, 
but they were likely to be altering the course to an extent. This approach for looking at the bulk 
population, while a good way for checking that the differentiation protocol was working 
successfully, was not going to allow us to view the results on a single-cell basis. If the changes 
being seen were replication-dependent, stochastic changes that were able to alter the epigenetic 
state of a cell, as previously described in the lab, then we would expect to see fluctuations in 
gene expression on an individual cell level (Sarkies et al., 2012). The simplest way to assess 
the differentiation in single cells would be using flow cytometry which is able to sort the 
fluorescence of each cell individually, and therefore monitor the gene expression at a cellular 
level. If these experiments were to be repeated, using single-cell RNA sequencing would have 
also been a very interesting approach, however at the point when these experiments were 
performed, we did not have the resources or bioinformatics power to perform this approach. 
 
3.1.6 Permeabilised flow cytometry to monitor differentiation 
Initially, permeabilised flow cytometry was performed using antibodies against REX1 as a 
marker of pluripotency, and therefore the mESC state, and against DNMT3A as a marker of the 
epiblast state. Cells maintained in the 2i state, as well as those in the EpiLC state, were collected 
and fixed, they were then permeabilised, stained for REX1 or DNMT3A protein expression and 
analysed using flow cytometry. The REX1 antibody did show a decrease in protein expression 
in the EpiLCs but there was not a complete separation between the two states (Figure 15a). The 
antibody against DNMT3A did show an increase in protein expression throughout the 
differentiation process as would be expected in a successful differentiation, but again there was 
not a clear separation between the cells cultured in 2i and the differentiated state, shown in 
Figure 15b, and this was not consistent between experiments. To give an insight into whether 
it was a problem with the differentiation or the antibody, Dnmt3a knockout mES cells known 
not to express protein (a kind gift from Gerry Crossan at the MRC LMB) were used to validate 
the antibody (Figure 15c). Despite the cells not being expected to express the protein, there was 
DNMT3A protein signal higher than the unstained secondary control, which should not have 
occurred. There was a difference between the knockout cells and differentiated cells but the 
difference was insufficient to see small changes: this antibody was not ideal for permeabilised 
flow cytometry and may well have been binding non-specifically. A number of optimisations 
were trialled but with no improvement to the results. Other research groups have tried to 
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optimise permeabilised flow cytometry for this cell state transition but have not found any 
successful antibodies for this. This approach was taken no further. 
 
 
 
 
 
 
 
 
Figure 15. Permeabilised flow cytometry data in E14 mESCs, data shown as histograms, repeats of different 
experiments are shown below giving the variability of this staining (a) staining for REX1 as a marker of the 2i 
state in cells grown in 2i (red) and EpiLCs (blue) (b) staining for DNMT3A as a marker of the EpiSC state in cells 
grown in 2i (red) and EpiLCs (blue) (c) staining for DNMT3A in EpiLCs (orange), Dnmt3a-/- EpiLCs (blue) and 
unstained cells (red). 
 
3.1.7 Gfp tagged genes to monitor pluripotency 
Another way to monitor expression on a single-cell basis was to use cells expressing 
fluorescently tagged pluripotency marker genes, such that they should be expressing GFP in 
mES cells but not in EpiLCs. The first cell line used was acquired from Austin Smith’s group: 
the pluripotency gene Zfp42 had been tagged with Gfp to monitor its expression during 
differentiation (Wray et al., 2011). The GFP used was a destabilised version (GFPd2) inserted 
into the Zfp42 locus of βcatfl/− E14 embryonic stem cells, using a less stable version meant 
that the protein did not remain in the cell for a long time after being synthesised. This was 
particularly useful during differentiation, allowing a decrease in expression to be seen 
quickly and giving an accurate readout for the gene expression of Zfp42. The other GFP-
tagged cell line was procured from Gerry Crossan, whereby the ES cells were derived from 
transgenic mice as described previously (Czechanski et al., 2014). The transgene was made 
using the BAC9 construct in which Dppa3 was tagged with an enhanced version of GFP 
(a) (b) (c) 
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(eGfp) before the 3’UTR and it was shown to behave in a similar manner to the endogenous 
gene (Payer et al., 2006).  
 
Preliminary experiments in both GFP marker cell lines showed a clear difference in expression 
when comparing cells cultured in 2i compared to differentiated cells, shown in Figure 16. 
However, there was a larger divide between the positive and negative populations in the Zfp42-
Gfp cell line, possibly due to the GFPd2 protein variant being expressed. I decided to continue 
the following experiments in the E14 Zfp42-Gfp cell line because this was in the same mouse 
ESC background as my previous experiments and the destabilised GFP gave a clearer 
separation between the two fluorescence profiles. E14 Zfp42-Gfp cells were cultured with G4-
binding ligands in the pluripotent mESC state; as previously, PDS and NMM were used during 
these experiments. 
 
 
Figure 16. Flow cytometry analysis of 
mESCs with pluripotency GFP 
reporters in the 2i (blue) and EpiLC 
states (orange) with control cells not 
expressing GFP (red) (a) Zfp42-Gfp (b) 
Dppa3-Gfp. 
 
 
 
 
Cells were cultured in the 2i state in the presence of either G4 ligands for three weeks and GFP-
fluorescence was monitored by flow cytometry: this was compared to untreated Zfp42-Gfp cells 
(Figure 17a and b). This shows that there was no difference in the GFP fluorescence in the 2i 
state of the cells grown with or without the drugs, suggesting that REX1 was not altered in the 
undifferentiated 2i state. Previous qPCR data suggested that there were small changes in the 
Zfp42 RNA in PDS and NMM treated cells in the 2i state, this will be discussed later. 
 
(a) (b) 
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Figure 17. Zfp42-Gfp E14 mESCs were monitored for GFP in the 2i or EpiLC states with or without 2 µM PDS 
or NMM (a) untreated cells in 2i (purple) and EpiLC state (green) (b) cells cultured in 2i with PDS (left panel) or 
NMM (right) for three weeks, untreated (red) and treated (blue) (c) cells were grown on ligands in 2i for three 
weeks and differentiated in the presence of drugs for three days as (b) (d) cells were differentiated with ligands 
without being grown on them in the 2i state as (b).  
 
The cells were also maintained in 2i with the drugs present and then differentiated with the drug 
to see whether this could alter the proportion of cells that lost GFP expression (Figure 17c). 
This experiment was repeated with the cells grown without drugs in the 2i state and then 
differentiated in the presence of the drug for 96 hours (Figure 17d). In each of the differentiated 
conditions the majority of the cells stopped expressing REX1-GFP and while this suggests that 
they may all have been differentiating well, REX1 was marking a loss of pluripotency rather 
than an end point of differentiation. While this experiment was only performed once and 
therefore the significance cannot be determined, the preliminary results suggested that there 
was not a difference. Therefore, a lack of GFP merely suggests that the cells have lost 
pluripotency. Interestingly, the mESCs were able to tolerate the ligands for much longer than 
the EpiLCs and could be maintained on them in both the 2i and serum conditions for up to three 
weeks. Whether the ligands were inducing genetic or epigenetic changes was unknown and this 
difference is discussed in greater detail in Results III with reference to the hiPSCs which 
showed the same trend. 
 
As this assay only gives a read-out for the loss of pluripotency and not the efficiency of 
differentiation, a GFP-tagged EpiSC marker gene would have been the most useful for analysis. 
(a) 
(c) (d) 
(b) 
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However, the pluripotency state of the cells helped to address the first question of whether the 
ligands can perturb the ground state. Interestingly, in the mESC system, cells which lose 
pluripotency when being maintained on 2i no longer adhere onto the culture dish and instead 
float to the surface of the medium. This was particularly obvious after passaging the cells but 
also happened throughout their culture; this was visible as ‘floating cells’ in the media, either 
as individual cells or clumps. The cells had lost pluripotency but may have remained alive, and 
therefore the G4 ligands may been altering the proportion of cells losing pluripotency but this 
was hard to confirm using flow cytometry of the cells which have remained adherent: to the 
eye, there were many more ‘floating cells’ in the drug-treated cells. Therefore, the REX1-GFP 
experiment may have been missing the cells that lose adherence and introducing bias. 
 
In order to investigate whether these cells that lost adherence were altering the proportion of 
REX1-GFP positive cells in the 2i state, the cell culture medium containing cells in suspension 
was analysed using flow cytometry. Some of the cells which lost adherence would be dead 
cells, therefore propidium iodide (PI) staining was performed in order to discount dead cells. 
By this method, screening for GFP-, PI- cells selects for the population of non-pluripotent, alive 
cells. Pluripotent cells maintained in the 2i state could be grown in the presence of drugs for 
around three weeks but on every passage there were fewer cells that re-adhered to the culture 
dish suggesting a loss in pluripotency over time. To test this hypothesis, the supernatant of cells 
grown in this manner was collected and analysed using flow cytometry for GFP- PI- cells. 
While there were fewer cells in the supernatant to monitor than adherent cells, it was possible 
to pool the supernatant from a number of wells to gain sufficient quantity for analysis. This 
experiment was performed in the presence PDS or NMM and the viable cell population in the 
supernatant was analysed and compared to the viable adherent cell population (Figure 18). 
These results suggest that while the adherent cells in each condition were uniformly expressing 
GFP, the supernatant cells treated with the drugs that were still alive did not express GFP and 
therefore had lost pluripotency, suggesting that this was why the cells had lost aherence. This 
was very clear in the PDS treated cells. In the untreated cells there was a large range of cells 
expressing and not expressing GFP, implying that lack of pluripotency was not the main reason 
for these cells to lose adherence but clearly did occur. However, when the cells were cultured 
for two weeks, this difference was no longer evident, perhaps because the toxicity of the ligands 
induced greater levels of cell death after culturing for this length of time. This result suggests 
that maintaining the cells in G4 ligand in the 2i state was able to alter the expression state of 
the cells, causing them to lose pluripotency and therefore stop adhering. The cells collected for 
RNA extraction may have contained greater number of ‘floating cells’ compared to those 
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collected for flow cytometry due to the different methods which may explain the difference in 
the Zfp42/REX1 levels between these two techniques. Alternatively, this could be explained by 
differences in RNA and protein expression not changing at comparable rates. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18. Flow cytometry data gating for PI- live cells in the supernatant (blue) compared to attached cells (red) 
in mESCs cultured in 2i. Untreated cells (left panel), 2 µM PDS treated (middle) and 2 µM NMM treated (right) 
(a) four days in the ligand (b) seven days. 
 
In the mouse E14 ES cells, genetic knockouts of Rev1, Brip1 and Primpol were performed using 
a CRISPR/Cas9 strategy but verification was not fully completed before making the decision 
to move onto using the human iPSC differentiation strategy. This will not be discussed in further 
detail. 
 
While this system gave some initial results to suggest that stabilising G4 structures may alter 
mouse embryonic development, it was difficult to monitor the efficiency of this transition on a 
single-cell basis and the efficiency was not high. The qPCR results showed that treating with 
G4 ligands decreased the expression of pluripotency markers in the 2i state, and the flow 
cytometry data using GFP markers showed that cells that lost pluripotency ended up losing 
adherence, and this happened to a greater extent when treated with PDS or NMM ligands. This 
transition from mES cells to EpiLCs is considered to be more of a ‘state change’ than a 
‘differentiation’ and despite being useful for preliminary experiments it was not particularly 
useful to test the initial hypothesis. Therefore, with significant cell culture teaching from the 
Vallier group, I moved onto hiPS cells and the differentiation to definitive endoderm. 
(b) 
(a) 
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3.2 Human induced pluripotent stem cells 
In order to focus on a more definitive differentiation protocol, a human iPSC line was chosen 
to differentiate, the BOBSC cell line (Yusa et al., 2011). This iPSC line was chosen as it had 
been employed by the Sanger Centre COMSIG project which therefore provided access to a 
range of genetic knockout cell lines. Cells can be maintained in the pluripotent state in a similar 
manner to the mESCs, with the main difference being that the human cells do not tolerate being 
maintained as single cells and are therefore kept as small colonies throughout the passaging 
process. These cells are considered to have a high efficiency of differentiation, highly valuable 
for these experiments.  
 
3.2.1 Differentiation to definitive endoderm 
I considered a number of differentiation systems with the main requirements being:  
1. A high enough efficiency of differentiation that relatively small deviations in the 
efficiency could be analysed. 
2. At least three cell cycles would occur in the normal process to allow for a replication-
dependent epigenetic change to be realised. 
3. A well described system whereby the major pathways were known. 
4. The possibility to monitor key gene expression changes on a single-cell basis by flow 
cytometry. 
Taking these factors into account, the differentiation of iPS cells to definitive endoderm was 
chosen. This occurs over 72 hours, during which the cells undergo around five cell cycles, and 
can achieve up to 90 percent efficiency, meaning that this system matched my criteria. The 
specific protocol used was provided by Rodrigo Grandy in Ludovic Vallier’s group in 
Cambridge, adapted from (Teo et al., 2011). 
 
These iPS cells were cultured in the pluripotent undifferentiated state on vitronectin coated 
culture plates with Essential 8™ medium; cells were maintained in the undifferentiated state 
and split onto a new plate one day before initiating the differentiation. To initiate the 
differentiation to definitive endoderm, the cell media was replaced with CDM-PVA media and 
insulin, the WNT pathway activator CHIR99021, the PI3K inhibitor LY294002 and the 
recombinant proteins Activin A, FGF2 and BMP4. After 24 hours the cells were already 
morphologically distinguishable from undifferentiated cells as the cells became more individual 
in nature and the cell boundaries were visible at the edges of colonies. However, I noticed a lot 
of cell death during this part of the differentiation as seen by the number of cells which lost 
adherence, but this is a qualitative observation. On the second day the WNT activator was 
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removed from the differentiation media and the cells begun to express WNT pathway inhibitors. 
At 48 hours the cells went through the epithelial mesenchymal transition (EMT) and the 
colonies became less visible. The BMP4 and LY294002 were removed at 48 hours and only 
Activin A and FGF2 were maintained in the media for the final 24 hours. At 72 hours the cells 
were harvested to assess their efficiency of differentiation.  
 
This system was used to answer a number of questions that were not fully addressed over the 
mES cell transition. 
1. Do G4 ligands perturb the ground state or alter the fate of definitive endoderm 
differentiation? 
2. Can genetic knockouts of enzymes known to be involved in processing G4s change gene 
expression in the pluripotent state or change the efficiency of differentiation? 
3. Do other replication impediments act in a similar manner to G4s in the undifferentiated 
state and during differentiation? 
 
3.2.2 Monitoring the efficiency of definitive endoderm differentiation 
The differentiation was monitored using methods including permeabilised flow cytometry and 
quantitative PCR, as previously discussed in the mouse system. Permeabilised flow cytometry 
using two antibodies to proteins expressed during different stages of the definitive endoderm 
differentiation gives a clear, quantitative read-out of the efficiency on an individual cell basis; 
this was missing from the mouse system. Eomesodermin (EOMES) is expressed from around 
eight hours into differentiation and therefore cells harvested at 24 hours express high levels of 
EOMES compared to the undifferentiated cells which do not express EOMES. The expression 
of EOMES decreases throughout differentiation but some protein remains at 72 hours. SOX17, 
a protein belonging to the SRY-box family, is considered to be a marker of definitive endoderm 
specification and the proportion of cells expressing this protein at 72 hours can be considered a 
read-out of the efficiency of a particular differentiation experiment (Teo et al., 2011). 
 
The cells were collected at the desired timepoint, fixed and then stored until performing flow 
cytometry. To perform flow cytometry, the cells were thawed, permeabilised, and stained with 
EOMES and SOX17 antibodies. The addition of DAPI allowed the cell cycle to be broadly 
quantified in terms of the proportion of cells in each phase of the cell cycle: G1, S and G2/M. 
A typical differentiation monitored using flow cytometry for the wildtype BOBSC cell line is 
shown in Figure 19a and b, and a schematic of the gene expression changes can be seen in 
Figure 19c. Permeabilised flow cytometry shows that the undifferentiated hiPSCs did not 
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express EOMES or SOX17, and a large proportion of the cells were in S phase of the cell cycle. 
During the differentiation process EOMES could be detected by 24 hours and was still present, 
although at a lower level, at 72 hours. SOX17 was expressed from 48 hours and most cells 
expressed the protein by 72 hours. The DAPI staining shows that during the differentiation 
process, there were a higher proportion of cells in G1 phase and there were fewer in S phase as 
expected from a less pluripotent cell type. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 19. Definitive endoderm differentiation of hiSPCs (a) DAPI staining of DNA content of undifferentiated 
cells (blue) compared to differentiating cells (red) measured every 24 hours (left panel), EOMES staining (middle 
panel), SOX17 staining (right panel) (b) percentage of cells expressing SOX17 at 72 hours, n=20, mean±SEM are 
plotted (c) a schematic to show the gene expression changes during the differentiation process, proteins checked 
by permeabilised flow cytometry are marked with a red box. 
 
The protocol required relatively few optimisations, but one major problem was selecting the 
most reliable inhibitors. The CHIR90021 inhibitor efficiency varied from batch to batch, 
altering the efficiency of the differentiation dramatically. After trialling several different 
manufacturers, the TOCRIS CHIR90021 was used as it gave the most consistent results, and 
this was added for all further experiments. The other main optimisation was the cell density and 
colony size of cells at the onset of differentiation, this has been shown to alter the efficiency of 
differentiation (Kempf et al., 2016). Splitting the cells 1:8 from full confluence 24 hours before 
(c) 
(a) 
(b) 
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initiating differentiation consistently gave the highest proportion of SOX17 expressing cells 
and this was used throughout the experiments. As the confluency could alter the percentage of 
cells expressing SOX17 this was maintained as similarly as possible between cell lines and was 
kept the same between different drug-treatments. Once the differentiation was set up with high 
efficiency and reproducibility, the next step was to look at perturbing the differentiation. There 
were three ways in which to address this: G4-binding ligands as used previously, genetic 
knockouts of G4-processing enzymes and replication ‘stress’ including low doses of 
hydroxyurea (HU) and DNA damaging agents. I began by using G4 ligands as their addition 
had shown some suggestion of altering the differentiation in the mESC system. 
 
3.2.3 G4-binding ligands 
The first assessment of whether G4s may play a role in differentiation was using G4-binding 
ligands. The three G4 ligands previously used in the mouse cell experiments were tried on the 
hiPSCs as well as another G4 ligand, PhenDC3 (De Cian et al., 2007). The cells were grown in 
the presence of the ligands, PDS, NMM or PhenDC3 at 2 µM or PDC12 at 80 µM, in the 
undifferentiated state for a week to see whether they could be tested during the differentiation. 
NMM killed all cells within 48 hours even when the dose was taken down to the lowest active 
concentration in cells, 0.5 µM, therefore this drug was not used in the human system. The PDS 
and PhenDC3 could be tolerated by the cells for two weeks at 2 µM and these drugs were used 
for the experiments in this system. The PDC12, as before, exhibited a tendency to crystallise in 
solution and in order to induce epigenetic instability over five cell divisions, the length of the 
definitive endoderm differentiation process, the drug concentration would need to be around 80 
µM. Since there was an adequate readout of the differentiation efficiency in this system, it was 
possible to test whether the volume of DMSO that would be added to the cells with PDC12 
could affect the differentiation, regardless of the drug (Czysz et al., 2015; Pal et al., 2012). The 
cells were differentiated in the presence of DMSO to the equivalent of 80, 120 and 200 µM 
PDC12. The cells looked morphologically identical to the untreated cells but when the SOX17 
percentage was analysed by flow cytometry it was clear that the higher the volume of DMSO 
added, the lower the proportion of SOX17 positive cells at the end of the differentiation process 
(Figure 20). While it was very interesting that high volumes of DMSO could alter the 
differentiation process so dramatically, it also meant that PDC12 could not be used on the 
human cells. Fortunately, each of the other drugs could be used at a much lower concentration 
whereby the DMSO was shown to have no effect (≤ 10 µM of a 10 mM solution). However, 
the control cells were usually vehicle-treated in these differentiation experiments. The results 
of this work are discussed in Results III. 
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Figure 20. Analysis of the efficiency of definitive endoderm 
differentiation of hiSPCs in the presence of increasing volumes of 
DMSO with concentrations added equivalent to dilution from 10 
mM stock (equivalent to the maximum solubility of PDC12): 0, 80, 
120 and 200 µM. The histogram shows a decrease in SOX17 
expression with increasing volumes of DMSO added. 
 
 
 
 
 
 
 
3.2.4 G4-processing enzyme genetic knockouts 
The Sanger Centre had generated many genetic knockouts in the BOBSC cell line for the 
COMSIG project, including REV1, WRN and PRIMPOL. This provided an opportunity to 
compare RNA sequencing data between these cell lines and wildtype cells treated with G4 
ligands, as well as combine the ligands with the knockout cells lines to see if this exacerbates 
any phenotype. This data is discussed in Results IV. 
 
3.2.5 Replication stress 
Low doses of HU have previously been shown to induce epigenetic instability by means of 
nucleotide pool depletion, in a similar manner to G4 ligands and genetic knockouts of REV1 
and PRIMPOL in DT40 (Papadopoulou et al., 2015). The low doses of HU can therefore lead 
to uncoupling of the DNA replication fork and the processive helicase, and this can cause 
epigenetic instability. Theoretically, DNA damage, another form of replication stress, could 
cause epigenetic instability by a similar mechanism: a lesion is formed in the DNA which the 
leading strand polymerase cannot process through and therefore histone deposition and leading 
strand DNA synthesis are not coupled. How replication stress can influence maintenance of the 
ground state and the differentiation process will be addressed in Results II. 
3.3 Neuroectoderm differentiation 
Having set up the endoderm differentiation protocol, another differentiation pathway from hiPS 
cells was performed to understand whether similar results could be seen in a different lineage 
specification pathway. Neuroectoderm differentiation takes longer than endoderm 
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differentiation, around seven days, and can be continued to neuronal differentiation. It is a very 
robust protocol and the number of cell cycles gives sufficient time to allow a replication 
dependent phenomenon to become visible. Cells were set up for neuroectoderm differentiation 
in a similar manner to endoderm differentiation and the cell media was changed daily. For the 
first 48 hours cells were cultured in CDM-PVA, as in endoderm differentiation, supplemented 
with FGF2, CHIR99021, LDN193189 and SB431542. From day three to six cells were cultured 
in N2B27 medium containing SB431542. At day seven the SB431542 was removed from the 
N2B27 medium and cells were kept in this state until analysis. The LDN193189 was added to 
inhibit BMP type I receptors and SB431542 to inhibit TGFβ. Both are small molecule inhibitors 
of SMAD signalling and this is referred to as the LSB protocol (Menendez et al., 2011). Cells 
differentiated down this pathway exhibited much lower cell death when compared to the 
endoderm differentiation. The efficiency was measured using permeabilised flow cytometry 
analysing PAX6 and SOX1 expression. 
 
A number of optimisations were required for this protocol: at day eight of differentiation the 
cells were very confluent, and the layer of adherent cells peeled off the plate so the 
differentiation could go no further. The cells were differentiated on gelatin instead of vitronectin 
to assess whether this could increase their attachment but there was further decreased 
attachment on gelatin. As before, the initial cell density was optimised to increase the efficiency 
of the process. The initial differentiation did not show any upregulation of PAX6 or SOX1 
compared to the undifferentiated cells and therefore different batches of LDN193189 (Source 
BioScience) were trialled. Upon using this new inhibitor, and varying the initial cell density, 
the permeabilised flow cytometry showed an increase in both SOX1 and PAX6 expression 
compared to the undifferentiated state (Figure 21). While the shift in PAX6/SOX1 expression 
was not as distinct as the SOX17/EOMES expression in definitive endoderm cells verses 
undifferentiated state, there was a change. While optimising this protocol, the cells were 
differentiated to neuroectoderm in the presence of the G4 ligands PDS and PhenDC3 as 
discussed previously. Using 2 µM of each ligand showed both PDS and PhenDC3 caused the 
cells to start to die within three days and by the fourth day almost all the cells treated with the 
ligands were dead. Therefore, the remainder of the thesis is focused on definitive endoderm 
differentiation.  
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Figure 21. Neuroectoderm differentiation of hiPSCs stained for PAX6 (left panel) and SOX1 (right panel) and 
DAPI, in the undifferentiated state (top panel), after six days (middle panel) and after seven days (bottom panel). 
Gates are measured at the percentage of cells expressing PAX6 or SOX1. 
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Chapter 4. Results II: The DNA damage 
response in the undifferentiated state and 
during endoderm differentiation of hiPS 
cells 
 
4.1 Changes to DNA damage markers in the pluripotent state 
4.1.1 The unperturbed undifferentiated state 
Early in the mES cell experiments, it was very clear that the cells could tolerate G4 ligands 
better in the ground state than during differentiation. This effect was more pronounced when 
comparing the hiPSC undifferentiated and definitive endoderm differentiating cell states, 
introduced in Results I and expanded on in Results III. Since the G4 ligand PDS has been shown 
to induce DNA damage (Rodriguez et al., 2012), the response to DNA damage in the 
undifferentiated and differentiating states are described in this chapter.  
 
4.1.1.1 2D-cell cycle plots in hiPSCs 
To give an insight into the cell cycle of these highly proliferative cells, undifferentiated, 
unperturbed replicating hiPSCs were cultured in the presence of the nucleotide analogue, EdU, 
for one hour and then fixed for flow cytometry analysis (Figure 22a). This revealed an 
unexpected 2D-cell cycle plot characterised by the presence of a late S phase population, 
possibly indicative of late damage repair, that also continued into the differentiation. This 
population of cells did not show an increase in γH2A.X (Figure 22b) or pRPA (Figure 22c) 
signal using flow cytometry. Therefore, it was not clear what this specific population was acting 
as and whether it was related to resolving DNA damage in late S phase in these highly 
proliferating cells. 
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Figure 22. 2D-cell cycle analysis of wildtype BOBSC cells (a) EdU / DAPI plot of undifferentiated (left) and 
differentiating cells (right) to show the late S phase cell cycle bulge (shown in the red box on both plots) (b) gating 
of γH2A.X positive cells  (positive cells shown in the middle plot with the black box) showing that these do not 
correlate with this bulge (c) gating of pRPA positive cells (positive cells shown in the middle plot with the black 
box)  and showing there is no increase in this population. Adjunct histograms are shown. 
 
4.1.2 Perturbing replication in the undifferentiated state 
The aim of this thesis was to understand whether perturbing replication could impact 
differentiation. In order to address this question, it must be first understood how these 
perturbations impact the undifferentiated cell state. 
(a) 
(b) 
(c) 
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4.1.2.1 Nucleotide depletion using hydroxyurea 
It has been shown previously in the group that a low dose of hydroxyurea (HU) is able to induce 
epigenetic instability at the BU-1 locus, in a similar manner to G4 ligands and genetic knockouts 
of enzymes involved in processing G4s (Papadopoulou et al., 2015). This phenomenon occurs 
due to the hydroxyurea causing nucleotide pool depletion and replication stress (Alvino et al., 
2007). Cells were grown in 50-150 µM HU without any observed changes in cell doubling time 
for five days; the cells could be maintained at these concentrations for over two weeks. Cells in 
the undifferentiated state were able to tolerate high doses of HU, again suggesting that the 
hiPSCs were capable of processing high levels of DNA damage. However, as very little change 
was seen in these cells the concentrations were increased to 300-500 µM where there was a 
slowing of growth (Figure 23). At the high dose of 500 µM, there was a large increase in the 
proportion of cells in S phase, as would be expected on treatment with HU, but very little cell 
death. Nucleotide pool depletion was used during definitive endoderm differentiation as 
discussed in Section 4.2.2. 
 
Figure 23. 2D-cell cycle plots of 
undifferentiated BOBSC cells cultured 
with 500 µM HU for 50 hours. The x-
axis shows DNA content stained with 
DAPI and the y-axis shows 
incorporation of EdU. 50 hours was 
used as a comparison to the changes 
during differentiation, discussed later.  
 
 
4.1.2.2 The effect of inducing DNA damage in the undifferentiated state 
In order to study the way in which undifferentiated cells deal with DNA damage, cells were 
treated with different DNA damaging agents, which would induce different lesions or breaks 
on the DNA, in the undifferentiated state. Methyl methanesulfonate (MMS) is a DNA alkylating 
agent that was added to induce replication stress and DNA damage. When added to aqueous 
solution at 37⁰C it has a half-life of 9.5 hours (Kilbey et al., 2012). It predominantly methylates 
DNA on N7-deoxyguanosine and N3-deoxyadenosine. In order to test the dose of MMS that 
could be tolerated without inducing excessive cell death or significant slowing of cell growth, 
the drug was added to undifferentiated cells at concentrations in the range of 0.25-10 ppm. Cell 
media was changed every 24 hours and new MMS was added, and after 72 hours the cells were 
checked with a microscope to analyse the rate of proliferation compared to untreated cells. At 
concentrations above 10 ppm there was a decrease in the rate of cycling visible by eye. Cells 
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treated with 2.5-5 ppm MMS showed very little difference in growth rate compared to untreated 
cells and 5 ppm was used for further experiments. MMS was added every 24 hours for three 
days and the cell cycle profile was analysed (Figure 24). There was very little cell death 
accompanied by smalls increases in the proportion of cells in G2/M phase of the cycle. These 
doses were used to perturb endoderm differentiation, discussed in Section 4.2.3.1. 
 
 
Figure 24. Flow cytometry plots to show DAPI staining of DNA content in undifferentiated cells treated with 5 
ppm MMS (blue) at 0-, 24- and 48-hours and collected every 24 hours to check the changes in the cell cycle 
compared to untreated cells (red).  
 
 
Figure 25. Flow cytometry plots to show the distribution of cells in the cell 
cycle after irradiation with 2 J/m2 UV-C (blue) compared to untreated 
(red). Cells were treated at 24 hours and collected 48 hours later, this was 
chosen in order to compare to differentiated cells discussed further in 
Section 4.2.3.2. 
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Irradiation with UV-C was used to induce cytotoxic DNA lesions including cyclobutane-
pyrimidine dimers (CPDs) and 6-4 photoproducts (6-4PPs). A range of UV-C doses were 
trialled, and the highest tolerated dose was used further, as for MMS. Two joules per square 
metre of radiation was used as this dose caused very little cell death in the undifferentiated state 
but still caused an increase in the proportion of G2/M phase cells after 48 hours, typical of a 
replication impediment (Figure 25). The cells were treated at 24 hours, allowing comparison to 
the differentiated experiments; the choice of timepoints will be discussed later in this chapter 
with reference to differentiation (Section 4.2.5). 
 
4.1.3 Changes to DNA damage markers after damage in the pluripotent state 
To understand whether the BOBSC cells responded in a similar manner to somatic cells on 
treatment with DNA damage, I assessed whether the levels of serine-139 γH2A.X increased 
when low doses of HU or MMS were added. Protein was collected after 51 hours of culture and 
analysed by western blotting (Figure 26a). This timepoint of 51 hours was used as an important 
comparison to differentiating cells, discussed later in the chapter. Cells were also analysed using 
flow cytometry (Figure 26b). It was clear that both treatments caused an upregulation in the 
phosphorylation of H2A.X, however this was more pronounced in HU treated cells: this will 
be discussed in further detail in Section 4.2. 
 
 
 
 
 
 
 
 
Figure 26. Analysis of H2A.X phosphorylation in the undifferentiated 
state 51 hours after treatment, used to compare to differentiation (Section 
4.2) (a) western blotting to show an increase in phosphorylation after 
MMS or HU treatment at the doses described. Unmarked lanes contain 
treatment with G4 ligands discussed in Results III. (b) flow cytometry 
analysis of phosphorylation. 
(a) (b) 
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4.2 Changes to DNA damage markers during endoderm 
differentiation 
4.2.1 Unperturbed differentiation 
Before addressing how the DDR is triggered by DNA damage during differentiation, it was 
crucial to understand whether DDR markers change over the course of endoderm differentiation 
from undifferentiated cells. Therefore, levels of CHK1, CHK2 and RPA in undifferentiated, 
24- and 48-hour differentiated wildtype cells were checked using western blotting (Figure 27a-
c). Total CHK1, CHK2 and RPA proteins were expressed undifferentiated cells but the 
expression of CHK1 and CHK2 decreased during differentiation. This decrease was not seen 
with RPA. pCHK1, pCHK2 and pRPA signals were only seen in the positive control cells and 
were not changed during differentiation.  
 
The tumour suppressor protein, p53, was also analysed by western blotting (Figure 27d).  Total 
levels of p53 were high in undifferentiated cells, as for the other DNA damage markers, and its 
expression decreased during the differentiation process. It is known that p53 plays a role in the 
initiation of differentiation (Murray-Zmijewski et al., 2006). Testing the levels of p63 and p73 
would have been useful as they are also known to play a role in differentiation (Wang et al., 
2017). However, all antibodies tested did not give any signal and RNA sequencing discussed 
in Section 4.4 showed that the RNA of these transcripts were expressed at very low levels in 
the undifferentiated state and this continued throughout differentiation. These western blots 
suggested that a number of proteins involved in the DDR were expressed at high levels in the 
pluripotent state and these levels decreased throughout differentiation. 
 
Phosphorylation of the histone variant H2A.X was also analysed as a marker of DNA damage 
using western blotting and flow cytometry. It was clear that the level of γH2A.X was inversely 
correlated with total CHK1 and p53 protein (Figure 27a, c, d). Undifferentiated cells had low 
levels of H2A.X phosphorylation, whereas at 48 hours into differentiation this γH2A.X signal 
increased to much higher levels compared to the undifferentiated state. This finding was entirely 
unexpected, as this marker is usually associated with DNA damage, and it was of interest to 
study what might be causing the increase at 48 hours into differentiation. 
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Figure 27. Western blotting analysis of proteins involved in the DDR during differentiation of BOBSC cells (a) 
CHK1 and CHK2 phosphorylation, total CHK1, RPA and γH2A.X in the undifferentiated state and every 24 hours 
of differentiation (b) RPA phosphorylated and unphosphorylated state in the undifferentiated state and every 24 
hours of differentiation (c) total CHK2 and p53, and γH2A.X every 24 hours of differentiation (d) total p53 and 
γH2A.X during differentiation. Unmarked lanes contain conditions not discussed in this chapter. UD is 
undifferentiated. UV and HU treatment were used as positive controls. 
 
 
 
 
 
(a) (b) 
(c) (d) 
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4.2.1.1 Phosphorylation of H2A.X during unperturbed differentiation 
To gain further insight into when the high level of γH2A.X was appearing during the 
differentiation, protein was collected across more intervals and western blotting was performed 
(Figure 28a). This shows that the marker was present from at least 48 to 52 hours into the 
differentiation. To look in more detail at an individual cell level, γH2A.X flow cytometry during 
differentiation was performed. Cells were collected from 7 hours to 52 hours throughout the 
differentiation process, as well as in the undifferentiated state, and analysed for γH2A.X (Figure 
28b). This experiment showed a clear increase in γH2A.X at both 48 and 52 hours. Interestingly 
the cells exhibiting this marker were mainly in G1 phase with some in G2/M. This was again 
unexpected because γH2A.X is normally seen in S phase cells. This suggests that what was 
seen may not have been the typical DNA damage response pathway.  
 
In order to ascertain at which stage of the differentiation H2A.X was phosphorylated, cells were 
collected every two hours from 36 to 58 hours and analysed using flow cytometry to check for 
both γH2A.X and SOX17 individually (Figure 28c). This showed that a small proportion of 
cells started upregulating γH2A.X from 38 hours and this continued until 58 hours: the highest 
levels were monitored from 46 to 54 hours, as previously seen. This increase in γH2A.X did 
not correlate with the onset of SOX17 expression, or a decrease in EOMES expression and was 
therefore unlikely to be associated with the expression of these genes. However, this time 
window did seem to correlate with the period in which the cells were believed to transition from 
being epithelial to mesenchymal. 
 
To confirm that there was no dependency of SOX17 upregulation on H2A.X phosphorylation, 
or vice versa, flow cytometry was performed to check individual cells for both SOX17 and 
γH2A.X expression (Figure 28d). The majority of cells expressing SOX17 did not have a 
positive γH2A.X signal, and vice versa, suggesting that upregulation of both may have been 
mutually exclusive. These cells may need to have H2A.X phosphorylated and then 
dephosphorylated before expressing SOX17, such that each cell goes through a transition of 
having H2A.X phosphorylated before specifying differentiation but confirming this would 
require live cell imaging and be almost impossible to monitor. 
 
Figure 28. (See next page). Analysis of the phosphorylation of H2A.X during definitive endoderm differentiation 
(a) western blotting analysis (b) flow cytometry analysis (c) flow cytometry analysis with a comparison to EOMES 
and SOX17 expression (d) comparison of the level of γH2A.X and SOX17 on a per cell basis, the red box shows 
cells negative for SOX17 expression but positive for H2A.X phosphorylation. 
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(a) (c) 
(b) 
(d) 
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To verify whether the total levels of H2A.X protein correlated with the level of phosphorylation, 
H2A.X was monitored using flow cytometry (Figure 29a and b) and western blotting (Figure 
29c). The flow cytometry data, while showing a greater spread in the level of H2A.X, did not 
show an increase in total H2A.X protein comparable to the phosphorylated variant, although 
the western blot did give a signal between 48 and 51 hours. This upregulation was not as great 
as the phospho-H2A.X spike, but since it was at an identical time it is not possible to rule out 
the possibility that the level of total protein was responsible for this difference. However, the 
antibody may be non-specific and could have a preference for phosphorylated H2A.X, it is 
expected to bind to the C-terminal region of the peptide, as the migration of the phosphorylated 
and unphosphorylated proteins appear very similar from the blots.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Previous work on the epithelial mesenchymal transition (EMT) in cancer has proposed a 
mechanism for H2A.X phosphorylation mediated by ATM and the SRY-box protein HMG2A 
(Singh et al., 2015). As H2A.X is thought to be able to be phosphorylated by DNA-PK, ATR 
Figure 29. Analysis of total unphosphorylated H2A.X at the time of the spike of phosphorylation during 
differentiation (a) flow cytometry analysis of H2A.X with DAPI staining (b) as in (a) but showing total H2A.X 
only (c) western blotting analysis of H2A.X phosphorylated and unphosphorylated. 
(a) 
(b) (c) 
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and ATM (Burma et al., 2001), inhibitors of ATM and ATR kinases, KU-60019 (Selleckchem) 
and AZD6738 (Selleckchem) respectively, were used in an attempt to understand which kinase 
was phosphorylating H2A.X during differentiation. Previous publications had used 10 µM of 
each inhibitor, and I tested this concentration in the undifferentiated state but this killed the 
cells in under 48 hours. Therefore, this approach was not able to answer the question, possibly 
because ATM and ATR are required in the pluripotent state. Rather, the ATM inhibitor was 
used at 2 µM and the ATR inhibitor at 1 µM as the undifferentiated cells could tolerate these 
concentrations for one week. Cells were differentiated or kept in the undifferentiated state in 
the presence of either one or both of the drugs. However, the differentiating cells reacted very 
poorly to the drugs and there was an increased level of cell death with each treatment. The cells 
were differentiated for 48 hours without inhibitors and 24 hours with inhibitors to minimise the 
time grown in the presence of the inhibitor, either 0-24, 24-48 or 48-72 hours, and assessed for 
SOX17 expression (Figure 30a). Adding the ATM inhibitor in the first 24 hours had no effect 
on the population of SOX17 expressing cells but all other conditions decreased the 
differentiation efficiency and therefore these pathways may be required during differentiation. 
The γH2A.X spike seen did not appear until much later than 24 hours, which could explain 
these observations. 
 
I next investigated whether the ATM or ATR inhibitors were able to alter the proportion of 
γH2A.X positive cells. To minimise the toxic effect caused by the inhibitors, cells were grown 
for four or 20 hours on either one or both of the inhibitors at a higher concentration of 5 µM 
prior to collection. Cells were differentiated to 52.5 hours and the level of γH2A.X was analysed 
using permeabilised flow cytometry (Figure 30b). However, this was not able to answer the 
question as most inhibitor treated cells had an increased percentage of γH2A.X positive cells. 
The only condition where there was a decrease in the phosphorylation was using the 
combination of inhibitors for four hours prior to collection but a small spike was still observed. 
A different ATM inhibitor KU-55933, that acts less specifically than KU-60019, and has been 
previously used when looking at inhibiting the EMT associated H2A.X was used (Singh et al., 
2015). The experiment was performed as before, with the drugs added four hours before 
collection, and cells were collected at 51.5 hours for permeabilised flow cytometry analysis 
(Figure 30c). However, there was an increase in the phosphorylation of H2A.X during 
differentiation compared to the other ATM inhibitor. 
 
The use of the inhibitors of ATM and ATR kinase activity did not give any clear results, so an 
ATM knockout cell line generated by the Sanger Centre COMSIG project was used: ATM-/-. 
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These cells differentiated with a similar efficiency to the wildtype cells as shown using flow 
cytometry (Figure 31a and b). This was expected because both ATM-/- human and mice are 
viable although display severe phenotypes (Barlow et al., 1996). The phosphorylation of 
H2A.X at the EMT also occurred in these cells (Figure 31c). This suggested that if ATM does 
phosphorylate H2A.X in this context, it is redundant in this pathway. Combining ATM-/- with 
the ATR inhibitor, as used above, the γH2A.X spike was analysed (Figure 31d). However, there 
was no suggestion that this decreased the level of phosphorylation, in fact there was an increase 
in the base level and the spike of phosphorylation in G2/M. The ATM knockout could not be 
clearly verified by western blotting (Figure 32), but the cells showed an increased sensitivity to 
bleomycin treatment (data not shown). RNA sequencing was performed but showed very few 
gene expression differences compared to wildtype cells, suggesting that this may not have been 
a true knockout cell line. In order to fully understand the mechanism by which H2A.X is being 
phosphorylated, a double knockout cell line of ATR and ATM could be used to see if this 
prevents phosphorylation. A triple knockout with PRKDC could be used if this approach 
yielded no results. Caffeine acts as a non-specific inhibitor of both ATR and ATM 
phosphorylation, treatment with this drug should prevent phosphorylation if these kinases are 
responsible. 
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. 
(a) (b) 
(c) 
Figure 30. Flow cytometry analysis of ATM and ATR inhibitors (a) analysis of the cells expressing SOX17 at 72 hours 
after treatment with 1 µM ATR inhibitor or 2 µM ATM inhibitor for 24 hours during differentiation (b) 5µM of ATM, 
ATR or both inhibitors were added either 20 or 4 hours before collection at 52.5 hours to monitor the spike of 
phosphorylation (c) the phosphorylation of H2A.X at 51.5 hours after four hours of treatment with different ATM 
inhibitors. The baseline level of H2A.X phosphorylation changed with treatment, therefore the gating is relative to the 
untreated and not the baseline in each sample. This increase is likely to be due to increased cell death and damage. 
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Figure 31. Flow cytometry analysis of differentiation of the ATM-/- cell line (a) analysis of the efficiency of 
differentiation every 24 hours monitoring DNA content, EOMES and SOX17 (b) replicate experiments n=2, 
mean±SEM are plotted, difference is not significant using an unpaired t test (c) the phosphorylation of H2A.X at 
50 hours of differentiation compared to the wildtype cell line (d) use of the ATR inhibitor (Figure 30) in the ATM-
/- cell line to monitor the level of H2A.X phosphorylation. As before, the positive gating is relative to the wildtype 
untreated and therefore the spike of phosphorylation above the baseline is not measured here. This is due to the 
inhibitors inducing damage in the cells, causing an increase in the baseline level of H2A.X phosphorylation. This 
spike of phosphorylation can be seen in all conditions. 
(a) (b) 
(c) 
(d) 
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During the canonical DDR, H2A.X is phosphorylated during S phase of the cell cycle but in 
this data, the upregulation occurs in G1 and G2/M. To find out whether this upregulation was 
initiated in G1 or G2/M, the cells were synchronised in nocodazole in the undifferentiated state 
before being released into differentiation medium and initiating differentiation. The cells were 
collected at the point of the EMT spike (Figure 33). Nocodazole was used because it has been 
shown to affect stem cell differentiation efficiency the least of any means of cell 
synchronisation (Yiangou et al., 2018), however this synchronisation is only complete for one 
cell cycle. Nonetheless, the nocodazole synchronisation caused a large amount of cell death and 
the base level of H2A.X phosphorylation was also higher, particularly soon after release. The 
cells did not all release at identical times so the results were not definitive. The synchronised 
cells lagged in differentiation, probably due to their slow release, and the γH2A.X spike was 
not as great compared to the unsynchronised cells. However, the initial upregulation seen at 48 
hours appeared to be in G1, suggesting that γH2A.X was upregulated in G1 phase of the cell 
cycle.  
 
H2A.X ChIPseq was performed on cells differentiated for 50 hours and cells maintained in the 
undifferentiated state. This was to understand whether this mark was associated with particular 
regions of the genome or a subset of genes, as it has been suggested to alter chromatin structure 
and transcription factor binding patterns at the EMT in cancer (Singh et al., 2015; Weyemi et 
al., 2016). The cells were collected for ChIP, and also for flow cytometry to check that the cells 
were differentiating (Figure 34). This figure shows that the cells were differentiating well and 
could be used for ChIPseq. The cells collected for ChIP were crosslinked, sonicated and the 
chromatin was spiked with HU treated DT40 chromatin at a 1:10 dilution. The 
immunoprecipitation was performed using an H3 antibody and a γH2A.X antibody. The DNA 
Figure 32. Analysis of the knockout of ATM in the ATM-/- cell line by 
western blotting, ATM should be seen at 350 kDa, unmarked lanes 
contain the TP53-/- cell line not discussed here, HU represents 2 mM 
hydroxyurea treatment for six hours prior to collection as a DDR positive 
control. 
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extracted was used to make DNA libraries and which were sent to the CRUK sequencing 
facility. This data is being analysed at the moment and therefore is not in the thesis at this stage. 
 
Figure 33. In an attempt to understand whether the phosphorylation of H2A.X was occurring during the cell cycle, 
cells were synchronised with 200 ng/mL Nocodozole for 16 hours in the undifferentiated state and when the 
Nocodazole was washed out the medium was replaced with the differentiation medium. EdU was added one hour 
prior to collection. The red box indicates synchronised cells at the point where H2A.X phosphorylation can first 
be seen in G1. 
 
 
 
 
Figure 34. Flow cytometry analysis of the cells 
collected for ChIP analysis. Undifferentiated and 
differentiating cells were collected at 50 hours and 
analysed for SOX17 and phosphorylation of H2A.X. 
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4.2.1.2  The role of p53 in definitive endoderm differentiation 
p53 is known to play a role in mesendoderm differentiation (Wang et al., 2017) and also to be 
downregulated at the EMT (Chang et al., 2011). It is also phosphorylated and activated for its 
role in the DNA damage response by ATM which was hypothesised to phosphorylate H2A.X 
at the EMT (Singh et al., 2015). Initial western blots, Section 4.2.1 (Figure 27c and d), 
suggested that total levels of p53 were high in the undifferentiated state and at the onset of 
differentiation. The levels then decreased throughout definitive endoderm differentiation. 
Phosphorylation of p53 at serine-15 was not detected unless cells were treated with MMS in 
either the undifferentiated or differentiating samples (Figure 35a and b). Preliminary flow 
cytometry data showed that cells which showed higher levels of γH2A.X at the spike of 
phosphorylation at 48 hours tended to express p53 to a lower level of SOX17 (Figure 35c). This 
data suggests that the level of p53 protein may be downregulated before H2A.X is 
phosphorylated at the EMT. 
 
Figure 35. Analysis of p53 protein during differentiation (a) western blotting analysis to show phosphorylated 
p53 compared to total p53 in undifferentiated BOBSC cells (b) western blotting analysis of the levels of p53 and 
phosphorylated p53 during differentiation and after MMS treatment, unmarked lanes are G4 ligands not discussed 
here (c) the correlation of total p53 and γH2A.X during differentiation, the red box at 48 hours marks H2A.X 
phosphorylation and low levels of p53 at the spike of phosphorylation. 
(a) (b) 
(c) 
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Because the levels of p53 decreased during differentiation, I attempted to stabilise p53 using 
the MDM2 inhibitor Nutlin-3a to probe whether this could inhibit the differentiation process. 
However, two brands of Nutlin-3a were trialled (Selleckchem and Cayman Chemicals) and 
both caused cell death within two days at the suggested effective concentration, so this approach 
was taken no further. 
 
To check whether the total level of p53 protein could still be upregulated in response to high 
levels of DNA damage during the differentiation process, cells were treated with high doses of 
HU (2 mM) and collected for flow cytometry (Figure 36a). The level of p53 decreased during 
differentiation, especially at 54 hours, but increased on treatment with HU regardless of the 
time of treatment.  
 
 
 
 
Figure 36. Flow cytometry analysis of the level of total p53 protein (a) in differentiating cells after treatment with 
2 mM HU at 24, 48 and 72 hours. Cells were collected six hours after treatment (b) in undifferentiated and 
differentiating cells at 48 hours. Cells were treated with 5 ppm MMS or 300 µM HU at 24 hours and collected at 
48 hours. The undifferentiated untreated level is marked. 
(a) (b) 
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It was clear that p53 levels were decreasing during differentiation and that this may coincide 
with the H2A.X spike. Addition of high doses of HU during differentiation could also increase 
the level of p53. In order to understand how these levels corresponded to that in the 
undifferentiated state, permeabilised flow cytometry was performed to analyse the p53 signal, 
both with and without the addition of DNA damaging agents (Figure 36b). This shows that the 
level of total p53 protein was higher in the undifferentiated state than the differentiated state, 
but the level could be increased in both undifferentiated and differentiated cells after treatment 
with DNA damaging agents. When HU and MMS were added at 24 hours and the cells were 
collected at 48 hours, the p53 level was increased to a level equivalent to that of the 
undifferentiated state. This is discussed further in relation to differentiation perturbation in 
Section 4.2.4.3.  
 
As TP53 knockout mice are viable (Donehower et al., 1992), it was interesting to understand 
the role this protein plays in definitive endoderm differentiation and how it controls the DNA 
damage response throughout. p53 cells generated by the Sanger Centre COMSIG project were 
used. The knockout cells were verified using western blotting (Figure 37), which shows that 
the p53 antibody was binding a lower molecular weight protein, likely to be a truncated form 
of p53. This antibody binds to the N-terminal region, amino acids 20-25, and since the knockout 
is in exon six this is likely to be causing the difference. Therefore, while this is a knockout, it 
is clearly not of the whole protein: some of the p53 capabilities may still be functional. The 
targeting method states that the homologously recombined allele left only the transactivation 
domain in the N-terminus functional, whereas the CRISPR/Cas9 knockout allele acted in the 
DNA binding domain. This suggested that the transactivation, and therefore MDM2 binding 
domain, would certainly be intact.  
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TP53-/- definitive endoderm differentiation was monitored using permeabilised flow cytometry 
(Figure 38a), replicate experiments are shown in Figure 38b. This shows that knocking out 
TP53 did not significantly affect the unperturbed differentiation efficiency. There was also a 
lower level of cell death during differentiation in these cells such that they were more confluent 
compared to the wildtype at 72 hours. This may suggest that they respond to external queues 
differently during differentiation, likely to be due to the role of p53 in apoptosis, which is 
discussed in Section 4.2.4.2. 
 
TP53-/- cells were differentiated and collected for flow cytometry between 47 and 52 hours to 
analyse the γH2A.X spike (Figure 38c). Surprisingly, this data shows that the level of γH2A.X 
was lower at all timepoints compared to the wildtype cell line. Either the spike of upregulation 
associated with the EMT was missed and occurred at a different time in these cells, or the lack 
of p53 was causing a lower level of γH2A.X.  
 
 
 
 
 
Figure 38. (See next page). Analysis of the TP53-/- cell line (a) SOX17, EOMES and DNA content at 24, 48 and 
72 hours (b) replicate experiments showing the differentiation of the TP53-/- cell line compared to wildtype, n=6, 
p=0.8126 not significant, mean±SEM are plotted (c) the spike of H2A.X phosphorylation during differentiation 
(d) 2D-cell cycle plots without treatment or after treatment with MMS or HU in the undifferentiated state for 24 
hours. The red lines indicate the increased EdU incorporation in the TP53-/- cell line.  
Figure 37. Analysis of the TP53-/- cell line using western 
blotting, βACTIN is shown as a loading control. The lack of the 
full length p53 is seen in the genetic knockout cell line. 
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(a) 
(d) 
(c) (b) 
102 
 
Interestingly, the cell cycle profile of TP53-/- cells differed from wildtype cells in that they 
seemed to synthesise DNA faster in S phase, as shown from the increased EdU fluorescence 
(Figure 38d). However, both the wildtype and TP53-/- cells reacted in a similar manner to MMS 
and HU treatment. The TP53-/- cells also had the late replication bulge in the EdU cell cycle 
plot suggesting that this checkpoint was activated even without p53. 
 
The level of MDM2 expression during differentiation in both wildtype and TP53-/- cells was 
examined using western blotting (Figure 39). This figure shows that the level of MDM2 was 
high in the undifferentiated cells and the total level decreased throughout differentiation: no 
difference between the wildtype and TP53-/- cells was seen. This suggested that p53 and MDM2 
were regulated in a similar manner to one another, and the levels of both decrease during 
differentiation. Since this was only performed once in the TP53-/- cell line, it cannot be 
ascertained whether the difference in MDM2 is different in the two cell lines. 
 
 
Figure 39. Analysis of MDM2 during 
differentiation using western blotting in 
the wildtype and TP53-/- cell lines. UD 
is the undifferentiated state. 2 mM HU 
and 20 J/m2 UV were used as positive 
controls in the undifferentiated state, 
cells were treated six hours prior to 
collection. 
 
 
 
 
4.2.2 Perturbing differentiation with low dose hydroxyurea 
Cells were differentiated in the presence of HU and collected for permeabilised flow cytometry 
to assess whether this replication impediment could alter differentiation. This was first 
performed using 50 - 100 µM HU, which did not affect growth in the undifferentiated cells and 
this was then increased to 300 – 500 µM when no changes to differentiation were seen. Using 
300 µM of HU or higher over the 72 hours of differentiation caused much greater cell death 
compared to the undifferentiated state, slowed the cell cycle, and increased the cell size which 
is indicative of a G2/M block. Cells were differentiated in the presence of 300 or 500 µM HU 
and collected every 24 hours (Figure 40a). This shows that the cells were not differentiating 
efficiently, and that the cell cycle was perturbed. EOMES was expressed in HU treated cells, 
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although possibly to a lower level than the untreated cells, and SOX17 was expressed in around 
50% of cells. This suggested that HU was able to cause a change in the differentiation, however 
it is possible that the decrease in SOX17 positive cells was due to HU slowing the cell cycle. 
The correlation of EOMES and SOX17 expressing cells was monitored (Figure 40b). This 
suggested that most cells expressing SOX17 were also expressing EOMES, implying a 
dependency of EOMES on SOX17. This was more pronounced with HU treatment, perhaps 
because this was causing slowing of growth. However, since this was only performed once, the 
significance of this results cannot be checked. 
 
 
Figure 40. Analysis of the 
efficiency of differentiation 
in the presence of HU (a) 
DAPI, SOX17 and EOMES 
analysis every 24 hours with 
300 or 500 µM HU. UT is 
untreated (b) comparison of 
SOX17 and EOMES 
expression in each cell. 
 
 
 
 
 
 
 
4.2.3 Differentiation in the presence of DNA damaging agents 
It is hypothesised that any replication fork blockage that causes the replicative DNA helicase 
to continue downstream of the obstruction to the replicative polymerase could cause epigenetic 
instability by the same means as the G4 at the BU-1 locus. In order to address this theory, while 
(a) 
(b) 
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also investigating how DNA damage affects the differentiation process, DNA damaging agents 
were added during differentiation. 
Figure 41. (See previous page)  Flow cytometry analysis of wildtype cells treated with 5 ppm MMS at 0-, 24- and 
48-hours (a) analysis of DNA content, EOMES and SOX17 (b) analysis of SOX17 at 72 hours and the proportion 
of the cells in S phase not expressing SOX17 (red box) (c) replicates of individual experiments n=8, where MMS 
was added at 0, 24 and 48 hours and the proportion of cells expressing SOX17 at 72 hours was compared to 
untreated samples, p<0.0001 using paired t test, mean±SEM are plotted (d) as for (c) but treating the cells only at 
24 hours and cells were collected at 72 hours, n=7, p=0.0001. 
(a) 
(b) 
(c) (d) 
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4.2.3.1 Methyl methanesulfonate treatment during endoderm differentiation 
MMS was well tolerated in the undifferentiated state; three doses of 5 ppm over 48 hours caused 
very little cell death or change in the cell cycle profile. Cells were differentiated with 5 ppm 
MMS added at 0-, 24- and 48-hours during differentiation; they were collected, and the 
differentiation efficiency was analysed using permeabilised flow cytometry (Figure 41a). It was 
evident that adding MMS during differentiation caused much more cell death compared to 
adding it in the undifferentiated state (Figure 24), suggesting that pluripotent cells were more 
able to deal with this treatment. The cell cycle profile suggested a similar pattern; more G2/M 
arrest occurred in the differentiated compared to the undifferentiated state. The addition of 
MMS in the early timepoints of differentiation caused a notable increase in the proportion of 
cells in G2/M, and there was no increase in the proportion of cells in G1 phase of the cell cycle 
at the endpoint of differentiation as there was in the untreated cells. The expression of EOMES 
was turned on as in the untreated, although may have been downregulated earlier. However, the 
most definite result was that SOX17 was not expressed at 48 hours and very few cells expressed 
this protein at 72 hours (Figure 41c and d). Of the cells in S phase of the cell cycle at 72 hours 
(Figure 41b), most of them were SOX17 negative, suggesting that this proportion of cells had 
not committed to differentiate and remaining in S phase was preventing the cells differentiating. 
 
To look more closely at the changes in the cell cycle profile during the early stages of 
differentiation and to see how this compared to treatment in the undifferentiated state, cells 
were treated with 5 ppm MMS at 0- and 24-hours and EdU was added for an hour prior to 
collection. The proportion of cells in each phase of the cell cycle was quantified and the results 
are shown in Figure 42a. Flow cytometry plots at a range of time points show clearly that there 
was a high proportion of cells in the G2/M phase in the undifferentiated state in cells treated 
with MMS. However, this was dramatically increased during differentiation. This increase in 
G2/M at 24 hours of differentiation with MMS treatment is shown in Figure 42b. To understand 
whether the efficiency of differentiation was dependent upon the dose of MMS added, different 
concentrations were added 24 hours into the differentiation and cells were collected at 72 hours. 
The reason that 24 hours was chosen is explained in Section 4.2.5: 24 hours induced the greatest 
perturbation of differentiation. Figure 43a shows that the differentiation efficiency was related 
to the dose of MMS added between 2.5 and 10 ppm. However, there was an increase in γH2A.X 
in these cells as the dose of MMS increased (Figure 43b), suggesting that there was an increase 
in DNA damage and this may have prevented efficient differentiation by some means. 
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Figure 42. Cell cycle analysis after treatment of cells with MMS (a) 
EdU analysis of the proportion of cells in each phase of the cell cycle 
at 25.5, 29.5 and 31.5 hours in the undifferentiated state and during 
differentiation. G1 is shown in black, S in grey and G2/M in white. 
Cells were treated with 5 ppm MMS at 0- and 24-hours. (b) replicates 
during differentiation of cells treated with MMS at 0 hours and analysis 
at 24 hours, n=2 independent experiments, p=0.0482 using paired t test, 
mean±SEM plotted. 
(a) 
(b) 
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4.2.3.2 UV irradiation during endoderm differentiation 
To address how UV damage impacts the differentiation process, a single dose of UV was added 
at 24 hours into the differentiation, the reason for which is discussed in Section 4.2.5. Cells 
were differentiated as usual but irradiated with 2 J/m2 UV at 24 hours. While this had very little 
effect on the undifferentiated cells such that there was very little cell death (Figure 25), the 
differentiated cells showed an increased level of cell death. This cell death increased with 
increasing dose, as with MMS treatment during differentiation. Cells were collected for flow 
cytometry at 72 hours and the level of SOX17 was monitored (Figure 44a and b). Upon 
treatment with UV, a population of cells did not express SOX17 at 72 hours, suggesting that 
causing damage prevented the differentiation occurring as efficiently. As with HU treatment, 
there were also fewer cells expressing EOMES at 72 hours compared to untreated, also 
suggesting that differentiation is perturbed, possibly from an early stage. It is also interesting 
that there were few cells blocked in G2/M phase of the cycle, which was different to MMS 
treated cells.  
 
In order to see if there was a differentiation efficiency dose response to UV treatment, different 
doses of UV were added at 24 hours and the cells were collected for flow cytometry at 72 hours 
(Figure 44b). At UV doses of 5 J/m2 and above, there was a high level of cell death: the doses 
0.5, 1 and 2 J/m2 were analysed. The results show that there was a clear UV dose response in 
the proportion of cells expressing SOX17 at 72 hours, in a similar manner to MMS treatment. 
Figure 43. The dose response of MMS treatment at 24 hours to the outcome of differentiation (a) the percentage 
of SOX17 positive cells relative to untreated at 72 hours, n=2 independent experiments, mean±SEM is plotted (b) 
the phosphorylation of H2A.X in response to damage at 72 hours, the black line shows the untreated level in one 
experiment.  
(b) (a) 
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However, since the dose response was only performed once due to the high level of error in 
using the UV box, this response is unlikely to be as significant as with the MMS treatment. 
 
 
4.2.3.3 Kinetics of the DDR after MMS treatment 
At this stage it was clear that undifferentiated and differentiating cells responded differently to 
damage and were also able to tolerate it differently to somatic cells. In order to analyse the 
DNA damage response following MMS treatment, wildtype cells were treated with 10 ppm 
MMS in both the undifferentiated and differentiated state at 24 hours, and cells were analysed 
Figure 44. Analysis of the efficiency of endoderm differentiation with 2 J/m2 UV irradiation at 24 hours (a) DAPI, 
EOMES and SOX17 at 72 hours (b) the percentage of cells expressing SOX17 at 72 hours after treatment with 2 
J/m2 UV at 24 hours, n=3, p=0.0252, paired t test, mean±SEM are plotted (c) the dose response of UV treatment 
added at 24 hours on the percentage of SOX17 positive cells at 72 hours relative to untreated, n=2, mean±SEM 
are plotted. 
(a) (b) 
(c) 
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for γH2A.X signal (Figure 45). The major signal was in S phase and did not appear until four 
hours in both the undifferentiated and differentiating state, much later than seen in somatic cells, 
and remained upregulated until at least eight hours after the induction of damage (Rogakou et 
al., 1998). The MMS was not washed out and the length of time it is active in aqueous solution 
is debated, so this could be a cumulative effect but is likely to represent the higher tolerance of 
hiPSCs to damage and shows their difference compared to somatic cells. There was also a 
similar change in the level of H2A.X in both the undifferentiated and differentiating samples. 
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4.2.4 The DDR during perturbed endoderm differentiation 
4.2.4.1 The γH2A.X spike after treatment with DNA damaging agents 
To understand whether perturbing differentiation in the face of DNA damage could alter the 
γH2A.X that had been seen at around 50 hours during the normal differentiation process, cells 
were differentiated with 300 µM HU or were treated with 5 ppm MMS and the cells were 
collected for flow cytometry analysis (Figure 46). Both HU and MMS treatment were seen to 
cause an upregulation of γH2A.X in the undifferentiated state. During differentiation at the 
point where γH2A.X spike was seen, the signal was also upregulated in the HU and MMS 
treated cells but not to the same extent as in the untreated. The base level was also increased 
during differentiation, to a slightly higher extent than the undifferentiated treated cells showing 
the general DDR. The differentiated cells showed a higher γH2A.X signal in response to 
damage and therefore may have been tolerating the damage in this differentiated state less well 
than in the undifferentiated state. However, the high signal seen during this point in 
differentiation was clearly separate from the DDR. 
 
 
Figure 46. Phosphorylation of H2A.X at the spike that occurs in unperturbed endoderm differentiation. Cells were 
collected at 51.5 hours and monitored for phosphorylation. MMS treated cells were treated at 0-, 24- and 48-hours 
with 5 ppm, HU treated cells were cultured with 300 µM HU throughout differentiation. The baseline level of 
H2A.X phosphorylation increases in damaged cells, but the gating is in relation to the untreated differentiating cells 
to compare the level of phosphorylation in the undifferentiated state and during the spike. 
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4.2.4.2 The role of p53 during differentiation in the presence of DNA damage 
In Section 4.2.1.1 it was shown that MMS and HU treatment during differentiation upregulated 
the level of p53 protein in the cells. This upregulation of p53 could be preventing the 
differentiation in these treated cells and if this were the case then a genetic knockout of TP53 
should prevent this. Previous data has shown that total levels of p53 decrease during the 
differentiation (Chang et al., 2011). The TP53-/- cell line, introduced in Section 4.2.1.1, was 
used in parallel to the wildtype hiPS cells, and differentiated with and without 5 ppm MMS 
added at 0-, 24- and 48-hours (Figure 47a). The TP53-/- cells exhibited a much lower level of 
cell death when treated with MMS compared to wildtype cells, suggesting they were not as 
sensitive to DNA damage or less able to undergo apoptosis due to the lack of p53. The treatment 
with MMS during differentiation in both cell lines caused an increase in the G2/M population 
of cells, suggesting that MMS caused a replication impediment in the TP53-/- cells as well. 
Interestingly however, the TP53-/- cells behaved in a very different manner to the wildtype cells: 
they differentiated to the same extent as the wildtype untreated cells (Figure 47b and c). This 
result clearly showed that the G2/M block was not preventing differentiation, but the presence 
of p53 was. Thus the cells did not have to be in G1 phase for efficient differentiation to occur. 
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Figure 47. Wildtype and TP53-/- cells were treated with 5 ppm MMS every 24 hours of differentiation and collected 
at 72 hours to analyse the proportion of SOX17 positive cells and the phase in the cell cycle compared to untreated 
cells. (a) flow cytometry analysis of one experiment (b) replicate experiments on treatment with 5 ppm MMS at 
0, 24 and 48 hours n=6, p<0.0001, unpaired t test, mean±SEM is plotted (c) as (b) but with treatment just at 24 
hours n=4, p=0.0009. 
 
UV irradiation was also used to induce damage in TP53-/- cells and compared to the wildtype 
cells as above with MMS treatment (Figure 48). The results were very similar: UV treatment 
caused a large G2/M blockage with 5 J/m2 UV, specifically in the TP53-/- cell line, but the cells 
differentiated with a high efficiency in the TP53-/- cell line. This result was in line with the 
MMS treatment during differentiation. 
(a) 
(b) (c) 
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Figure 48. As in Figure 47 but 
with 2 J/m2 UV irradiation at 24 
hours.  
 
 
 
 
 
 
 
 
 
 
 
 
It was likely that ATM would be phosphorylating both H2A.X and CHK2 in this system, and 
that having high levels of DNA damage would upregulate total CHK2 protein, allowing it to be 
phosphorylated around the time of the H2A.X phosphorylation. To attempt to prevent the large 
proportion of cells in the G2/M phase of the cell cycle when differentiating in the presence of 
MMS or UV, a CHK2 inhibitor was used (NSC109555 Tocris). However, the CHK2 inhibitor 
did not stop the G2/M blockage in MMS treated cells at 0.5 µM: the highest dose that did not 
cause toxicity to the cells (Figure 49). Higher doses prevented efficient differentiation and this 
strategy was not continued further.  
 
 
 
 
 
 
Figure 49. Flow cytometry analysis of the G2/M blockage induced in 
differentiation with cells treated with MMS every 24 hours. The CHK2 
inhibitor was added at 0.5 µM in an attempt to prevent this blockage. 
 
 
 
 
 
 
 
On the other hand, ATM-/- cells responded in an opposite manner compared to TP53-/- cells when 
DNA damaging agents were added during the differentiation process: the addition of MMS 
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caused the cells to become very sick and there was increased cell death (Figure 50). The 
differentiation efficiency was decreased dramatically compared to the untreated sample: this 
suggested that inflicting damage without ATM prevented cells differentiating efficiently, and 
that this protein may be required to deal with damage in differentiation. This experiment was 
only performed once due to the high level of cell death. 
 
 
 
 
Figure 50. Wildtype and ATM-/- cells were treated 
with 5 ppm every 24 hours during differentiation 
and flow cytometry analysis was performed to at 
72 hours to monitor the SOX17 positive cells. 
 
 
 
 
 
 
4.2.5 Altering the time of DNA damage induction during differentiation 
It was of interest to work out whether the time at which DNA damage was introduced could 
affect the outcome of the differentiation. To get an insight into whether there was a crucial 
window of time in which adding damage could affect the differentiation, single doses of 5 ppm 
MMS were added at different points (Figure 51a and b). This shows that differentiation was 
most affected when MMS was added at around 24 hours into the process. This time broadly 
correlates with the point in which the levels of DDR proteins decrease during differentiation. 
The resulting upregulation of DDR proteins after treatment with DNA damaging agents may 
prevent further differentiation in these cells, in effect a differentiation checkpoint. This window 
of time may also be crucial for cell fate choice and lineage commitment pathway decisions. The 
outcome of treatment with damaging agents may be affected by the position of the cells in the 
cell cycle when damage was induced, as the cell cycle distribution was altered throughout 
differentiation. 
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Cells were also treated with MMS after 72 hours to see whether this decreased the percentage 
of cells expressing SOX17. Cells were treated at different times after 72 hours and collected at 
79 hours (Figure 51c). There was no decrease in SOX17 expression after treatment with MMS, 
suggesting that MMS had to be added during the process of differentiation to affect the 
outcome. However, collecting the cells at a later point after MMS addition could have increased 
the effect.  
 
 
 
 
 
Figure 51. Analysis of the effect 
of 5 ppm MMS differentiation 
depending on the point of 
treatment (a) analysis of SOX17 
positive cells at 72 hours 
compared to untreated when 
MMS was added between zero 
and 66 hours, n=3 technical 
replicates, mean±SEM plotted, (b) 
biological replicates n=3, 
mean±SEM plotted (c) SOX17 
expression at 79 hours after 
treating between 72 and 75.5 
hours.  
 
 
 
(a) 
(b) 
(c) 
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4.2.6 Does inflicting DNA damage prevent cell cycle progression? 
A simple answer to why inducing DNA damage was preventing differentiation was that it was 
either slowing or completely stopping the cell cycle and therefore the cells were not becoming 
specified to definitive endoderm. 
 
4.2.6.1 Does the length of the cell cycle increase in cells treated with DNA damage inducing 
agents? 
If the damage exposed cells were not differentiating because they were lagging in the number 
of cell divisions compared to untreated cells, then letting these cells differentiate for longer 
should increase the efficiency of differentiation to untreated levels. Cells were treated with 5 
ppm MMS at 0-, 24- or 48-hours and the cells were collected for flow cytometry at 96 hours to 
allow an extra 24 hours of differentiation after treatment (Figure 52). This result shows that the 
extra 24 hours did not allow the treated cells to catch up with the untreated differentiation and 
suggests that the undifferentiated cells at 72 hours do not go on to differentiate given an extra 
24 hours. Maintaining the untreated cells in this state for over 118 hours caused the cells to 
become too confluent and lose adherence so timepoints later than 118 hours were not used. The 
percentage of SOX17 in untreated samples at later timepoints also decreased. 
 
 
 
Figure 52. The percentage of SOX17 positive cells at 
96 hours (after an extra 24 hours of differentiation) 
after treatment with 5 ppm MMS at 0-, 24- or 48-hours. 
There was a decrease in expression regardless of the 
time of treatment, and treatment at 24 hours still caused 
the biggest decrease. One experiment shown. 
 
 
 
 
 
 
 
 
 
 
 
4.2.6.2 Does the cell cycle stop in damaged cells? 
In order to understand whether cells treated with DNA damaging agents were not differentiating 
efficiently simply because they had stopped dividing, the number of cell divisions was 
monitored. This was done using the CellTrace™ Cell Proliferation Kit (ThermoFisher) which 
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stains the cells with a fluorescent dye. The fluorescence of a cell decreases by half at every cell 
division, allowing the number of cell divisions that a given cell has gone through to be counted. 
This method was performed in the undifferentiated and differentiated state, with and without 
the addition of 5 ppm MMS at 24 hours and the cells were collected at different timepoints and 
analysed using flow cytometry (Figure 53a). The cell division staining showed that cells treated 
with MMS during differentiation did have a small but significantly different decrease in the 
number of cell divisions (Figure 53b). However, SOX17 was able to be expressed from cell 
cycle number three in the untreated cells. The slight cell cycle slowing of MMS treated cells 
was also the case in TP53-/- cells (Figure 53c and d), showing that the lack of p53 did not 
increase the percentage of SOX17 positive cells by simply increasing the cell cycle speed. 
However, the experiment in the TP53-/- cell line was only performed once and would need to 
be verified. This data suggested that it was not a decrease in the number of cell cycles that was 
inhibiting efficient differentiation. 
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Figure 53. CellTrace™ analysis of the number of cell divisions occurring during differentiation (a) 5 ppm MMS 
was added at 24 hours and cells were collected for analysis at 24-, 48- and 72-hours. Untreated cells had gone 
through a median of 4.96 cell cycles compared to the MMS treated cells which had done 4.65. (b) replicate 
experiments of the CellTrace™ experiment showing the number of cell cycles at 72 hours will MMS treatment at 
24 hours compared to untreated cells. Mean±SEM is shown, n=3, p=0.0097 use paired t test (c) flow cytometry to 
show the number of cell divisions with TP53-/- fluorescence decreases by half on each cell division (d) a graph 
showing the number of cell divisions from (d).  
 
4.3 Cell death during differentiation 
During the unperturbed differentiation in vitro there was consistently large amounts of cell 
death compared to the undifferentiated state, an increased number of cells lost adherence 
throughout the process and floated to the surface compared to the undifferentiated state. To 
understand why this might be happening, Annexin V-7AAD cell death staining was performed 
(Figure 54a) and analysed using flow cytometry (Figure 54b).  
 
4.3.1 Analysis of the type of cell death during endoderm differentiation 
Surprisingly this showed that at 24 and 48 hours into the differentiation process, the cells that 
had lost adherence and were in the supernatant were mostly alive, with a proportion of late 
(d) 
(c) 
(a) (b) 
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apoptotic cells. This suggests that these cells were not dying and therefore may have been losing 
adherence for another reason, such as not differentiating correctly. At 72 hours most of the 
supernatant cells were late apoptotic suggesting that programmed cell death was occurring 
again at the end of the differentiation process. However, during the differentiation process, the 
adherent cells seem to be showing increased apoptosis at the later time points. This shows that 
there was a large amount of cell death in vitro in the differentiation process although the reasons 
why remain unknown. In the undifferentiated state, the cells that had lost adherence were mostly 
apoptotic cells, and therefore not alive. There were also much fewer ‘floating cells’ in the 
undifferentiated cells compared to during differentiation. This experiment shows comparable 
data to the mES ‘floating cell’ experiments and shows that a large amount of data can be 
obtained from the cells that lose adherence. 
 
 
Figure 54. Annexin V / 7-AAD staining to analyse necrotic and 
apoptotic cells (a) schematic to explain the gating (b) untreated 
wildtype undifferentiated and differentiating cells were collected every 
24 hours. The adherent and non-adherent population were separated 
prior to analysis. 
 
 
 
 
 
 
4.3.2 Analysis of the reason behind losing adherence during differentiation 
To see whether the cells that had lost adherence during the differentiation process were 
expressing either EOMES or SOX17, adherent and non-adherent cells were collected at 72 
hours and permeabilised flow cytometry was performed to check the protein levels (Figure 
(a) 
(b) 
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55a). The cells that had lost adherence displayed very low SOX17 or EOMES, suggesting that 
not expressing the markers could prevent them from remaining adherent in the culture 
conditions. However, it could be that the cells were initially losing adherence and this loss of 
adherence was preventing the expression of the proteins EOMES and SOX17. It was also clear 
that the non-adherent cells were not cycling and did not show a cell cycle profile typical of 
differentiated cells. 
 
To check which proteins were expressed only in the alive cells in the supernatant, non-adherent 
cells were collected and the live cells were separated from dead cells using the MACS® dead 
cell removal kit. These live cells were fixed and analysed for the expression of EOMES and 
SOX17 (Figure 55b). The non-adherent live cells at 24 hours were not expressing EOMES. 
This suggested that the reason that they were no longer attached to the plate was because they 
were not differentiating towards the endoderm lineage. At 48 hours into the differentiation none 
of the alive cells were expressing SOX17 when it would be expected that around 40-60% of 
differentiating cells would be expressing it at this time. However, they were expressing EOMES 
at this time and therefore had partially differentiated. This implies that at least some of the cells 
that did not remain adherent during the differentiation were not dying and were also not 
differentiating. This could be caused by a problem occurring during differentiation, after 
EOMES was switched on but before definitive endoderm was specified. 
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Figure 55. Analysis of the expression of non-adherent cells (a) the expression of SOX17 and EOMES at 72 hours 
in the ‘floating cells’ (b) the gene expression of live cells in the supernatant at 24 and 48 hours, the EOMES and 
SOX17 positive population in adherent cells is marked with an arrow. 
 
 
 
 
 
(a) 
(b) 
123 
 
4.4 Using RNA sequencing to understand the consequence of 
inflicting DNA damage on differentiation 
As showed throughout this chapter, treatment of cells with DNA damaging agents caused a 
very different effect during differentiation compared to in the undifferentiated state. The levels 
of DDR proteins, the quantity of cell death and the DNA damage response upon treatment with 
MMS, UV and HU were very different between these states. The TP53-/- cell line was also able 
to differentiate to a greater extent when treated with DNA damaging agents compared to 
wildtype cells. In order to understand the differences seen throughout the differentiation, RNA 
sequencing was performed in wildtype and TP53-/- cells, in both the undifferentiated state and 
during differentiation, with and without MMS treatment. MMS was added to cells at 5 ppm at 
24 hours and the cells were collected for RNA every 24 hours in triplicate.  
 
The principle component analysis (PCA) plot for the total experiment is shown in Figure 56a; 
this gave an overview of the data and showed the ‘vector of differentiation’. The basis of a PCA 
is to simplify the data to, in this instance, two dimensions to display the greatest variance 
between the individual datasets. This allows a pattern in the data to be seen before analysing 
individual genes. This showed that the undifferentiated samples clustered well together, as did 
the 24-, 48- and 72-hour samples. During differentiation, before MMS treatment, at 24 hours 
the wildtype and TP53-/- cells were defined in slightly different locations but close to one 
another. At 48 hours the wildtype and TP53-/- triplicates remained very close but the wildtype 
MMS treated did separate out slightly from the wildtype untreated: this is seen in a similar 
manner in the PDS treated cells in Results III. This was not the case for the TP53-/- cells. At 72 
hours there was a definite clustering of wildtype and TP53-/-separately with the wildtype MMS 
treated and untreated forming separate clusters. The TP53-/- treated and untreated did not 
separate as well, possibly due to the MMS having less effect in this cell line.  
 
Although the undifferentiated cells did cluster together there were clear gene expression 
changes between these cells and the PCA was rerun with just the undifferentiated cells and is 
shown on a different scale due to the number of deregulated genes being much smaller (Figure 
56b). This showed that the wildtype cells all clustered to the left of the plot and the TP53-/- to 
the right of the plot. The 24-, 48- and 72-hour RNA each clustered together, showing that there 
was a ‘day effect’ discussed further in Results III and Results IV. The untreated and wildtype 
MMS treated clustered separately, which was less pronounced with TP53-/-, again highlighting 
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the fact that the wildtype cells react transcriptionally in a different manner to TP53-/- cells when 
treated with damage.  
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Figure 56. PCA analysis of this dataset to show the variance of the datapoints (a) the undifferentiated points 
are circled and the TP53-/- and wildtype are not marked due to the similarity on this scale. Cells were treated 
with 5 ppm MMS at 24 hours (circles) or untreated (triangles), 24 hours (red), 48 hours (green) and 72 hours 
(blue), wildtype cells have a central black dot whereas TP53-/- is left as symbols. Data was performed in 
triplicate and libraries at 48 hours of differentiation were run twice for sufficient reads (hence double the 
points) (b) as above but just with undifferentiated samples. 
(a) 
(b) 
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4.4.1 Changes to the expression of DDR markers during unperturbed differentiation 
As the western blots showed changes in DDR markers during differentiation, the RNA of these 
transcripts was checked and is shown in Figure 57. The RNA used for these graphs were taken 
from the RNAseq experiment in Results III as this was performed first. Interestingly there were 
a number of genes with altered expression throughout differentiation, but there were also a 
number where there were not significant differences despite knowledge that there is a difference 
in the protein level. For example, TP53 mRNA did decrease slightly during differentiation but 
not significantly and it is known that MDM2 controls the level of p53 protein during 
differentiation and is expressed to a similar level. CHEK2 mRNA decreased significantly 
during differentiation, in line with the idea that it may decrease so that it cannot be 
phosphorylated by ATM at the EMT. RPA2 decreased significantly at 48 hours, also at the time 
of the EMT, and this RPA subunit is able to be phosphorylated by ATM. PARP1 and TERT, a 
subunit of telomerase, decreased throughout differentiation in line with these being expressed 
at higher levels in the undifferentiated cells. Interestingly the level of TP53BP1 increased 
throughout differentiation, potentially suggesting an increase in the use of NHEJ during 
differentiation. 
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Figure 57. The mRNA of factors involved in processing DNA damage and 
orchestrating the DDR. Time zero is taken to be 24 hours undifferentiated and 
significance is measured related to this at p<0.05, marked with * calculated 
using the CuffDiff program which uses a student’s t test. The mean±SD are 
plotted, n=3 with RNA collected on the same day from different cultures.  
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4.4.2 Gene expression differences between untreated wildtype and TP53-/- cells 
Before analysing the changes upon treatment with MMS, the differences between the wildtype 
and TP53-/- cells in both the undifferentiated state and throughout differentiation were 
compared. 
 
4.4.2.1 Differences in the undifferentiated state 
Using the sequencing data from undifferentiated wildtype and TP53 knockout undifferentiated 
cells (in Results IV) there were over 50 genes differentially expressed and this is shown in the 
scatterplot in Figure 58. Using these genes, the ten most significant gene ontology (GO) terms 
associated with the differences between these cells were analysed (Table 8). TRANSFAC TFBS 
(genexplain) was also used to analyse these deregulated genes for transcription factor binding 
site motifs (Table 9). These enrichment analyses showed that the gene expression changes were 
in p53-related pathways, suggesting that the genetic knockout prevented upregulation of genes 
with p53-target binding sites. This was expected for these undifferentiated cells, and it was clear 
that the lack of p53 did not alter the expression of pluripotency genes upregulated in the 
undifferentiated state. While there were no transcription factor binding sites with significant p-
values (p<0.05), probably due to the small number of deregulated transcripts, the most 
significant results were members of the p53 family, again suggesting that these cells are true 
genetic knockouts. 
 
 
 
 
Figure 58. A scatter plot to show the genes with differential expression in the wildtype compared to the TP53-/- cell 
line in the undifferentiated state. Significantly differentially expressed genes are marked in red and these occur off 
the line x=y. 
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GO ID Description Count Adjusted p-
value 
0043068 Positive regulation of programmed cell death 11/628 0.0000769 
0043065 Positive regulation of apoptotic processes 11/622 0.0000769 
0045569 TRAIL binding 3/5 0.0000769 
0010942 Positive regulation of cell death 11/682 0.000106 
0072332 Intrinsic apoptotic signaling pathway by p53 
class mediator 
5/82 0.000381 
0006919 Activation of cysteine-type endopeptidase 
activity involved in apoptotic process 
5/82 0.000381 
0097193 Intrinsic apoptotic signaling pathway 7/295 0.00113 
0070242 Thymocyte apoptotic pathway 3/17 0.00129 
0009612 Response to mechanical stimulus  6/212 0.00129 
0097190 Apoptotic signaling pathway 9/601 0.00129 
Table 8. The ten most significant GO terms associated with the list of genes with deregulated expression between 
wildtype and TP53-/- cells in the undifferentiated state. 
 
Term ID Description Count Adjusted 
p-value 
M01651 Factor: p53; motif: RGRCATGYCYRGRCATGYYY 15/2249 0.0963 
M01651_0 Factor: p53; motif: 
RGRCATGYCYRGRCATGYYY; match class: 0 
15/2249 0.0963 
M01656_1 Factor: p63; motif: RRACATGTCNRGACATGTYY; 
match class: 1 
17/2681 0.0963 
M09629_1 Factor: IRF-1; motif: 
NAAANNGAAAGTGAAASTRN; match class: 1 
3/35 0.0963 
Table 9. A list of the most significant transcription factor binding sites in the genes deregulated between wildtype 
and TP53-/- cells. 
 
This was then confirmed using the undifferentiated collected TP53-/- cells collected every 24 
hours in the MMS endoderm experiment and compared to the wildtype cells. The Venn diagram 
is shown in Figure 59. There was the greatest difference at 72 hours, probably when the cells 
were slightly overconfluent, and 21 genes deregulated at every timepoint. The GO analysis and 
transcription factor binding site analysis was almost identical to that shown above in Table 8 
and Table 9. The majority of differences were p53-specific, as expected. 
 
Figure 59. Comparison of the deregulated 
genes between wildtype and TP53-/- at 24-, 48- 
and 72-hours in the undifferentiated state in 
Venn diagram format. 
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4.4.2.2 Differences between wildtype and TP53-/- cells during differentiation 
As in the undifferentiated state, the gene expression profiles of TP53-/- cells were compared to 
wildtype cells every 24 hours during differentiation (Figure 60a). As in the undifferentiated 
cells, the greatest change was seen at 72 hours, with only ten genes shared between the three 
conditions. The GO analysis overlap in these conditions is shown in Table 10, there were no 
significant transcription factor binding sites in this gene list. These terms were very similar to 
the undifferentiated state and are all directly relevant to the lack of p53. At 72 hours, 37 genes 
were shared between the undifferentiated and differentiated, suggesting these are specific for 
lack of p53 (Figure 60b). However, there were clearly many more deregulated genes during 
differentiation than in the undifferentiated state. 
 
 
Figure 60. Venn diagrams to 
show the comparison of 
deregulated genes in the 
wildtype versus TP53-/- cell 
lines (a) every 24 hours during 
differentiation (b) comparing 
the undifferentiated and 
differentiated state at 72 hours. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(a) 
(b) 
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GO term Description Count Adjusted p-
value 
GO:0097193 Intrinsic apoptotic signaling pathway  4/295 0.00113 
GO:0072332 Intrinsic apoptotic signaling pathway by 
p53 class mediator 
3/82 0.00113 
GO:0043068 Positive regulation of programmed cell 
death 
4/628 0.00315 
GO:0044065 Positive regulation of apoptotic process 4/622 0.00315 
GO:0010952 Positive regulation of peptidase activity 3/179 0.00315 
GO:2001056 Positive regulation of cysteine-type 
endopeptidase activity 
3/162 0.00315 
GO:0042772 DNA damage response, signal 
transduction resulting in transcription 
3/135 0.00315 
GO:006978 DNA damage response, signal 
transduction by p53 class mediator 
resulting in transcription of p21 class 
mediator 
2/20 0.00315 
GO:0097190 Apoptotic signaling pathway 2/19 0.00315 
GO:0010950 Positive regulation of endopeptidase 
activity 
4/601 0.00315 
Table 10. The GO enrichment of the ten transcripts deregulated between the wildtype and TP53-/- cells at 24-, 48- 
and 72-hours in differentiation. 
Comparing the wildtype and TP53-/- cells at 72 hours into the differentiation had over 500 genes 
and the GO enrichment and transcription factor analysis are shown in Table 11 and Table 12. 
More of the gene ontology terms were enriched in developmental processes, suggesting that 
TP53-/- cells may have slightly altered differentiation. This may be due to the confluence of 
these cells, or the lack of cell death experienced during normal differentiation in these cells. 
There were a number of enriched transcription factor binding sites, however, none of them were 
in the p53 family of transcription factors. This suggested that TP53-/- was not the key 
transcription factor regulating these changes. 
 
GO term Description Count Adjusted p-
value 
GO:0048856 Anatomical structure development 220/5793 8.29x10-8 
GO:0007275 Multicellular organism development 206/5321 8.29x10-8 
GO:0032502 Developmental process 230/6212 1.36x10-7 
GO:0009653 Anatomical structure morphogenesis 120/2598 1.66x10-7 
GO:1905114 Cell surface receptor signaling pathway 
involved in cell-cell signaling 
43/569 5.57x10-7 
GO:0016477 Cell migration 78/1466 0.00000102 
GO:0009888 Tissue development 94/1926 0.00000107 
GO:0023051 Tube morphogenesis 56/899 0.00000107 
GO:0023051 Regulation of signaling  144/3482 0.00000141 
GO:0048646 Anatomical structure formation involved 
in morphogenesis 
65/1144 0.00000143 
Table 11. GO enrichment of significantly differentially expressed genes between wildtype and TP53-/- cells at 72 
hours during differentiation. 
132 
 
TRANSFAC 
TFBS 
Factor Motif Count Adjusted p-
value 
TF:M07039 ETF CCCCGCCCCYN 418/13652 5.38x10-7 
TF:M00986 Churchill CGGGNN 432/14245 5.38x10-7 
TF:M03876 Kaiso GCMGGGTGCRGS 307/9094 5.38x10-7 
TF:M07040 GKLF NNRRGRRNGNSNNN 397/12747 5.38x10-7 
TF:M09723 BTEB1 GGGGGCGGGGCNGSGGNGS 325/9991 0.0000048 
Table 12. Transcription factor binding site enrichment analysis of genes deregulated between wildtype and TP53-
/- cells at 72 hours in differentiation. 
 
4.4.3 Treatment with MMS in wildtype and TP53-/- cells 
The differences in the wildtype and TP53-/- cells after treatment with MMS was compared in 
both the undifferentiated state and during differentiation. 
 
4.4.3.1 Treatment with MMS in the undifferentiated state 
MMS was added to the undifferentiated and differentiating cells at 24 hours and then the cells 
were collected at 48 and 72 hours. The changes in gene expression in wildtype and TP53-/- cells 
in the undifferentiated state are shown in Figure 61a and b. Very few genes were deregulated 
at 48 hours and 72 hours in the undifferentiated state of both cell lines when the cells were 
treated with MMS. This explained the low level of death and lack of any observable changes in 
these cells. Interestingly, there were fewer changes at 72 hours, suggesting that the cells have 
processed any damage by this point, this is on the contrary to the differentiating cells where the 
differences were greater at 72 hours. There were also only five deregulated genes which 
overlapped between the wildtype MMS treated and TP53-/- MMS treated cells at 48 hours, 
suggesting common pathways are not triggered possibly due to the lack of p53. 
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Figure 61. Venn diagram comparisons of changes in the undifferentiated state after MMS treatment (a) comparison 
of 48 hours to 72 hours in the wildtype cell line (b) as (a) but with TP53-/-. Venn diagrams not to scale between 
cell lines. 
 
The enrichment in the MMS treated cells compared to the untreated cells at 48 hours were 
analysed for GO terms in both TP53-/- and wildtype (Table 13). There were no significantly 
enriched transcription factor binding sites in these gene lists. In the wildtype cell line these GO 
terms were associated with responses to external stimuli and cell death, as well as development. 
Suggesting that MMS treatment induces a number of significant responses in these cells. The 
enrichment showed different pathways deregulated in TP53-/- cells, probably due to the lack of 
p53. These terms were associated with calcium signalling pathways and muscle hypertrophy, 
which p53 has been previously implemented in (Mak et al., 2017). 
 
 
 
 
 
 
 
 
 
 
 
 
(a) 
(b) 
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GO term Description Count Adjusted p-
value 
Wildtype 
GO:0048513 Animal organ development 26/3428 0.000745 
GO:0009605 Response to external stimulus 24/3141 0.000794 
GO:1901700 Response to oxygen-containing 
compound 
35/6513 0.000794 
GO:0007154 Cell communication 16/1571 0.000794 
GO:0065009 Regulation of molecular function 20/2332 0.000794 
GO:0023052 Signaling 36/6554 0.000794 
GO:0009893 Positive regulation of metabolic process 24/3333 0.000794 
GO:0010604 Positive regulation of macromolecule 
metabolic process 
23/3134 0.000794 
GO:0010941 Regulation of cell death 15/1378 0.000794 
GO:0043067 Regulation of programmed cell death 17/1676 0.000794 
TP53-/- 
GO:0032501 Multicellular organismal process 24/7414 0.00794 
GO:0014896 Muscular hypertrophy 4/109 0.00794 
GO:0014897 Striated muscle hypertrophy 4/107 0.00794 
GO:0003300 Cardiac muscle hypertrophy 4/105 0.00794 
GO:0007267 Cell-cell signaling 11/1559 0.00794 
GO:0099094 Ligand-gated cation channel activity 4/103 0.00794 
GO:0005219 Ryanodine-sensitive calcium-release 
channel activity 
2/4 0.00794 
GO:0048763 Calcium-induced calcium release activity 2/4 0.00794 
GO:0060079 Excitatory postsynaptic potential  4/113 0.00814 
GO:0071495 Cellular response to endogenous signal 10/1347 0.00815 
Table 13. The GO enrichment analysis of the genes deregulated in the MMS treated cells compared to the untreated 
cells at 48 hours in both undifferentiated wildtype and TP53-/- cell lines. The ten most significant terms are shown. 
 
The differences in the MMS treated TP53-/- treated cells compared to the MMS treated wildtype 
cells at both 48 and 72 hours had a high level of overlap (Figure 62). This suggested that there 
were distinct differences in the transcriptome in wildtype versus TP53-/- cells when treated with 
damaging agents. These differences had significant enrichment in stress, checkpoints and p53 
pathways, shown in Table 14. The enriched transcription factor binding sites are shown in Table 
15. Clearly the lack of p53 was causing big differences in the control of DNA damage signalling 
pathways, and p53 was one of the key transcription factors implicated in these differences. 
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GO term Description Count Adjusted p-value 
GO:0072331 Signal transduction by p53 class 
mediator 
14/223 3.39x10-8 
GO:0072332 Intrinsic apoptotic signaling pathway 
by p53 class mediator 
10/82 3.39x10-8 
GO:0009628 Response to abiotic stimulus 25/1120 8.34x10-7 
GO:0044783 G1 DNA damage checkpoint 8/66 0.0000135 
GO:0044819 Mitotic G1/S transition checkpoint 8/65 0.0000135 
GO:0031571 Mitotic G1 DNA damage checkpoint 8/65 0.0000135 
GO:0033554 Cellular response to stress 31/1870 0.00000272 
GO:0097193 Intrinsic apoptotic signaling pathway 13/295 0.00000272 
GO:0034644 Cellular response to UV 8/77 0.00000313 
GO:0006974 Cellular response to DNA damage 
stimulus 
20/815 0.00000355 
Table 14. The GO enrichment of genes deregulated at both 48 and 72 hours in the undifferentiated state with MMS 
treatment in TP53-/- compared to wildtype cells. 
 
 
TRANSFAC 
TFBS 
Factor Motif Count Adjusted p-
value 
TF:M01873 Egr-1 GCGGGGGCGG 62/6728 0.00119 
TF:M01655 p53 GGACATGYYCGGACATGYYC 40/3503 0.00173 
TF:M02089 E2F-3 GGCGGGN 93/13182 0.00235 
TF:M08878 EGF CGCCCCCGCNN 64/7482 0.00286 
TF:M07354 Egr-1 GCGGGGGCGG 65/7783 0.0043 
Table 15. Transcription factor binding site enrichment of genes overlapping in Figure 62. 
 
 
Figure 62. A Venn diagram to 
show the comparison of the 
deregulated genes in the 
undifferentiated state in the 
wildtype and TP53-/- cell lines 
after MMS treatment at 48 and 
72 hours. 
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4.4.3.2 MMS treatment during differentiation 
Comparing the untreated and MMS treated differentiating samples at 48 and 72 hours in the 
wildtype and TP53-/- cell lines showed that there were many more deregulated genes at both 
times in the wildtype cell line (Figure 63). There were also more changes at 72 hours compared 
to 48 hours in the wildtype cell line suggesting that the treatment continues to exacerbate the 
phenotype over 24 hours after treatment. In the TP53-/- cells there were many fewer deregulated 
genes at both times, and a very small overlap between the times. There were also fewer genes 
deregulated at 72 hours compared to 48 hours in this cell line, again suggesting that 
differentiation is not affected in the same manner. The GO analysis for the difference between 
the treated and untreated, differentiating cells at 72 hours were analysed in each cell line (Table 
16) and the significant transcription factor binding sites for these are shown in Table 17, there 
were no significant sites in the TP53-/- gene list. The GO terms in the wildtype deregulated 
transcripts were mainly associated with development and morphogenesis whereas in TP53-/- 
they were mainly transporters and channels. Comparing the wildtype and TP53-/- deregulated 
genes at both 48 and 72 hours there were low levels of overlap, suggesting that some of the 
differences were the same with or without MMS (Figure 64). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 63. Venn diagrams to show the comparison of deregulated genes after MMS treatment during differentiation 
at 48 hours and 72 hours (a) TP53-/- (b) wildtype. Venn diagram scales are not comparative between cell lines. 
 
 
 
 
 
 
 
 
 
(a) 
(b) 
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Figure 64. Venn diagram comparison of wildtype and TP53-/- MMS treated cells at (a) 48 hours and (b) 72  
hours. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(a) 
(b) 
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GO term Description Count Adjusted p-
value 
Wildtype 72 h 
GO:0009653 Anatomical structure morphogenesis 241/2598 1.75x10-34 
GO:0048856 Anatomical structure development 400/5793 1.39x10-33 
GO:0007275 Multicellular organism development 378/5321 1.39x10-33 
GO:0032502 Developmental process 413/6212 2.19x10-31 
GO:0009887 Animal organ morphogenesis 129/969 3.71x10-31 
GO:0048731 System development 336/4760 9.98x10-28 
GO:0048731 Animal organ development 265/3428 6.23x10-26 
GO:0032501 Multicellular organismal process 449/7414 1.17x10-25 
GO:0048646 Anatomical structure formation involved 
in morphogenesis 
129/1144 3.23x10-24 
GO:0035295 Tube morphogenesis 124/1079 6.04x10-24 
TP53-/- 72 h 
GO:0008324 Cation transmembrane transporter 
activity 
7/664 0.00942 
GO:0046873 Metal ion transmembrane transporter 
activity 
6/457 0.00942 
GO:0022803 Passive transmembrane transporter 
activity 
6/470 0.00942 
GO:0015267 Channel activity 6/469 0.00942 
GO:0005261 Cation channel activity 5/320 0.0148 
GO:0005215 Transporter activity 8/1251 0.0223 
GO:0015075 Ion transmembrane transporter activity 7/897 0.0223 
GO:0022890 Inorganic cation transmembrane 
transporter activity 
6/605 0.0223 
GO:0015077 Monovalent inorganic cation 
transmembrane transporter activity 
5/392 0.0223 
GO:0022842 Narrow pore activity 2/19 0.0288 
Table 16. GO enrichment for transcripts deregulated between untreated and MMS treatment at 72 hours of 
differentiation in wildtype and TP53-/- cells. MMS treatment was performed at 24 hours. 
 
 
TRANSFAC TFBS Factor Motif Count Adjusted p-
value 
TF:M07354 Egr-1 GCGGGGGCGG 443/7783 5.63x10-18 
TF:M01104 MOVO-B GNGGGGG 345/5567 1.26x10-17 
TF:M03876 Kaiso GCMGGGRGCRGS 493/9094 3.22x10-17 
TF:M07040 GKLF NNRRRGRRNGNSNNN 628/12747 7.4x10-17 
TF:M00695 ETF GVGGMGG 404/7004 7.4x10-17 
Table 17. Significantly enriched transcription factor binding sites in genes deregulated at 72 hours in wildtype 
MMS treated cells compared to wildtype untreated cells during differentiation. There were no significant results 
in the TP53-/- cells. 
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The genes differentially expressed between the wildtype and TP53-/- differentiating cells after 
MMS treatment were compared at 48 hours and 72 hours (Figure 65). This showed that there 
was a large overlap between these times, suggesting the differences in how the two cell lines 
deal with damage. The GO term enrichment for this overlap is shown in Table 18. These terms 
were mainly responses due to oxygen levels, possibly due to the different ways of processing 
DNA damage, and developmental pathways. The transcription factor binding site enrichment 
is shown in Table 19. 
 
GO term Description Count Adjusted p-
value 
GO:0070482 Response to oxygen levels 23/339 1.5x10-8 
GO:0036293 Response to decreased oxygen levels 22/316 1.5x10-8 
GO:0009628 Response to abiotic stimulus 40/1120 3.34x10-8 
GO:0001666 Response to hypoxia 21/306 3.34x10-8 
GO:0007275 Multicellular organism development 101/5321 2.51x10-7 
GO:0048856 Anatomical structure development 106/5793 4.64x10-7 
GO:0031012 Extracellular matrix 21/376 7.74x10-7 
GO:0009653 Anatomical structure morphogenesis 61/2598 0.00000177 
GO:0032502 Developmental process 109/6212 0.00000187 
GO:0050840 Extracellular matrix binding 9/53 0.00000278 
Table 18. GO term enrichment of the overlap at 48 and 72 hours of deregulated genes in the TP53-/- MMS treated 
cells compared to wildtype treated cells during differentiation. Cells were treated with MMS at 24 hours. 
 
TRANSFAC TFBS Factor Motif Count Adjusted p-
value 
TF:M01219 SP1:SP3 CCGCCCCCYCC 122/6823 2.86x10-7 
TF:M00986 Churchill CGGGNN 195/14245 0.00000133 
TF:M00333 ZF5 NRNGNGCGCGCWN 201/15142 0.00000338 
TF:M02089 E2F-3 GGCGGGN 184/13182 0.00000338 
TF:M00982 KROX CCCGCCCCCRCCCC 129/7814 0.00000338 
Table 19. Transcription factor binding site enrichment of the overlap at 48 and 72 hours of deregulated genes in 
the TP53-/- MMS treated cells compared to wildtype treated cells during differentiation. 
Figure 65. Venn diagram to compare the differences at 48- and 72-hours between the wildtype and TP53-/- cell 
lines after treatment with MMS during differentiation. 
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4.5 Preliminary data using human ES cells show a similar trend on 
treatment with MMS 
4.5.1 Endoderm differentiation 
The BOBSC cells are hiPS cells, not hES cells, and are known to have a single translocation 
near the MYC gene. To understand whether the observations from these cells can be generalised 
to a greater extent across differentiation the key experiments were repeated in the H9 hES cell 
line. Ideally these would also be repeated in the BOBSC cell line without the translocation. The 
cells were initially differentiated without any treatment to analyse their differentiation 
capability (Figure 66a). This showed that they differentiate with a high efficiency under the 
same conditions as the hiPS cells, but the level of EOMES at 72 hours remained higher in the 
H9 cells. Further experiments were compared.  
 
4.5.2 MMS treatment 
Initial observations suggested that the undifferentiated H9 cells did not tolerate MMS treatment 
as well as the BOBSC cells: there was a greater level of cell death using 5 ppm MMS. However, 
the endoderm differentiated cells were still much sicker than the undifferentiated cells, as in the 
hiPSCs. H9s were differentiated with MMS treatment, either one dose at 24 hours or three 
single doses at 0-, 24- and 48-hours (Figure 66b). When the cells were administered three doses, 
the H9 cells were much sicker than the BOBSC cells in both the undifferentiated and 
differentiated state, possibly suggesting that the dose many need to be decreased to see the same 
effect. There was also notably less G2/M arrest in the 0-, 24- and 48-hour MMS treated H9 cells 
but this may have been biased due to the increased cell death. However, MMS clearly decreased 
the expression of SOX17 during the differentiation in the H9 cells, although possibly to a lesser 
extent. Suggesting that DNA damage prevents differentiation in H9s and may be a more general 
phenomenon. 
 
4.5.3 The spike of H2A.X phosphorylation in differentiation 
The cells were also analysed between 48 and 52 hours to see if there was a spike of γH2A.X 
around the time that this was seen in the BOBSC cells (Figure 66c). This shows that there was 
an upregulation of phospho-H2A.X at this time, suggesting that this is specific to the 
differentiation and showing that the H9s act in a similar manner to the BOBSC cells. However, 
the level of upregulation appeared to be lower in the H9s compared to the BOBSC cell line. 
This is likely to be a general phenomenon of cells moving through the EMT. 
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Figure 66. (See next page.) Analysis of the H9 hESCs in comparison to the BOBSC hiPSC cell line (a) unperturbed 
differentiation monitored by DAPI, EOMES and SOX17 at 72 hours (b) SOX17 expression at 72 hours after MMS 
treatment as labelled (c) phosphorylation of H2A.X at the point of the spike during differentiation. 
(a) 
(b) 
(c) 
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Chapter 5. Results III: The effect of G-
quadruplex-binding ligands in the 
undifferentiated state and during 
differentiation of hiPSCs 
5.1 Culturing hiPSCs with G4 ligands in the pluripotent state 
5.1.1 Maintaining the cells in the undifferentiated state 
Having analysed the effect of inducing DNA damage on the endoderm differentiation capacity 
of hiPSCs, I wanted to understand how growing and differentiating the cells with G4 ligands 
would compare to the DNA damaging agent treatment. BOBSC cells were cultured in the 
undifferentiated state with the G4 ligands PDS and PhenDC3 (De Cian et al., 2007; Rodriguez 
et al., 2008), discussed previously in Results I, to see how well the cells were able to tolerate 
the ligands. Concentrations up to 4 µM of both ligands were added to cells in the 
undifferentiated state for five days and there were minimal differences in doubling times 
suggesting that these concentrations could be used further for differentiation experiments. 
However, as in the mESCs, there were more ‘floating cells’ in the wells treated with G4 ligands, 
possibly also suggesting a loss of pluripotency or increased cell death. The following 
experiments were performed using PDS or PhenDC3 at a concentration where the DMSO was 
known not to alter the outcome of differentiation and had previously been shown to stabilise 
G4s in DT40 cells (Guilbaud et al., 2017).  
 
5.1.2 The cell cycle profile 
To understand whether the G4 ligands were causing replication stress, as has been previously 
shown (Guilbaud et al., 2017), undifferentiated BOBSC cells were grown with either PDS or 
PhenDC3 for two days and EdU labelling was performed, as previously. The proportion of cells 
in each phase of the cell cycle with and without the ligand was quantified (Figure 67), replicates 
are shown in comparison to differentiation (Figure 69b). Culturing the cells in PDS in the 
undifferentiated state caused a very slight increase in the proportion of cells in G2/M, as would 
be expected, but did not suggest that there was a block in the cell cycle that would alter doubling 
time significantly. This result is in agreement with previous data showing that PDS can induce 
DNA damage (Rodriguez et al., 2012). The PhenDC3 treated cells showed no increase in G2/M 
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arrest compared to both the untreated and DMSO treated conditions. This suggested that 
PhenDC3 was not causing a replication impediment in a similar manner to PDS.  
 
Figure 67. Cells were cultured in the undifferentiated state for 50 hours with 1 µM PDS, PhenDC3 or an equivalent 
volume of DMSO. EdU was added for incorporation into the synthesising DNA for one hour prior to cell 
collection. Cells were then collected and fixed for flow cytometry and the Click-iT reaction was performed 
(above). The number of cells in each phase was quantified and plotted for each condition (below), G1 (black), S 
(grey) and G2/M (white).  
 
5.1.3 The DNA damage response to G4 ligands 
To see whether the G4 ligands were increasing DNA damage in treated cells, I analysed the 
level of γH2A.X using permeabilised flow cytometry. Cells were grown in the undifferentiated 
state with PDS or PhenDC3 for 50 hours, as above, and collected for flow cytometry analysis 
of γH2A.X (Figure 68a). The data show that culturing in PDS did cause a shift in the level of 
phospho-H2A.X in cells compared to the mock-treated and PhenDC3 treated cells. However, 
the level of increase of γH2A.X in PDS treated cells was much smaller than of those cells treated 
with HU, suggesting that the level of damage was minimal. Interestingly, PhenDC3 did not 
cause an increase in this DNA damage marker, further suggesting that PDS and PhenDC3 were 
not acting in an exactly analogous manner in the cells. 
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Figure 68. Analysis of phosphorylation of DDR proteins after treatment with G4 ligands (a) flow cytometry 
analysis of the phosphorylation of H2A.X in the BOBSC cells in the undifferentiated state after treatment with 1 
µM PDS or PhenDC3 for 50 hours, to compare with the spike of phosphorylation during differentiation. HU 
treatment was included as a positive control. The median level with mock-treated cells is shown with a line. (b) 
western blotting analysis of the phosphorylation of CHK1, CHK2 and H2A.X in 2 µM PDS treated cells. HU and 
UV treatment were used as positive controls. 
 
Following γH2A.X, levels of pCHK2 and pCHK1, were analysed using western blotting to 
check whether there was any upregulation of the DDR in PDS treated cells (Figure 68b). Only 
the positive control cells treated with 2 mM HU gave a pCHK2 signal on the blot and the UV 
treated sample gave a positive pCHK1 signal on the blot. This suggested that PDS was not 
causing phosphorylation of checkpoint proteins at a level detectable by western blotting during 
differentiation. Phosphorylation of H2A.X could only be detected by flow cytometry, showing 
that the level of phosphorylation was low. Despite both ligands being shown to induce G4-
dependent replication stress (Guilbaud et al., 2017), only PDS triggers H2A.X phosphorylation 
and cell cycle perturbation in this system. 
 
5.1.4 RNA expression changes in the pluripotent state induced by G4 ligands 
BOBSC cells were cultured in the undifferentiated state with 2 µM PDS, PhenDC3 or the 
equivalent volume of DMSO for three days. RNA was extracted every 24 hours to understand 
whether gene expression changes were induced by G4 ligands in the undifferentiated state. The 
RNA was converted into DNA libraries and sequenced. The ligands induced a change in gene 
expression and this data will be discussed in Section 5.3 in comparison to the changes induced 
in differentiation. 
(a) (b) 
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5.2 G4 ligand treatment during definitive endoderm differentiation 
5.2.1 Changes induced by G4 ligands during endoderm differentiation 
5.2.1.1 The cell cycle profile 
Throughout definitive endoderm differentiation the cell cycle profile changes from cells being 
mostly in S phase of the cell cycle to mainly in G1, as is indicative of a more differentiated cell 
type. When cells were differentiated in the presence of PDS there was a clear hold up of cells 
in G2/M phase at 24 hours, shown in the DAPI plot in Figure 69, and at 72 hours a smaller 
proportion of cells were in G1 phase. While growing the undifferentiated cells in PDS (Figure 
67) may have slightly increased the proportion of cells in G2/M at any one time, this effect was 
much more pronounced during differentiation (Figure 69b). However, when PhenDC3 was used 
during differentiation there was a minimal change in the cell cycle profile until 72 hours where 
there were a higher proportion of cells in G1 phase typical of a differentiated cell (Figure 69a 
and c), this is discussed in more detail in Section 5.2.2.2. This further suggested that the ligands 
could be acting in different manners during differentiation. 
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Figure 69. Cell cycle changes during differentiation in the presence of PDS and PhenDC3 G4 ligands monitored 
using DAPI staining to analyse the DNA content. (a) Ligand treated samples are shown in blue and mock-treated 
in red (b) replicate values of the percentage of cells in G2/M with PDS treatment either in the undifferentiated 
state. Mean±SEM are plotted, n=4, p=0.0172 during differentiation and not significant for the undifferentiated 
state using a paired t test. (c) replicate experiments to show the percentage of cells in G1 at 72 hours of 
differentiation with DMSO or PhenDC3 treatment, mean±SEM are plotted, n=8, p=0.0049 using a paired t test. 
 
 
(a) 
(b) (c) 
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As the effect of PDS was so pronounced at 24 hours, earlier timepoints during differentiation 
were analysed using EdU incorporation, as before, and compared to DMSO and PhenDC3 
treated cells. Cells were treated with ligand in the undifferentiated and differentiating states and 
were incubated with EdU before being collected between five and 23 hours after the initiation 
of differentiation (Figure 70). There was no increase in the G2/M population in PDS treatment 
until 23 hours, and this was not shared with the PhenDC3 treatment or, importantly, the 
undifferentiated cells. This further highlighted the idea, proposed in Results II, that on the 
transition from undifferentiated to differentiating the cells were less able to tolerate damage, if 
DNA damage was the means through which PDS was acting. The height of the S phase 
population was also slightly lower in the treated cells (Hwang et al., 2016), suggesting that cells 
differentiated with PDS may be synthesising DNA slower. Interestingly, there was a clear 
change in the speed DNA synthesis in all conditions during differentiation: the EdU 
fluorescence change was the smallest between G1 and S phase at five hours. This early 
timepoint is likely to be a key point for cell fate commitment. 
 
Figure 70. (See next page) 2D-cell cycle analysis using EdU to analyse the proportion of cells in each phase of the 
cell cycle in the undifferentiated state (left) and during differentiation (right) cultured with 2 µM PDS, 2 µM 
PhenDC3 or an equivalent volume of DMSO. The red box shows the increase in G2/M phase of the cell cycle after 
PDS treatment during differentiation. Quantification is shown in the table below. 
 
 
 
 
 
 
 
 Undifferentiated Differentiated 
% cells G1 S G2/M G1 S G2/M 
 5 h 
DMSO 10.3 67.4 22.1 11.5 65.3 22.7 
2 µM PDS 10.3 63.3 25.9 11.4 63.5 25.1 
2 µM 
PhenDC3 
11.1 65.9 23.1 11.0 64.9 23.4 
 8.5 h 
DMSO 11.7 65.1 23.2 8.04 66.1 23.5 
2 µM PDS 11.8 61.8 26.4 6.75 67.5 25.1 
2 µM 
PhenDC3 
11.4 64.1 24.5 7.16 67.2 25.6 
 23 h 
DMSO 15.4 63.3 21.2 10.9 64.7 24.3 
2 µM PDS 14.3 64.8 20.8 9.48 52.2 38.2 
2 µM 
PhenDC3 
15.8 64.1 20.1 10.9 63.0 26.1 
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5.2.1.2 The spike of H2A.X phosphorylation after treatment with G4 ligands 
In the previous chapter, it became clear that the levels of DNA damage response proteins 
changed dramatically during differentiation. The ligands altered the proportion of cells in each 
phase of the cell cycle during differentiation, and treatment with PDS caused more cell death 
than in the undifferentiated state. Therefore, as shown on treatment with DNA damaging agents, 
it was likely that the G4 ligands would pose differing problems during differentiation compared 
to maintenance in the undifferentiated state.  
 
To analyse whether the G4 ligands altered the level of γH2A.X at around 50 hours of 
differentiation during the epithelial mesenchymal transition, as discussed in the previous 
chapter, permeabilised flow cytometry was used. This was initially performed on cells treated 
with PDS throughout differentiation (Figure 71a). When cells were differentiated in the 
presence of PDS, the phosphorylation of H2A.X still occurred, suggesting that the cells were 
able to transition through the EMT. However, the level was in fact increased in the base 
population, indicative of DNA damage.  
 
This upregulation of H2A.X, believed to be associated with the EMT, also occurred in 
PhenDC3 treated cells but to a slightly lower extent (Figure 71b). There was no increase in the 
base level of H2A.X phosphorylation compared to mock-treated cells, suggesting that this 
ligand was acting in a different manner to PDS. However, PhenDC3 treated cells did reveal that 
the γH2A.X spike continued until 72 hours (Figure 71c), longer than the DMSO treated cells. 
However, since this was only performed once at these timepoints it is not possible to draw 
conclusions from this data. 
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Figure 71. Analysis of the H2A.X spike of phosphorylation during differentiation in the presence of G4 ligands 
(a) in the presence of PDS (b) in the presence of PhenDC3 (c) PhenDC3 analysis at 72 hours. There is a baseline 
shift in the PDS treated cells, due to the damage induced non-specifically to the point of the EMT. Gating is relative 
to the DMSO treated spike of phosphorylation. 
 
5.2.2 Gene expression changes during differentiation in the presence of G4 ligands 
It was instantly clear when differentiating the cells in the presence of G4 ligands that not only 
were they perturbing the differentiation, but that PDS and PhenDC3 were doing so in distinct 
ways. PDS treated cells were larger by eye, especially at 24 hours, which was reflected in the 
2D-cell cycle plots, there was more cell death and they looked similar to MMS treated cells. 
PhenDC3, however, caused the cells to metabolise more than untreated cells as seen by the 
(a) 
(b) 
(c) 
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acidification of the medium and the cells remained as clumps rather than forming a 
mesenchymal sheet, this is discussed further in Section 5.2.2.2. 
 
5.2.2.1 RNA changes during differentiation monitored by qPCR  
RNA was collected from cells treated with PDS to understand whether the morphology and cell 
cycle differences described above were by changes to the gene expression profile. RNA was 
extracted from wildtype BOBSC cells grown with or without PDS in the undifferentiated state 
for three weeks and then differentiated for 72 hours and qPCR was performed (Figure 72a). 
This suggested that the cells treated with PDS were differentiating less efficiently than untreated 
cells, both in terms of the lower expression of the SOX17 marker gene and in terms of 
maintaining higher expression of T. The higher level of POU5F1 and NANOG suggested that 
these cells may be remaining in the undifferentiated state instead of committing to 
differentiation. The increased level of T mRNA is indicative of a more mesodermal fate, again 
suggesting that these cells are not fully committing to endodermal differentiation. This result 
implied that stabilising G4s in the genome could alter differentiation. 
 
 
 
Figure 72. qPCR analysis of definitive endoderm differentiation in the presence of G4 ligands, n=3 technical 
replicates, mean±SD is plotted, multiple t tests were used to calculated significance (a) undifferentiated (black), 
differentiated (grey) and PDS treated (white), the first four transcripts should decrease during differentiation and 
the remaining increase, * denotes p<0.05 compared to the untreated differentiated samples (b) separate experiment 
to (a) the relative SOX17 expression at 72 hours of differentiation in mock-treated samples compared to PDS and 
PhenDC3 treated samples normalised to the GEOMEAN. * denotes p<0.05, compared to differentiated untreated 
or DMSO treated cells.  
(a) (b) 
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This experiment was repeated using both PDS and PhenDC3: cells were differentiated in the 
presence of 2 µM PDS, PhenDC3 or DMSO and RNA was extracted for qPCR (Figure 72b). 
The level of SOX17 decreased in the cells treated with ligand when normalised to the geometric 
mean of three control genes, GAPDH, HPRT1 and PBDG. However, it was clear that PhenDC3 
was altering the expression of HPRT1, which had been being used as a control gene. G4 ligands 
can affect the expression of control genes, and this was hard to predict. As this was hard to 
control for, further work was done using permeabilised flow cytometry and RNA sequencing 
in which this method of normalisation would not cause a problem. Since the experiment with 
PhenDC3 was only performed once, the significance cannot be tested but further experiments 
were used to verify these results. 
 
5.2.2.2 Differentiation changes monitored using permeabilised flow cytometry 
To get an initial picture of whether the ligands could perturb differentiation, the cells were 
grown in the undifferentiated state and differentiated in the presence of PDS (with reference to 
the schematic in Figure 11 (2)). This was so that they were grown in the presence of ligands for 
the longest period of time and an effect would have been likely to be seen. Cells were 
maintained in 2 µM PDS for over two weeks and then differentiated in the presence of PDS. 
They were collected for permeabilised flow cytometry every 24 hours during the differentiation 
process and stained with αSOX17 and αEOMES antibodies (Figure 73). Cells differentiated in 
the presence of PDS exhibited more cell death than untreated cells. The cell cycle of the treated 
cells was perturbed such that at 24 hours there was a large G2/M block, as seen previously, and 
by 72 hours the cells were not cycling in a normal manner. The expression of the mesendoderm 
marker EOMES was upregulated at 24 and 48 hours in both the ligand and untreated conditions 
but was downregulated to a greater extent at 72 hours when treated with PDS, possibly due to 
the sickness of the cells at this point. While the differentiation in this experiment had not been 
particularly efficient, it was clear that SOX17 was not being expressed at all in PDS treated 
cells at 48 hours and the level had not increased much by 72 hours. The G2/M phase cell cycle 
block early in differentiation was reminiscent of that seen with MMS treatment discussed in 
Results II. This increase in proportion of G2/M cells was clearly visible from the increase in 
size seen down a microscope at 24 hours. While this was at a high concentration of PDS, the 
same trend was seen at all concentrations and was likely to be impacting differentiation 
severely. 
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Once it was clear that culturing cells in PDS in both the undifferentiated state and during 
differentiation prevented efficient SOX17 upregulation I wanted to ask the question, does PDS 
perturb the ground state and does it have a permanent and heritable impact on ground state 
genes expression and the ability to differentiate? This had been addressed previously in the 
mouse cells (with reference to the schematic in Figure 11 (1) with continued differentiation). 
Cells grown on the drug for 2.5 weeks were cultured without the drug for 2.5 weeks and then 
differentiated without PDS. The proportion of SOX17 expressing cells was quantified and 
compared to the untreated cells (Figure 74). This experiment clearly demonstrated that if PDS 
was not present at the time of differentiation then there was very little or no effect on the 
differentiation. There were also no changes to the morphology, or any increased cell death by 
observation. However, the cells maintained in PDS differentiated only half as efficiently. 
 
 
 
 
 
 
 
 
Figure 73. Analysis of the differentiation of BOBSC 
cells cultured in the undifferentiated state with PDS 
before being differentiated in the presence of this 
ligand. Cells were cultured in the undifferentiated state 
with 2 µM PDS for over two weeks before being 
differentiated in the presence of the ligand and 
differentiation was analysed every 24 hours for DNA 
content, EOMES and SOX17 expression.  
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Figure 74. Analysis of whether G4 ligands 
in the undifferentiated state could alter 
differentiation without the ligands being 
present during this process. Cells were 
cultured with 2 µM PDS for 2.5 weeks and 
then either washed out of drug and 
cultured for a further 2.5 weeks without 
the drug before being differentiated 
without the drug (PDS -). Cells kept in 
culture with PDS throughout this time 
were used as a control (PDS +) and 
without any drug (untreated). 
 
The next question to address was whether the presence of G4 ligands during differentiation 
alone could alter the outcome. The differentiation was repeated in the presence of 2 µM PDS 
using cells that had not been grown on drugs prior to differentiation and cells were collected at 
72 hours for permeabilised flow cytometry (Figure 75). This showed a similar picture to the 
cells grown in 2 µM PDS prior to differentiation and differentiated in the ligand: SOX17 was 
not upregulated to the same extent as in the untreated cells (Figure 75c). 
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Figure 75. Flow cytometry analysis of cells cultured with 2 µM PDS from the onset of differentiation, throughout 
differentiation. Cells were collected at 72 hours to analyse the proportion of SOX17 positive cells with or without 
treatment (a) a plot showing SOX17 positive cells in relation to the DNA content (b) histograms showing the 
expression of SOX17 (c) replicate experiments showing the proportion of cells expressing SOX17 at 72 hours 
n=7, paired t test p=0.0001, mean±SEM are plotted. 
 
From these preliminary experiments it was evident that if PDS was not present during endoderm 
differentiation then there was no effect on the SOX17 positive population of cells. All further 
experiments were performed without growing the cells in ligand prior to differentiation but 
adding the G4 ligand at the initiation of differentiation, with the ligand being replaced every 24 
hours when the differentiation media was changed. This also made the experiments easier to 
interpret with respect to the pathways of perturbed gene expression changes. 
 
PDS exposure during differentiation decreased the efficiency of differentiation but it was also 
causing some damage and death to the cell as well as altering the cell cycle, comparable to the 
effect experienced in MMS treated cells in Results II. In order to understand whether PDS was 
causing a G4-specific effect that was independent of inducing damage, the G4 ligand PhenDC3 
was used. This ligand has been shown to stabilise G4s in DT40 at the concentrations used in 
this thesis (Guilbaud et al., 2017). Cells were differentiated in the presence of 2 µM PhenDC3 
and collected every 24 hours for permeabilised flow cytometry (Figure 76a and b). EOMES 
was upregulated at 24 hours to a similar extent in both the untreated and PhenDC3 treated cells 
(a) (b) 
(c) 
157 
 
but SOX17 was upregulated to a lesser extent at both 48 and 72 hours in the PhenDC3 treated 
cells (Figure 76c). As is expected during endoderm differentiation, the proportion of cells in 
G1, as seen with DAPI staining, increased during differentiation which was in contrast to the 
PDS treated cells. Another interesting point to note was that cells differentiated in the presence 
of PDS exhibited more cell death than the untreated cells whereas PhenDC3 treated cells 
metabolised to a greater extent than untreated cells, shown with the greater acidification of the 
medium. Looking down the microscope, there were also some small phenotypic differences 
between the conditions including PhenDC3 treated cells remaining as individual colonies rather 
than forming a monolayer as in the unperturbed differentiation. 
 
Higher concentrations of PhenDC3 did not cause increased cell death over 72 hours compared 
to the PDS treatment and therefore it was possible to analyse the dose response of the efficiency 
of differentiation to this G4 ligand over a range of concentrations (Figure 77). There was a clear 
decrease in the percentage of SOX17 expressing cells as the PhenDC3 concentration increased, 
showing a dose response to this ligand. 
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Figure 77. The proportion of SOX17 expressing cells at 72 hours 
of definitive endoderm differentiation with cells cultured in 
increasing concentrations of PhenDC3. 
 
 
 
 
 
 
 
Figure 76. Analysis of the differentiation efficiency when 
cultured in the presence of the G4 ligand PhenDC3. 2 µM 
PhenDC3 was added at the initiation of differentiation and 
cells were maintained in this throughout differentiation (a) 
analysis of the proportion of SOX17 positive cells at 48 and 
72 hours (b) analysis of DNA content, EOMES and SOX17 
expression every 24 hours throughout differentiation (c) 
replicates of the differentiation in the presence of PhenDC3 
showing SOX17 expression at 72 hours, n=15, paired t testing 
gives a p-value <0.0001, mean±SEM are plotted. 
(c) 
(b) (a) 
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5.2.2.3 Differences between the G4 ligands 
These experiments showed that there were many differences between the cells treated with 
these two G4-binding ligands. While this made the observations hard to interpret, it was 
interesting that they were exhibiting different effects. As the PDS caused many changes that 
were comparable to the DNA damaging agents, these experiments were repeated in the TP53-/- 
cells described in Results II. 
 
5.2.3 Comparison of G4 ligand effects with DNA damaging agents 
5.2.3.1 The role of p53 in differentiation in the presence of G4 ligands 
In Results II it was shown that TP53-/- cells did not inhibit endoderm differentiation in response 
to DNA damage as wildtype BOBSC cells. In order to understand whether this was also the 
case with the ligands, these experiments were repeated using PDS and PhenDC3. The G4 
ligands were added to TP53-/- cells throughout differentiation and compared to wildtype treated 
cells (Figure 78a and b). PDS treated TP53-/- cells differentiated with a much greater efficiency 
compared to the wildtype treated cells: the knockout of TP53-/- at least partially compensated 
for the addition of the drug. PDS appears to act, at least in part, by inducing DNA damage. 
However, the PhenDC3 treated cells showed a different picture compared to the MMS, UV and 
PDS treated TP53-/- cells: the PhenDC3 treated TP53-/- cells showed the same perturbation of 
differentiation as wildtype cells. This provided further evidence that PhenDC3 specifically was 
not simply preventing differentiation by inducing DNA damage.  
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5.2.3.2 Monitoring a delay in differentiation with G4 ligands 
In order to see whether PDS was simply slowing differentiation down and the cells would 
require longer to catch up with SOX17 expression, the differentiation was continued for a 
further 24 hours, until 96 hours. However, this experiment caused so much cell death that there 
were not enough cells to analyse for permeabilised flow cytometry. This suggested that the cells 
would not differentiate in the presence of PDS, regardless of the length of time. To see whether 
removing the drug could reverse the effect on differentiation, cells were differentiated for 72 
Figure 78. Analysis of the role of p53 in differentiation in the presence of the G4 ligands by using the TP53-/- cell 
line as in Results II (a) plots to show the percentage of SOX17 positive cells at 72 hours in each condition (b) 
histograms showing the expression of SOX17 at 72 hours (c) replicate experiments showing the expression of 
SOX17 at 72 hours in the wildtype vs TP53-/- cell lines with PDS (left) or PhenDC3 (right) compared to untreated. 
n=2 for PDS, unpaired t test p=0.0326, n=5 for PhenDC3 with no significance found, mean±SEM are plotted. 
(a) 
(b) (c) PDS PhenDC3 
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hours in the presence of PDS and then the PDS was removed for 24 hours and the cells were 
collected for flow cytometry at 96 hours (Figure 79a). Although there were not many cells left 
to analyse at this timepoint, it seemed that removing the drug for the final 24 hours did slightly 
increase the number of cells expressing SOX17 but since there were not many cells left alive it 
was not clear. 
 
 
 
Figure 79. Differentiating the cells for over 72 hours (a) PDS was added for the first 72 hours and then removed 
for the final 24 hours before the cells were collected at 96 hours to analyse the proportion of SOX17 positive cells 
(b) cells were cultured in the presence of PhenDC3 for an extra 24 or 46 hours and analysed for the proportion of 
SOX17 positive cells. 
(a) 
(b) 
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PDS treatment caused a high level of cell death and therefore it is hard to maintain the 
differentiating cells for over 72 hours, but this was not the case for PhenDC3. PhenDC3 treated 
cells were differentiated for longer than 72 hours to monitor whether the differentiation could 
catch up (Figure 79b). This showed that an extra 46 hours of differentiation did not allow the 
PhenDC3 treated cells to express SOX17 to as high a level to the untreated, there was still a 
distinct population not expressing SOX17. This suggested that the cells would not differentiate 
even given the extra time. Again, suggesting that PhenDC3 perturbs a pathway early on in the 
differentiation process. However, the untreated cells got too confluent over this time so the 
proportion of cells expressing SOX17 decreased. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 80. Analysis of the number of cell divisions gone through during differentiation in the wildtype and TP53-
/- cell lines with each treatment at 72 hours (a) a table to show the median number of divisions (b) the proportion 
of SOX17 expressing cells in each condition in relation to the number of cell divisions. Fluorescence decreases by 
half on each cell division. One experiment shown. 
 
 
(a) 
(b) 
163 
 
The CellTrace™ approach, as used in Section 4.2.6.2, was also used to monitor the number of 
cell divisions in cells treated with 2 µM PDS or PhenDC3 in wildtype and TP53-/- cells (Figure 
80). As in the MMS treated cells there was very little difference between the DMSO and 
PhenDC3 or PDS treated cells in terms of the number of cell divisions, suggesting it was not a 
lack of cell division that prevented differentiation in this case. In all cases it was clear that the 
cells had gone through enough rounds of division for SOX17 to be expressed. However, this 
experiment should be repeated to assess whether these changes are significant. 
 
5.2.3.3 Activity of PhenDC3 on the cells throughout differentiation 
In the case of MMS addition, the results showed that there was a key window in which this had 
the greatest effect on altering the differentiation: this may be a DNA damage specific response. 
To ask whether the PhenDC3, which was not thought to be inducing DNA damage, was acting 
in a similar manner, the experiment was repeated by differentiating the cells in PhenDC3 for 
either 0-24, 24-48 or 48-72 hours during differentiation and analysing the differentiation at 72 
hours (Figure 81). Despite PhenDC3 decreasing the proportion of cells committing to definitive 
endoderm differentiation at all times, the biggest decrease was seen if cells were treated for the 
first 24 hours of differentiation. This suggested that the most crucial time for having PhenDC3 
present was in the first 24 hours of the differentiation, consistent with it not causing general 
DNA damage. 
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In a similar manner to the DNA damaging agents experiment in which the exposure was made 
after 72 hours of differentiation and the SOX17 positive population was monitored, Section 
4.2.5, this was performed using the G4 ligands. This experiment allowed an understanding of 
whether the expression of SOX17 could only be altered when the cells were differentiating, as 
with the DNA damaging agents, or if they can be altered once the cells had differentiated 
(Figure 82). As seen for the DNA damage, these results show that PhenDC3 and PDS only 
affected the differentiation if they were added during the differentiation process, and when 
SOX17 was stably expressed, the cells did not stop expressing it regardless of the treatment. 
This suggested that PhenDC3 and possibly PDS were altering a pathway early in differentiation. 
 
To understand the gene expression changes caused by these ligands, RNA sequencing was 
performed throughout differentiation. 
 
Figure 81. PhenDC3 was added for 24-hour windows during differentiation to understand whether there was a critical 
point for the addition on altering the course of differentiation. The percentage of SOX17 expressing cells was 
monitored at 72 hours and compared to the DMSO treated cells (a) one experiment (b) n=2, no significance using 
paired t test, mean±SEM are plotted. 
(a) (b) (a) 
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Figure 82. Analysis of whether the addition of 
G4 ligands after 72 hours alters differentiation. 
Cells were cultured in 4 µM ligand for between 
two and eight hours before collection and 
analysis of the SOX17 expressing cells at 80 
hours of differentiation. PDS (left panel) and 
PhenDC3 (right panel).  
 
 
 
 
 
 
5.3 RNA sequencing analysis of G4 ligand treated cells in the 
undifferentiated state and during differentiation 
In order to get a detailed analysis of the way in which the G4 ligands were perturbing 
differentiation, RNA sequencing was performed. Cells were differentiated in triplicate in the 
presence of 2 µM PDS, 2 µM PhenDC3 or the equivalent volume of DMSO and RNA was 
collected every 24 hours. This was performed in parallel with maintaining the cells in the 
undifferentiated state with the drugs to understand which effects were specific to differentiation, 
as discussed in Section 5.1.4. Some compromises were made with respect to the density and 
time of collection as there was no perfect solution for collecting RNA for sequencing; although 
initial data using the BOBSC knockout cells showed that there was a large ‘batch effect’ on the 
transcriptome likely to be due to the confluence of the cells, Section 6.3.1, it is also known that 
the efficiency of the mesendoderm pathway is affected by the confluence of the cells during the 
first 24 hours and this had been noted in my experiments (Kempf et al., 2016). Therefore, cells 
were plates at the same density and colony size and each timepoint was collected 24 hours after 
the previous timepoint, therefore not all at the same time. After the RNA was extracted and the 
quality was checked, RNA libraries were created. 
 
The principle component analysis (PCA) plot was generated by Alastair Crisp (Figure 83a and 
b). This shows a good clustering of the undifferentiated cells at each timepoint with each of the 
drugs on the left side of the plot. However, as discussed in Section 6.3.1, it was clear that the 
undifferentiated cells were still experiencing a ‘batch effect’ likely to be due to the confluency 
of the cells in the well. These undifferentiated, ligand-treated cells did not show any major 
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differences compared to the DMSO treated cells in their expression profiles as seen in the PCA. 
What was very clear was that cells differentiating to definitive endoderm showed very large 
gene expression changes during differentiation, compared to the undifferentiated cells, as 
expected. The number of gene expression changes during DMSO differentiation was compared 
to the undifferentiated 24-hour DMSO treated cells and the Venn diagram is shown in Figure 
84.  
 
However, the PhenDC3 treated cells had a very different gene expression program compared 
with the vehicle-treated cells and this was very clear from 48 hours into the differentiation. This 
was less dramatic in the PDS treated cells which showed only 376 genes significantly altered 
between its expression and the mock-treated cells at 72 hours compared to 2576 in PhenDC3 
treated cells and over half of the PDS differentially expressed genes were shared with PhenDC3 
(Figure 85), genes considered to be differentially expressed are discussed in the materials and 
methods section. The PCA was very different between the two drugs supporting the conclusion 
that the drugs were acting through different mechanisms. This gave further support to the idea 
that PhenDC3 did not cause DNA damage and upregulate the DDR. Deregulated transcripts 
were compared to those deregulated at 72 hours in the MMS treated cells, normalised to 
untreated and TP53-/- MMS treated cells (Figure 86a and b). This clearly shows that the majority 
of transcripts associated with PDS treatment, were also altered on the addition of MMS, 
whereas the majority of those deregulated on treatment with PhenDC3 were not common to 
MMS treatment. I hypothesise that the changes not associated with MMS are likely to be 
specific to G4 formation. 
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Figure 83. The PCA generated to show the maximum variance between all of the samples in the G4 ligand 
differentiation RNA sequencing experiment. (a) All samples: undifferentiated cells are clustered together on the 
left-hand side of the plot (shown in the blue circle), whereas differentiating samples fall to the right-hand side. 
DMSO mock-treated cells are shown as circles, PDS as triangles and PhenDC3 as squares. Samples collected at 
24 hours are shown in red, 48 hours in green and 72 hours in blue. (b) Only undifferentiated samples, labelled as 
(a). 
(a) 
(b) 
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Figure 84. A Venn diagram to show the number of genes significantly 
changing expression during unperturbed differentiation compared to 
the undifferentiated 24-hour mock-treated cells. The number of genes 
which change expression increase every 24 hours.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 85. Venn diagrams to show the comparison of genes deregulated in PDS and PhenDC3 treated cells during 
differentiation. Differentiation was compared to the DMSO treatment at each time point. Venn diagrams are not 
to scale between conditions. 
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Figure 86. A comparison of ligand treatment with MMS treatment in Results II. The genes with altered expression 
at 72 hours of differentiation when treated with PDS (a) or PhenDC3 (b) were compared to DMSO treatment. 
These genes were then compared to genes with deregulated expression in wildtype MMS treated cells compared 
to wildtype untreated cells, as well as genes with altered expression when comparing the wildtype cell line treated 
with MMS and the TP53-/- cell line treated with MMS. 
 
5.3.1 Gene expression changes in the undifferentiated state with PDS and PhenDC3 
In order to understand whether the G4 ligands were perturbing the undifferentiated state in the 
BOBSC cells, the deregulated genes were compared with both ligands. The undifferentiated 
PDS and PhenDC3 treated cells grown with the drug for 72 hours were compared with 
undifferentiated cells grown in DMSO. This was the most direct comparison to minimise and 
effects of confluence on separate days. The deregulated genes in both conditions were compared 
between the drugs and this is shown in the Venn diagram in Figure 87. This clearly shows that 
only 49 genes were deregulated in the PDS treated cells, and 16 in the PhenDC3 treated cells. 
There were 150-fold fewer deregulated genes in the PhenDC3 treated undifferentiated cells 
compared to the differentiated cells, highlighting the difference in response to this ligand 
between the two cell states. In the PDS treatment this difference was less pronounced, the 
difference further agreed with the findings that these ligands were not perturbing the gene 
expression in the undifferentiated state. The overlap between the drug treated cells was only six 
genes: RNF170, AMH, NRBP2, MEF2C, GAN and ANXA1.  
(a) 
(b) 
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Figure 87. A Venn diagram to show the number 
and overlap of genes with deregulated expression 
in the undifferentiated state after 72 hours of 
treatment with either PDS (left) or PhenDC3 
(right). 
 
 
 
The ligands were causing much greater expression changes during differentiation. This may be 
due to the fact that there are such vast changes during differentiation and therefore more 
pathways to perturb. It may also be that when cultured in the pluripotent state, cells often lose 
adherence when they lose pluripotency, therefore cells that have lost expression of key genes 
and floated off the dish could not be counted. The deregulated genes are compared to the 
knockout cell lines in Results IV. The GO term analysis for the 72-hour undifferentiated cells 
treated with G4 ligands is shown in Table 20.  
 
In the PDS treated cells there were a number of highly significant gene ontology functions 
associated with this gene list. These were mainly related to development, suggesting that PDS 
may be causing the cells to differentiate or lose pluripotency in the undifferentiated state. 
However, with PhenDC3 treatment, there were not many significant pathways and almost all 
of them were only significant due to the deregulated expression of three genes: ANXA1, IDO1 
and MEF2C. ANXA1 encodes Annexin A1 which is a membrane-localised protein which binds 
phospholipids. This protein has anti-inflammatory activity and loss of function is detected in 
many tumours. IDO1 encodes indoleamine 2,3-dioxygenase which is a heme enzyme catalysing 
tryptophan catabolism. MEF2C encodes myocyte enhancer factor 2C which is a MADS box 
transcription enhancer factor 2. It is involved in cardiac morphogenesis and myogenesis. 
Analysis of the overlap of PDS and PhenDC3 was skewed due to lack of genes but consisted 
of RNF170, AMH, NRBP2, MEF2C, GAN and ANXA1. 
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GO term Description Count Adjusted p-
value 
PDS 
GO:0032835 Glomerulus development 5/61 0.00024 
GO:0048869 Cellular developmental process 25/4270 0.00024 
GO:0030154 Cell differentiation 25/4088 0.00024 
GO:0035850 Epithelial cell differentiation involved in 
kidney development 
4/45 0.00107 
GO:0070848 Response to growth factor 10/713 0.00107 
GO:0071363 Cellular response to growth factor 
stimulus  
10/685 0.00107 
GO:0070431 Nucleotide-binding oligomerisation 
domain containing 2 signaling pathway 
3/13 0.00107 
GO:0001655 Urogenital system development 7/317 0.0018 
GO:0061005 Cell differentiation involved in kidney 
development 
4/55 0.00188 
GO:0033209 Tumor necrosis factor- mediated 
signaling pathway 
5/127 0.00224 
PhenDC3 
GO:2000108 Positive regulation of leukocyte apoptotic 
process 
3/29 0.00167 
GO:0033034 Positive regulation of myeloid cell 
apoptotic process 
2/8 0.0105 
GO:2000106 Regulation of leukocyte apoptotic process 3/83 0.0137 
GO:0071887 Leukocyte apoptotic process 3/100 0.0179 
GO:0006925 Inflammatory cell apoptotic process 2/20 0.046 
GO:0033028 Myeloid cell apoptotic process 2/32 0.046 
GO:0033031 Regulation of myeloid cell apoptotic 
process 
2/28 0.046 
GO:0002828 Regulation of type 2 immune response 2/30 0.046 
GO:0036211 Protein modification process 9/4097 0.047 
GO:0006464 Cellular protein modification process 9/4097 0.047 
Table 20. The ten most significantly enriched gene ontology (GO) terms associated with PDS compared to DMSO 
and PhenDC3 compared to DMSO after 72 hours of culture with the ligands in the undifferentiated state. 
5.3.2 Gene expression changes during differentiation with G4 ligands 
Firstly, the main genes that are known to change expression during the differentiation process 
were analysed from the sequencing data (Teo et al., 2011) (Figure 88). The pluripotency genes, 
NANOG, POU5F1 and SOX2, decreased expression throughout the differentiation process, as 
expected (Figure 88a). SOX2 was switched off in the first 24 hours and this was the case with 
both ligands as well as the mock treatment. NANOG and expression was switched off by 48 
hours and POU5F1 by 72 hours, but this occurred to a significantly lesser extent on treatment 
with ligands and this was more pronounced with PhenDC3. This expression of pluripotency 
markers in the PhenDC3 treated samples was higher and indicative that these treated cells were 
not fully differentiating, or least not as efficiently as the DMSO treated cells. 
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The expression of EMT associated genes was monitored and compared between the samples 
(Figure 88b). The expression of E-cadherin (CDH1) is expected to decrease at the EMT and be 
replaced with N-cadherin (CDH2) (Teo et al., 2011). Both switching off of E-cadherin and 
turning on of N-cadherin occurred to a lower extent in the PhenDC3 treated cells which may 
explain why they did not completely differentiate, possibly having not completed the epithelial 
mesenchymal transition and causing the cells to remain in a mesenchymal state. The expression 
of SNAI1, SNAI2 and TWIST1 was also higher in the PhenDC3 treated cells, suggesting that the 
EMT was perturbed, there were some changes in the PDS treated cells but to a lower extent. 
 
Expression of the proteins associated with mesendoderm, and therefore early differentiation 
markers were compared (Figure 88c). Expression of these genes had altered kinetics in both 
PDS and PhenDC3 treated cells. GSC was very clearly being expressed to a lower level in both 
conditions.  
 
All definitive endoderm markers showed a clear trend: PhenDC3 treated cells did not express 
any of these marker genes as highly as the DMSO treated cells and PDS expressed slightly 
lower levels (Figure 88d). This suggested that SOX17 expression had been a good efficiency 
read-out for the endoderm differentiation and that both of the G4 ligands were perturbing this 
process, especially in the PhenDC3 treated cells.  
 
Surprisingly, genes that had been used for qPCR normalisation and western blotting loading 
controls also changed during the differentiation process suggesting that these were a bad set to 
use (Figure 88e). Some of these were also altered with the ligands, further suggesting that 
permeabilised flow cytometry had been a better read-out for monitoring differentiation as 
discussed in Results II. 
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(a) 
(b) 
(c) 
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Figure 88. Normalised transcripts were calculated as fragments per kilobase of transcript per million mapped reads 
(FPKM) were calculated at each time point for each treatment condition and plotted. The mean is plotted, and error 
bars show the standard deviation of RNA triplicates. The triplicates were performed at the same time but using 
different biological samples. DMSO (to the equivalent volume of ligand) is shown in black, PDS in pink and 
PhenDC3 in blue. The zero-hour timepoint is taken to be the 24-hour undifferentiated sample, the rest are shown 
during differentiation. Significance is calculated for p<0.05 using the CuffDiff statistics test. Pink * (PDS) and blue 
* (PhenDC3) show significant difference compared to DMSO apart from in (e) where significance is DMSO 
treatment compared to the undifferentiated control (a) pluripotency genes (b) EMT-associated genes gene name for 
E-cadherin CDH1, gene name for N-cadherin CDH2 (c) mesendoderm genes (d) definitive endoderm specification 
genes (e) qPCR and western blotting normalisation genes.  
(d) 
(e) 
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5.3.2.1 Enrichment analysis in G4 ligand treated cells during differentiation 
The top ten GO terms and transcription factors were analysed for differentiation in the presence 
of both drugs at 72 hours and are shown below in Table 21. Most of the GO terms associated 
with the PDS treatment were developmental, showing that this treatment can alter 
differentiation. However, with PhenDC3 treatment the GO terms were associated with 
organelles and metabolism which is likely due to perturbing mitochondrially-encoded genes, 
for example a number of tRNAs and COX genes. The cells also showed altered metabolism 
from the medium colour and this may be due to remaining in the state of transferring through 
the EMT. These GO terms may also be due to the prolonged perturbed signalling pathways in 
this treatment. The overlap between these two conditions showed a large enrichment in 
developmental genes, suggesting that these are perturbing the same pathways and both alter the 
outcome of differentiation. 
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GO term Description Count Adjusted p-
value 
PDS 
GO:0032502 Developmental process 117/6212 2.01x10-14 
GO:0048856 Anatomical structure development 170/5793 2.01x10-14 
GO:0007275 Multicellular organism development 160/5321 2.01x10-14 
GO:0032501 Multicellular organismal process 196/7414 1.06x10-13 
GO:0048513 Animal organ development 119/3428 1.06x10-13 
GO:0009653 Anatomical structure morphogenesis 97/2598 2.44x10-12 
GO:0048731 System development 142/4760 6.76x10-12 
GO:0008283 Cell proliferation 83/2121 3.04x10-11 
GO:0048646 Anatomical structure formation involved 
in morphogenesis 
57/1144 4.37x10-11 
GO:0009887 Animal organ morphogenesis 51/969 1.26x10-10 
PhenDC3 
GO:0044424 Intracellular part 1883/14266 9.05x10-37 
GO:0005622 Intracellular 1906/14606 5.97x10-34 
GO:0043229 Intracellular organelle 1674/12497 2.48x10-28 
GO:0043231 Intracellular membrane-bounded 
organelle 
1467/10736 2.43x10-24 
GO:0031323 Regulation of cellular metabolic process 938/6223 1.54x10-23 
GO:0043226 Organelle 1736/13288 1.54x10-23 
GO:0044237 Cellular metabolic process 1459/10713 2.15x10-23 
GO:0019222 Regulation of metabolic process 1009/6819 2.32x10-23 
GO:0080090 Regulation of primary metabolic process 924/6175 5.64x10-22 
GO:0005515 Protein binding  1540/11522 6.57x10-22 
Overlap of PDS and PhenDC3 
GO:0009653 Anatomical structure morphogenesis 57/2598 1.14x10-8 
GO:0001568 Blood vessel development 29/743 1.14x10-8 
GO:0048514 Blood vessel morphogenesis 28/664 1.14x10-8 
GO:0035295 Tube development 34/1079 2.07x10-8 
GO:0072358 Cardiovascular system development 29/788 2.07x10-8 
GO:0001944 Vasculature development 29/779 2.07x10-8 
GO:0023051 Regulation of signaling 66/3482 2.07x10-8 
GO:0010646 Regulation of cell communication 66/3447 2.07x10-8 
GO:0048856 Anatomical structure development 90/5793 2.83x10-8 
GO:0032502 Developmental process 93/6212 5.48x10-8 
Table 21. GO term enrichment of genes with deregulated expression at 72 hours in differentiation when treated 
with the ligands compared to the DMSO treated cells. The top panel shows the ten most significant GO terms upon 
PDS treatment, the middle on PhenDC3 treatment and the lower panel shows the enrichment of the overlap of the 
two treatments. 
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TRANSFAC 
TFBS 
Factor Motif Count Adjusted 
p-value 
PDS 
TF:M01587 FPM315 SRGGGAGGAGGN 91/3242 0.000296 
TF:M00986 Churchill CGGGNN 277/14245 0.000296 
TF:M02105 NF-E4 CHCCCTCKCCWG 76/2635 0.000654 
TF:M04863 TF3C-
beta 
CCNGGAGGGCTTCCTGGAGGAG 186/8554 0.000654 
TF:M01860 AP-4 NCAGCTGYNGNCN 142/6048 0.000654 
PhenDC3 
TF:M00716 ZF5 GSGCGCGR 1964/14128 4.39x10-71 
TF:M04866 hdac2 CGCGCGCGC 2016/14708 4.39x10-71 
TF:M00803 E2F GGCGSG 1856/13193 8.01x10-63 
TF:M04869 Egr-1 GCGCATGCG 1518/10244 3.86x10-52 
TF:M00695 ETF GVGGMGG 1533/10416 4.97x10-51 
Table 22. The top five most enriched transcription factor binding sites in the genes deregulated on PDS (top) or 
PhenDC3 (bottom) treatment at 72 hours. There were no significantly enriched transcription factor binding sites 
in the overlap of the two treatments. 
 
The most significant transcription factor binding sites in both treatments was analysed (Table 
22). Interestingly, the transcription factor binding sites associated with PhenDC3 treatment 
gene deregulation were enriched in guanine bases. Although no statistical tests were performed, 
this observation suggests that PhenDC3 could be interfering with transcription factor binding 
sites and altering gene expression in this manner. Further analysis is being performed. 
 
The transcripts which were deregulated compared to DMSO at every timepoint when treated 
with ligands are shown in the Venn diagrams (Figure 89a and b). In the PDS treated samples 
there were only eleven genes and the GO enrichment for these were all significantly associated 
with DNA damage and programmed cell death. Interestingly, some of these genes have found 
to be upregulated by p53 in unperturbed mESC differentiation, such as CDKN1A. In the 
PhenDC3 treated cells there were 26 deregulated transcripts shared at each timepoint. The 
significantly deregulated GO terms for this gene list were all associated with the respiratory 
chain, oxidative phosphorylation and the mitochondria. This suggests that the common 
deregulation at each time was associated with the ability of this ligand to alter the mitochondrial 
genome or alter signalling pathways involved in reprogramming metabolism. However, just 
comparing 48 and 72 hours shows much more highly significant GO terms associated with 
developmental process, suggesting that this ligand impacts differentiation in the latter stages. 
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5.3.2.2 Key pathway changes induced by the G4 ligands during differentiation  
The PhenDC3 treated cells expressed deregulated levels of WNT and TGFβ pathway transcripts 
throughout differentiation, compared to the DMSO treated samples, and PDS showed similar 
changes but to a lower extent (Figure 90a). The KEGG pathways are shown in (Figure 90b and 
c). The CHIR90021 GSK3 inhibitor was added during the first 24 hours of differentiation and 
this upregulates WNT pathway genes. The cells then produce WNT pathway inhibitors such as 
CER1 and DKK. TGFβ pathway inhibitors such as LEFTY1 and LEFTY2 are produced to high 
levels during differentiation. However, it was clear that these inhibitors were turned on to a 
lower extent in the drug treated cells, and this was extremely pronounced in PhenDC3 treated 
cells. In the PhenDC3 treated cells, BAMBI, a WNT pathway activator was also upregulated, 
suggesting an enhancement in this pathway. 
 
 
 
 
 
 
 
 
 
Figure 89. A comparison of the genes differentially expressed between DMSO and the G4 ligand treatment every 
24 hours during differentiation (a) PDS treatment (b) PhenDC3 treatment. 
 
 
 
(a) (b) 
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Figure 90. Analysis of deregulated pathways in ligand-treated differentiating cells (a) 
RNA sequencing reads of WNT and TGFβ signalling pathway transcripts during 
differentiation. The mean±SD are plotted and differentially expressed genes are marked 
as * (p<0.05 measured using CuffDiff differential expression pipeline) in comparison 
with the DMSO treatment at the same point in differentiation, PDS (pink) and PhenDC3 
(blue) (b) the TGFβ signalling pathway taken from KEGG (c) the WNT pathway taken 
from KEGG.  
(a) 
(b) (c) 
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In order to see whether the maintenance of the WNT pathway in differentiation was able to 
mimic the addition of PhenDC3 to wildtype cells, cells were differentiated either removing the 
inhibitor at 24-, 48- or 72-hours (Figure 91). Maintaining the GSK3 inhibitor for longer than 
24 hours caused the cells to proliferate to a greater extent while also decreasing the expression 
of SOX17, as seen in PhenDC3 treated cells. Therefore, an extension of the time that the WNT 
pathway was activated decreased the expression of endoderm specification markers. This 
experiment, along with the analysis of WNT pathway genes using RNAseq during 
differentiation in ligand-treated cells, suggests that PhenDC3 may partly exert its effect through 
this pathway. However, further analysis would be required to draw a definitive conclusion. 
IWP2, a WNT inhibitor, acts at the level of activation of the pathway by inhibiting porcupine. 
Since this was earlier in the WNT pathway it was used instead of CHIR99021 to prevent the 
PhenDC3 effects. However, the solubility of this inhibitor was not high and in initial trials the 
volume of DMSO affected the cellular differentiation, this was not used further. However, the 
WNT pathway expression changes were thought to stem from BMP changes and it was clear 
that this pathway was highly perturbed. 
 
Figure 91. The WNT pathway activator CHIR99021 is added for the first 24 hours in unperturbed differentiation 
and then removed. To understand whether continual activation of the WNT pathway prevented efficient 
differentiation it was added for an extra 24 or 48 hours and the percentage of SOX17 expressing cells was 
monitoring at 72 hours using flow cytometry. 
 
The EMT was clearly altered in the ligand treated cells. As the phosphorylation of H2A.X had 
remained up at 72 hours in the PhenDC3 treated cells, the level of H2AFX transcript in the 
RNAseq experiment was monitored (Figure 92). This data showed that the level was 
upregulated at 48 and 72 hours in the PhenDC3 treated cells but there is no direct evidence 
linking this to the EMT. 
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Figure 92. The level of H2AFX mRNA in ligand-treated and 
mock-treated cells during differentiation, taken from the RNA 
sequencing data. Mean±SD are plotted, with n=3 collected on 
the same day. Differential expression is calculated using the 
CuffDiff program in comparison to the DMSO treatment at 
each point in differentiation. Blue * denote significantly 
different expression of H2AFX on treatment with PhenDC3. 
 
There were also a number of mitochondrially-encoded genes which have their transcripts 
deregulated upon ligand treatment, including ATP8 and ND4, although a stress response did not 
seem to be induced. Table 21 shows an enrichment for metabolic processes and organelles, 
suggesting that there may be a primary effect of G4-stabilising on this genome. There seems to 
be an altered metabolism in these PhenDC3 treated cells but this may be due to changes in a 
number of signalling pathways, including in the EMT. 
 
5.3.2.3 Lineage specification in G4 ligand treated cells 
While it was clear that PhenDC3 cells were not differentiating as efficiently towards endoderm 
specification, and PDS to a lesser extent, gene expression changes were checked to analyse 
whether these treated cells were differentiating to a different lineage: mesoderm or 
neuroectoderm. This was not easy to analyse as there were no positive controls for the 
expression of these genes. Mesodermal gene expression changes were checked as the initial 
pathway specification is similar in both processes (Figure 93a). The level of HAND1 was higher 
in both PhenDC3 and PDS treated cells at 48 and 72 hours. This change was more pronounced 
when looking at IGFBP3 expression at 72 hours, where both PDS and PhenDC3 had very 
upregulated expression. Interestingly, both of these transcripts were significantly upregulated 
in the wildtype MMS treated cells at 72 hours in the RNAseq experiment from Results II. While 
these gene expression changes do not imitate the kinetics of differentiation to mesodermal 
lineage, this may suggest that when endoderm differentiation is perturbed the cells differentiate 
towards the mesodermal lineage.  
 
The neuroectodermal lineage genes were also checked in order to see whether the cell fate was 
being specified in this direction (Figure 93b). As before, there were no positive controls so it 
was hard to know what the level of expression would be in a neuroectodermal cell. PDS may 
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have slightly increased the expression of NES but this was not the case in PhenDC3 treated 
cells. SOX1 and FGF5 were expressed at very low levels with all treatments. This suggested 
that the ligands were not altering the lineage specification to ectoderm, probably due to 
divergence of these pathways in vitro. Expression of 14 transcripts of each lineage were 
compared with each treatment (Figure 93c) which showed that definitive endoderm genes were 
expressed to the highest level in general, as expected from the differentiation protocol. 
Definitive endoderm genes looked to be expressed lower in both treatments, but this was more 
pronounced with PhenDC3. The mesoderm analysis showed that both PDS and PhenDC3 were 
upregulating these transcripts with respect to the DMSO treatment. No difference was seen in 
the ectoderm specification pathway, likely due to the culture conditions and the general low 
expression of these transcripts. The probability associated with these changes is hard to interpret 
due to the large differences in the expression of the transcripts in FPKM, especially as a value 
below one suggests no expression and many of the ectoderm genes are lowly expressed. 
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Figure 93. Analysis of genes involved in lineage pathway specification (a) mesoderm, mean±SD are plotted, 
differential expression is calculated using CuffDiff, p<0.05 compared to the DMSO treatment, PDS (pink) and 
PhenDC3 (blue) (b) as (a) but neuroectoderm genes (c) plots to show the expression of lineage specific marker 
genes at 72 hours in the different treatments. 14 transcripts known to be expressed in each lineage had expression 
calculated in FPKM and the average is plotted. Significance was calculated using a paired t test and p values are 
shown above the comparison in the figure. 
(a) 
(b) 
(c) 
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5.3.3 Recombinant proteins give insights into key changes induced by G4 ligands 
In order to definitively show that the G4 ligands were having a G4-specific effect on gene 
expression, G-quadruplexes playing a role in differentiation would need to be removed using 
gene editing. However, during differentiation there were a huge number of genes that were 
upregulated or downregulated. There were also a vast number of genes deregulated during 
differentiation in the RNAseq data when the cells were differentiated in the presence of G4 
ligands. It would be a laborious if not impossible task to remove every potential G4 in every 
deregulated gene. While a hierarchical approach is much better to narrow down the genes that 
are altered earliest during differentiation, this still does not give a reasonable number of G4s to 
remove. Therefore, in the first instance, recombinant proteins were added to ligand treated cells 
to see if it was the lack of these proteins which was preventing differentiation. The recombinant 
proteins used were the products of genes predicted to have G4s (Figure 94). 
 
Figure 94. Mapping of potential G4s in genes shown to have altered expression on treatment with ligands. 
Predictions were performed using QGRS mapper using the motif GxNyiGxNy2GxNy3Gx and using the assumptions 
that shorter loops are more common than larger loops, G4s tend to have loops roughly equal in size and the greater 
the number of guanines the more stable the G4. Predictions with a G-score ≥ 30 are shown, the greater the number, 
the higher the likelihood to form. Exons are not to scale, the length of the gene is marked above the TSS. 
 
 
In order to check whether reconstituted proteins would be a good way forward, a media switch 
experiment was performed in a similar manner to that described by Kempf et al, in the Nature 
Communications paper (Kempf et al., 2016). They showed that the secreted proteins produced 
by cells in the first six hours were crucial in directing differentiation. This experiment was 
performed such that untreated cells were differentiated for six hours and then this media had 
DMSO, PhenDC3 or PDS added and was transferred to a new well to set up differentiation 
(Figure 95). This experiment showed that the PhenDC3 treated cells expressed a much higher 
level of SOX17 when the media had been switched, in contrast to DMSO and PDS. This 
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suggested that PhenDC3 was preventing an early expressed secreted protein from being 
expressed and its expression was able to bypass some of the problems occurring in 
differentiation with PhenDC3. This was in line with the results that showed PhenDC3 needed 
to be present in the first 24 hours of differentiation in order to induce a change to differentiation. 
However, the fact that the first six hours were important suggested that this may not be a G4-
replication dependent, epigenetic phenomenon as the timescale was too short. The paper also 
highlighted CER1 and LEFTYA as key secreted components and since both were not 
upregulated in the PhenDC3 treated cells, these recombinant proteins were used.  
 
 
CER1 gene expression did not increase in the PhenDC3 treated cells as in the DMSO treated 
cells during differentiation (Figure 90a). The cerberus protein is known to act as an inhibitor of 
the WNT pathway, acting during embryonic differentiation. Since this transcript was not 
upregulated in the PhenDC3 treated cells, the recombinant protein CER1 (R&D) was added 
during the differentiation process to see if this could compensate, at least partly, and allow cells 
treated with PhenDC3 to differentiate more efficiently. The CER1 protein was added to the cell 
culture medium (100 or 200 ng/mL) from 24 to 72 hours, with and without PhenDC3 (Figure 
96). LEFTYA (R&D) recombinant protein was also added individually and in combination with 
CER1 for the final 48 hours of differentiation (Figure 96). There was a small increase in SOX17 
protein expression with the addition of both CER1 and LEFTYA in the PhenDC3 treated cells, 
Figure 95. Media switching differentiation experiment to show the importance of secreted factors on the outcome 
of differentiation. Cells were differentiated for six hours in the presence of DMSO and then this media was added 
to undifferentiated cells to initiate differentiation in these cells, DMSO, PDS or PhenDC3 were also added when 
the media was switched, and the cells were differentiated for a further 72 hours to assess the efficiency of 
differentiation. Efficiency was analysed by the proportion of SOX17 expressing cells at 72 hours. 
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but this was not enough to rescue the 25% loss in the treated cells and the increases were only 
small. The combination of the two recombinant proteins did not increase the differentiation 
efficiency which was surprising. This did not show convincingly that reconstitution of these 
proteins rescued the experiment, however despite the fact that it was shown to be upregulated 
at 48 hours in the RNA sequencing data, the expression may have been needed from six hours 
or earlier if this is in line with the media switch experiments. This experiment needs to be 
repeated, adding CER1 and LEFTYA from the onset of differentiation to understand whether a 
lack of these proteins is contributing to the PhenDC3 treated cell phenotype. 
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5.4 Initial differentiation of hESCs in the presence of G4 ligands 
The H9 hES cells were previously verified to differentiate efficiently, Section 4.5, and they 
responded to MMS in a similar although not identical manner to the BOBSC cells. In order to 
compare the response to G4 ligands in differentiation, these experiments were repeated in the 
presence of PDS and PhenDC3. 
 
5.4.1 Differentiating H9 hESCs with PDS and PhenDC3 
H9 cells were differentiated in the presence of PDS and compared to the hiPS cells (Figure 
97a). The cells appeared to react to the ligand in a similar manner, there was increased cell 
death in the differentiating wells compared to the undifferentiated. The percentage of SOX17 
expressing cells also decreased, although not to as great an extent as the BOBSC cells. 
However, the PDS treated H9 cells not expressing SOX17 did not have an increased proportion 
of G2/M phase cells, unlike the BOBSC cell line. This suggested that the cells did not alter the 
cell cycle in the same way in the response to treatment.  
 
A dose response of endoderm differentiation in BOBSC and H9 cells to PDS and PhenDC3 was 
performed to see if the cells tolerated different concentrations of ligands (Figure 97b). By eye 
the H9 cells reacted in a similar manner as BOBSCs to the ligands: PDS treated cells had 
increased cell death and cell size whereas PhenDC3 treated cells had a higher metabolism seen 
from the colour of the medium and the number of cells. This shows that while both the cell lines 
did exhibit a dose response to PDS and PhenDC3, the H9 cells were able to tolerate much higher 
doses of both G4 ligands and therefore the response was different. The reason behind these 
differences would be interesting to study and may be related to the differences in gene 
expression in the differentiation processes in normal differentiation, shown by the increased 
upregulation of EOMES discussed in Section 4.5.1.  
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Figure 97. Analysis of G4 ligand treatment of H9 hESCs during differentiation (a) differentiation in the presence of 2 
µM PDS and analysis of the proportion of SOX17 positive cells at 72 hours (b) the percentage of SOX17 positive cells 
relative to mock-treated cells at 72 hours in H9 and BOBSC cell lines treated with 2 µM PDS or PhenDC3, one 
experiment. 
(b) 
(a) 
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Chapter 6. Results IV: Genetic knockouts 
of proteins involved in the processing of 
G-quadruplexes  
6.1 The G4-processing enzyme knockout BOBSC cell lines 
I used the knockout BOBSC cell lines of enzymes known to be involved in processing G4s 
generated by the Sanger Centre: REV1-/-, WRN-/- and PRIMPOL-/-. The knockouts were verified 
using qPCR, with primers designed downstream of the targeted exon (Figure 98). These results 
showed that the transcript levels were much lower in the knockout cells and these cell lines 
were used throughout this chapter. 
 
 
 
 
 
 
 
 
 
 
Figure 98. Verification of knockout cell lines from the Sanger Centre COMSIG project for REV1-/-, WRN-/- and 
PRIMPOL-/- qPCR data normalised to GAPDH, bar orientation reversed for clarity. Mean and standard deviation 
of one biological replicate are shown, n=3 technical replicates, multiple t testing was used and * denotes p<0.05. 
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6.1.1 The undifferentiated state 
6.1.1.1 The cell cycle of REV1-/-, WRN-/- and PRIMPOL-/- cells 
Undifferentiated cell cycle profiles in each of these cell lines were performed, using the EdU-
2D cell cycle plot, and compared to wildtype cells (Figure 99a). This approach showed that the 
REV1-/- cells had a slightly increased proportion of cells in G2/M phase of the cell cycle, 
mimicking the wildtype cells treated with PDS or DNA damaging agent (Figure 99b). 
 
 
 
 
 
 
 
 
 
Figure 99. (a) 2D-cell cycle plots of EdU verses DAPI in genetic knockout cell lines in the undifferentiated state. 
REV1-/- shows an increase in the proportion of cells in G2/M of the cell cycle. (b) Quantification of the proportion 
of cells in G2/M phase of the cell cycle in REV1-/- cells compared to the wildtype cell line. Unpaired t test, 
p=0.0256, n=3, mean±SEM are plotted.  
 
6.1.1.2 DNA damage response markers in the undifferentiated state 
γH2A.X flow cytometry was performed on undifferentiated knockout cells and compared to the 
wildtype cell line (Figure 100a). Each of these cell lines showed a similar level of γH2A.X to 
the wildtype, suggesting that there was no accumulation of damage in these cell lines when 
cultured in the undifferentiated state. 
(a) 
(b) 
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Another DDR marker was checked using western blotting in undifferentiated REV1-/-, WRN-/- 
and PRIMPOL-/- cell lines: pCHK1 and CHK1 were analysed and compared with wildtype cells 
and wildtype cells treated with 2 mM HU to induce strong CHK1 phosphorylation (Figure 
100b).  Only the positive control cells gave a pCHK1 signal on the blot, suggesting that CHK1 
is not phosphorylated in any of these three cell lines. Again, suggesting there is no base line 
damage in these cell lines. Surprisingly, the level of CHK1 in REV1-/- cells was lower than in 
the other cell lines. While it has been shown in Xenopus that REV1 is important for the 
ATR/CHK1 checkpoint (DeStephanis et al., 2015), there is no obvious reason why there would 
be a lower level of protein in this cell line. Further experiments would be required to understand 
whether this was a repeatable difference. 
 
Figure 100. Analysis of DDR markers in the knockout cell 
lines in the undifferentiated state (a) flow cytometry analysis 
of γH2A.X shows no increase in these cell lines compared 
to the wildtype (b) western blotting analysis of 
phosphorylated CHK1 protein which is only seen in the 
control of 2 mM HU treatment. Unlabelled lanes contained 
ligand treated cell lines not discussed here. 
 
 
 
 
6.1.1.3 Loss of adherence in the undifferentiated state 
The knockout cells were cultured in the undifferentiated state to see if their epigenetic status, 
and gene expression profile, were altered over time. However, it was clear that there were 
increased numbers of REV1-/- cells that had lost adherence in the dishes, in a similar fashion to 
the ligand treated mESCs (Figure 101). While this loss of adherence is a very non-specific 
phenotype, this could suggest that REV1-/- cells were not maintained in the undifferentiated state 
as well as the wildtype cell line. If his were the case, a change in epigenetic state or gene 
(a) 
(b) 
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expression may have caused cells to lose adherence to the tissue culture dish which will be 
interesting to explore further. 
 
Figure 101. A table to show two separate experiments whereby the cells which has lost adherence in each cell line 
were counted and the viability checked. The experiments were performed with different numbers of cells but in 
the REV1-/- cell line (red) there were greater numbers of total cells and total viable cells in this population, 
compared to all other cell lines.  
 
6.1.1.4 Gene expression profiles of REV1-/-, WRN-/- and PRIMPOL-/- cell lines 
These rev1 and primpol DT40 knockout cell lines are known to have altered gene expression 
profiles owing to replication impediment induced epigenetic changes: BU1 protein loss occurs 
due to a G4 at the BU-1 locus. However, BLM and WRN are thought to be redundant in the 
DT40 system with respect to processing of G4s, such that there is only a defect in these double 
knockout cell lines (Sarkies et al., 2012). It would be very interesting if a similar pattern of gene 
expression changes occurred during maintenance of the undifferentiated state in these hiPS 
cells. In order to analyse the gene expression changes in these cells, RNA sequencing was 
performed. This set of sequencing was the first set performed in the thesis and therefore some 
interesting observations were learnt for further experiments. This data is discussed in Section 
6.3. 
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Figure 102. (a) Flow cytometry analysis of the differentiation to definitive endoderm from six to 72 hours of 
wildtype, REV1-/-, WRN-/- and PRIMPOL-/- cell lines. DAPI monitored DNA content, REV1-/- cells showed an 
increase in G2/M at 30.5 h (48.0 vs 40.2%). All cell lines had an increased population in G1 phase at 72 hours. 
EOMES was upregulated by 24 hours in all cell lines, SOX17 was expressed in all cell lines at 72 hours. (b) 
Percentage of cells expressing SOX17 at 72 hours, n=4, mean±SEM are plotted. Significance measured using 
unpaired t test, all changes were not significant compared to the wildtype cell line.  
 
6.2 Definitive endoderm differentiation of knockout BOBSC cell 
lines 
6.2.1 Differentiation of knockout cell lines 
Each of the cells lines, REV1-/-, WRN-/- and PRIMPOL-/-, were differentiated alongside wildtype 
cells and the differentiation was analysed every few hours using permeabilised flow cytometry 
(Figure 102a). The flow cytometry shows that each of the knockout cell lines differentiated 
efficiently: they expressed EOMES at 24 hours and SOX17 at 72 hours to high levels equivalent 
(a) 
(b) 
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to the wildtype (Figure 102b). This was in contrast to the cells differentiated in the presence of 
G4 ligands. This suggested that if these enzymes are required during the differentiation process, 
they are likely to be redundant. However, as seen previously, the cell cycle profile seen with 
DAPI staining showed that REV1-/- cells exhibited an increased proportion of cells in G2/M 
phase, especially around 30 hours into differentiation. This raised the possibility that these cells 
cause some form of replication impediment, in a similar manner to the PDS treated cells, and 
this may play a role during prolonged cell culture. 
 
6.2.2 The γH2A.X spike in knockout cell lines 
Wildtype, REV1-/-, WRN-/- and PRIMPOL-/- cells were differentiated and collected for 
permeabilised flow cytometry (Figure 103). This figure shows that each of the mutants showed 
an increased H2A.X signal at 53.5 hours compared to the wildtype cells. This was three hours 
after the strongest upregulation in wildtype cells, suggesting that these cells may have gone 
through the EMT later than the wildtype, or were remaining at this transition for longer. 
However, since this was only monitored at 53.5 hours for this one experiment, the 
reproducibility cannot be commented on as the significance cannot be ascertained. 
 
Figure 103. Flow cytometry plots to show the phosphorylation of H2A.X at 53.5 hours in the wildtype, REV1-/-, 
WRN-/- and PRIMPOL-/- cell lines during differentiation. DAPI staining on the x-axis labels the DNA context, the 
y-axis shows H2A.X phosphorylation. At this point each of the knockout cell lines showed higher levels of this 
marker.  
 
6.3 RNA sequencing data reveals changes to gene expression profiles 
in knockout cell lines compared to the wildtype 
In order to give a detailed understanding of the global transcriptome in these knockout cell 
lines, RNA sequencing was performed in the undifferentiated and differentiated state of    REV1-
/-, WRN-/- and PRIMPOL-/-, as performed in Results II and III. 
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6.3.1 The undifferentiated state 
This experiment was the first RNA sequencing experiment performed, therefore some of the 
information learnt was used in Results II and III when designing these sequencing experiments. 
Cells in the undifferentiated state were cultured for one month and RNA was extracted from 
each of the three knockout cell lines, and the wildtype cell line, at three separate timepoints. 
The theory behind this was that each replicate for a given cell line would be collected at a 
variety of points whereby the cells had different levels of confluence, were collected on 
different days of the week and at different times of day: giving the greatest variability in the 
results. RNA libraries were produced using RNA collected in this manner and sent to be 
sequenced as explained previously. The principal component analysis plot was produced and 
the result was surprising (Figure 104). This result showed that the ‘batch effect’ with these cells 
was larger than the gene expression difference between each of the knockout cell lines. This 
was likely to be due to the difference in confluence in these adherent cells and that there were 
not large differences in gene expression profile between these cells compared to the wildtype.  
 
Figure 104. A PCA shows the variation within this dataset. Wildtype, REV1-/-, WRN-/- and PRIMPOL-/- cell lines 
were collected in the undifferentiated state on different days. These results show that the samples cluster together 
in terms of their expression in terms of the day collected, rather than with the different cell lines. This suggests 
that there was not much variation but in order to see variation the cells had to be collected on the same day. 
 
However, to remove this effect, the experiment was repeated using RNA triplicates collected 
on the same day, at the same time, in all cell lines: this was used where possible in all sequencing 
experiments. In the undifferentiated state, there were not many deregulated genes compared to 
the wildtype cells: REV1-/- had 41, WRN-/- 17 and PRIMPOL-/- 58, summarised in Figure 105 
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and Table 23. This showed that there were very few overlaps between each of these cell lines 
which was not very surprising as there were not many deregulated genes in total. 
 
 
Figure 105. A Venn diagram to show the deregulated 
transcripts in the undifferentiated state in each cell 
line: PRIMPOL-/- in red, REV1-/- in green and WRN-/- 
in blue. The overlaps between each cell line are 
shown.  
 
 
 
 
Table 23. A list of genes commonly deregulated between cell lines in the undifferentiated state. C7orf43 is an 
uncharacterised open reading frame containing c-Myc and Sp1 transcription factor binding sites in the promoter. 
ESRP2 is epithelial splicing regulatory protein 2 which regulates splicing during the EMT. 
 
The PCA of the RNA collected on the same day in all samples was performed and is shown in  
Figure 106. In this instance the triplicates clustered together well in the PCA and each genetic 
knockout cell line had an individual location on the PCA related to the gene expression state. 
This showed that the PRIMPOL-/- and TP53-/- cell lines grouped the furthest from the wildtype 
cell line, and also furthest from each other. This experiment showed that there were differences 
in the gene expression between these cell lines, but that the changes in confluence are great 
enough to override these differences. 
REV1-/- vs 
PRIMPOL-/- 
REV1-/- vs WRN-/- PRIMPOL-/- vs 
WRN-/- 
REV1-/- vs 
PRIMPOL-/- vs 
WRN-/- 
ESRP2  
C7orf43 
ENSG00000255026 
ENSG00000233056 
RNR1  
TEX41 
C7orf43 
ENSG00000248215 
ESRP2 
ESRP2  
C7orf43  
MAGI2  
CER1 
SCN8A  
PILRB  
CHCHD2 
C7orf43  
ESRP2 
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Figure 106. The PCA of undifferentiated knockout cell lines, as in Figure 104 but with RNA collected on the same 
day. TP53-/- was included for comparison as it was being performed for Results II. This showed that each cell line 
clustered together on the plot but the PRIMPOL-/- cell line had the greatest differences compared to the other cell 
lines. 
The gene ontology analysis is described below in Table 24, with all enriched hits with a p-value 
0.05 shown for each or the top ten, whichever had fewer values. The WRN-/- cell line had very 
few GO terms enriched, due to the lack of deregulated genes. The GO analysis associated with 
REV1-/- showed enrichment of nucleic acid processes, as expected from a polymerase. However, 
the GO enrichment for PRIMPOL-/- cells showed very significant p-values, many orders of 
magnitude lower than the other two cell lines. Most of these terms are associated with DNA 
and chromatin, which does appear to be promising. However, a number of histone proteins have 
deregulated expression levels in PRIMPOL-/- cells and it is known that these alter vast numbers 
of GO terms. Therefore, this is likely to be overrepresented by the histone proteins. 
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GO ID Description Count Adjusted p-
value 
REV1-/- 
GO:1902679 Negative regulation of RNA 
biosynthetic process 
9/1221 0.0274 
GO:1903507 Negative regulation of nucleic acid-
templated transcription 
9/1219 0.0274 
GO:0045892 Negative regulation of transcription, 
DNA-templated 
9/1171 0.0274 
GO:0051253 Negative regulation of RNA metabolic 
process 
9/1302 0.0339 
GO:2000113 Negative regulation of cellular 
macromolecule biosynthetic process 
9/1408 0.0421 
GO:0045934 Negative regulation of nucleobase-
containing compound metabolic process 
9/1423 0.0421 
GO:0031643 Positive regulation of myelination 2/13 0.0421 
GO:0010558 Negative regulation of macromolecule 
biosynthetic process 
9/1408 0.0455 
WRN-/- 
GO:0010225 Response to UV-C 2/14 0.0325 
GO:0002467 Germinal center formation 2/15 0.0325 
GO:0032926 Negative regulation of activin receptor 
signaling pathway 
2/10 0.0325 
PRIMPOL-/- 
GO:0000786 Nucleosome 12/108 4.56x10-14 
GO:0044815 DNA packaging complex 12/116 5.55x10-14 
GO:0032993 Protein-DNA complex 13/201 7.98x10-13 
GO:0006334 Nucleosome assembly  10/143 7.75x10-10 
GO:0031497 Chromatin assembly 10/162 2.17x10-9 
GO:0034728 Nucleosome organisation  10/174 3.69x10-9 
GO:0000785 Chromatin 14/525 4.41x10-9 
GO:0006333 Chromatic assembly or disassembly 10/187 5.67x10-9 
GO:0006323 DNA packaging  10/206 1.31x10-8 
GO:0065004 Protein-DNA complex assembly  10/246 6.75x10-8 
Table 24. An analysis of the GO terms significantly enriched in the genes deregulated between the knockout cell 
lines and the wildtype cells. GO terms with p<0.05 are shown unless there are greater than ten, in which case the 
top ten most significant hits are shown. 
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6.3.1.1 Comparisons of the knockout cell lines with wildtype cells cultured with G4 ligands in 
the undifferentiated state  
To understand whether these genetic mutants were causing similar changes compared to 
culturing wildtype cells with G4 ligands in the undifferentiated state (from Results II), the 
deregulated genes were compared in the pluripotent state (Figure 107). This showed that there 
were very few overlaps between these conditions. The overlap was the greatest between PDS 
and PhenDC3 treated wildtype cells, suggesting that these changes were specific to ligand 
addition and not necessarily G4-specific. The overlapping genes with REV1-/- were GAN, 
ENSG00000251095, TOMM40L. With WRN-/- it was MEF2C and PILRB and with PRIMPOL-
/- it was GDF15 and PILRB. This data again supports the hypothesis that the undifferentiated 
cells are very capable of dealing with the G4 ligands as well as functioning without these 
enzymes. 
 
Figure 107. Venn diagrams to show overlapping genes deregulated in the undifferentiated state with the G4-
binding ligands (Results III) compared with the knockout cell lines. REV1-/- is shown in the top left with only one 
gene deregulated in the three conditions, WRN-/- is shown on the bottom, again with only one shared gene and 
PRIMPOL-/- in the top right with no overlapping genes. 
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6.3.2 Gene expression changes during differentiation 
6.3.2.1 Definitive endoderm differentiation of knockout cell lines 
As was done in Section 6.3.1, RNA sequencing was performed in triplicate on the knockout 
cell lines REV1-/-, WRN-/-, PRIMPOL-/- and the wildtype cell line at 72 hours of definitive 
endoderm differentiation.  
 
The deregulated gene expression was compared within each condition using Venn diagrams, as 
before (Figure 108) and the overlaps are shown in Table 3. As in the undifferentiated knockout 
cell line comparison, there were very few overlapping genes deregulated between each cell line. 
However, it was clear that the REV1-/- cells had a much higher number of genes deregulated in 
the differentiated state, suggesting a perturbed differentiation. 
 
 
 
Figure 108. A Venn diagram to show the overlap of the 
deregulated genes in each of the knockout cell lines 
compared to the wildtype cell line. The names of the genes 
within each overlap are shown in Table 25. The REV1-/- cell 
line had the most perturbed gene expression but some genes 
were shared with WRN-/- and PRIMPOL-/-. 
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REV1-/- vs 
PRIMPOL-/- 
REV1-/- vs WRN-/- PRIMPOL-/- vs 
WRN-/- 
REV1-/- vs 
PRIMPOL-/- vs 
WRN-/- 
ADAMTSL5 SCN8A  
SLIT3  
CST1  
ZFP57  
PID1  
URB1-AS1 
PYROXD2 
LRRC61 
GAN 
HIST1H2BJ 
HIST1H2BK 
ATRX 
NOG 
 
LAYN 
FOXQ1  
EDN1  
CRHBP  
SOX21  
CD48  
GAN  
SCN8A  
SNAI2  
PRUNE2  
LRRC61  
CCDC80  
COL7A1  
MARF1  
CALB2  
NOG  
LEFTY2  
IL11  
PID1  
NEAT1 
ENSG00000237094 
ADAMTSL5 SLC2A6  
MAMDC2 
TOMM40L  
URB1-AS1 COL2A1  
CDKN2B  
NMI 
ADAMTSL5 SCN8A  
PIEZO1 RAB11FIP4  
PID1  
URB1-AS1 LRRC61  
GAN  
GRIK4  
PLEKHA4  
NOG 
 
ADAMTSL5 SCN8A  
PID1  
URB1-AS1 LRRC61  
GAN  
NOG 
 
Table 25. A list of the overlap of deregulated genes in each knockout cell line at 72 hours of definitive endoderm 
differentiation, compared to the wildtype cell line. The largest comparison was seen in REV1-/- and WRN-/- with 29 
genes.  
 
The PCA of this data was generated (Figure 109) and this showed that the triplicates clustered 
well in each cell line at 72 hours. This PCA shows that the REV1-/- cell line showed the greatest 
expression difference compared to the wildtype. However, PRIMPOL-/- and WRN-/- show very 
little variance compared to the wildtype and therefore were able to differentiate to definitive 
endoderm with a similar efficiency. 
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Figure 109. The PCA showing the variance of the wildtype and REV1-/-, WRN-/- and PRIMPOL-/- cell lines at 72 
hours of definitive endoderm differentiation. PC1 showed a much greater percentage of the variance, explaining 
why the REV1-/- cell line had the most different expression during differentiation. The WRN-/-, PRIMPOL-/- and 
wildtype cell lines clustered individually but with very few changes between them.  
 
6.3.2.2 Knockout cell line expression differences between undifferentiated and differentiated 
states 
In order to compare the gene expression perturbations in each of the cell lines, the differences 
between the wildtype untreated and the knockout cell lines were compared in the 
undifferentiated and differentiated state: the deregulated gene lists were then contrasted within 
each mutant (Figure 110). The REV1-/- cell line had many more deregulated genes in the 
differentiated state, as seen in the PCA plot but there was a small overlap between these two 
states. Interestingly, PRIMPOL-/- cells did not have much change in the gene expression pattern 
in either state and there was a higher percentage of overlap of deregulated genes in both states. 
This suggested that this enzyme was required to similar levels in both the undifferentiated state 
and during differentiation. The overlapping genes are shown in Table 26. The WRN-/-  cell line 
did not seem to alter gene expression significantly, possibly due to the known redundancy with 
BLM (Sarkies et al., 2012). The PRIMPOL-/- cell line had perturbed expression of a number of 
histone coding genes in both conditions, this was shared with the PhenDC3 G4 ligand treatment 
during differentiation, from Results III. 
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Figure 110. Venn diagrams to show the shared genes with deregulated expression in the undifferentiated state 
compared to 72 hours of definitive endoderm differentiation in each of the knockout cell lines. The highest 
similarity was seen in PRIMPOL-/- cells with 14 genes. A list of the genes is shown in Table 26. 
 
 
REV1-/- WRN-/- PRIMPOL-/- 
RASL10A  
ZFP57  
TOMM40L  
URB1-AS1 
ENSG00000233056 
ENSG00000229618 
LRRC61  
GAN  
FOXC1  
ATRX  
ENSG00000251095 
 
SCN8A  
WRN 
 
SCN8A  
MED7  
LOC102724334  
THG1L  
HMMR  
SLU7  
HIST1H2BK  
HIST1H2BJ  
PTTG1  
MAT2B  
HIST1H1C  
LINC02506 
ENSG00000255026 
IGLON5 
Table 26. A list of deregulated genes shared by both the undifferentiated and differentiated state in each knockout 
cell line. 
 
6.3.2.3 Comparison of gene expression profiles with PDS and PhenDC3 treated cells 
The genes deregulated at 72 hours during the differentiation process can be compared between 
the PhenDC3 and PDS treated wildtype cells, and the REV1-/- cells (Figure 111). Interestingly 
there were 117 statistically significant differentially expressed genes shared by the PhenDC3, 
PDS and REV1-/- cells, and a greater number shared with just the PhenDC3 treated cells. The 
GO analysis is shown in Table 27. As these cells should all have G4-dependent gene expression 
changes, either due to the presence of ligands or the knockout of a processing enzyme, this 
suggests that the overlap of these genes is likely to be enriched in G-quadruplexes and this is 
likely to narrow down the search. On the other hand, there was no overlap between the three 
conditions with PRIMPOL-/- cells, and only four with WRN-/-: NEAT1, IL11, CD48 and APOA1. 
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Figure 111. A Venn diagram to show the overlap 
of deregulated genes in ligand-treated wildtype 
cells compared to the REV1-/- cell line at 72 hours 
of definitive endoderm differentiation. 117 genes 
were common to all conditions. 
 
 
 
 
 
 
 
 
GO ID Description Count Adjusted         
p-value 
GO:0032502 Developmental process 64/5686 4.25x10-8 
GO:0048856 Anatomical structure development 61/5342 1.77x10-7 
GO:0048514 Blood vessel morphogenesis 17/404 4.50x10-7 
GO:0030154 Cell differentiation 48/3642 7.49x10-7 
GO:0001568 Blood vessel development 18/486 8.42x10-7 
GO:0032501 Multicellular organismal process 69/6886 8.52x10-7 
GO:0048731 System development 53/4367 9.00x10-7 
GO:0001944 Vasculature development 18/509 1.74x10-6 
GO:0048869 Cellular developmental process 48/3734 1.81x10-6 
GO:0072358 Cardiovascular system development 18/519 2.36x10-6 
Table 27. The GO enrichment of the 117 genes common to PhenDC3 and PDS treatment, with the REV1-/- cell 
line at 72 hours of differentiation, shown in Figure 111. 
 
 
6.3.3 Combining knockout cell lines with G4 ligands 
While REV1-/- cells differentiated less efficiently than wildtype cells, differentiating in the 
presence of G4 ligands had not been tested, and this was likely to further perturb replication. 
REV1-/- cells were differentiated with 2 µM PDS and analysed using flow cytometry (Figure 
112). Before analysis it was very clear that the cells were experiencing a greater level of cell 
death compared to the wildtype, and the data showed that the differentiation was incredibly 
inefficient, suggesting that this was very toxic to the cells: this may be by deregulating more 
genes containing G4s or by increasing DNA damage in the cells. This was repeated using 2 µM 
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PhenDC3, shown in Figure 113, and while there was a decrease in the efficiency of 
differentiation it was not as pronounced as with PDS. In both of these experiments, it was clear 
that REV1-/- cells were differentiating less efficiently than they had been previously, and this 
appeared to correlate with the length of time the cells had been cultured for. This is discussed 
in the following section. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 112. Flow cytometry data to show the differentiation at 72 hours in the wildtype and REV1-/- cell lines in 
the presence of 2 µM PDS. The efficiency is measured as the percentage of SOX17 positive cells at 72 hours, 
measured on the y-axis. The DNA content is measured on the x-axis. 
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Figure 113. As in Figure 112 but with 2 µM PhenDC3. 
 
6.4 Accumulation of changes over time  
The knockout cell lines were differentiated to endoderm numerous times and it became clear 
that the longer the cells had been maintained in culture, the less efficient the differentiation 
became in the REV1-/-  cell line specifically (Figure 114). The proportion of SOX17 positive 
cells decreased dramatically over the course of these experiments. Conveniently, the RNA 
sequencing was performed in cells cultured with a relatively high passage number and therefore 
the differentiation changes seen could be a build-up of epigenetic or genetic changes in the 
undifferentiated state. This was not the case in the undifferentiated state and may explain why 
fewer changes were seen. Ideally this would be repeated in cells cultured in the undifferentiated 
state for a longer period of time. This was incredibly interesting, and further work to analyse 
undifferentiated REV1-/- RNA over a number of passages would be very informative. It was 
also clear that the undifferentiated REV1-/- cells became sicker with each passage, and this may 
have contributed to the number of cells which had lost adherence, possibly perturbing the 
undifferentiated results discussed earlier. This is explained in further detail in the discussion. 
 
 
 
 
209 
 
Figure 114. A graph to show the percentage of SOX17 
positive REV1-/- cells compared to wildtype cells at 72 
hours of definitive endoderm differentiation at four 
different points.  
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Chapter 7. Discussion 
7.1 Initiation of the project 
7.1.1 Previous work in the group 
Previous work from the Sale group has focussed on the processing of secondary structures in 
DNA, exemplified by G-quadruplexes, and how the presence of such structures can alter DNA 
replication. The changes in DNA replication cause a local uncoupling of the replicative DNA 
helicase and polymerase which leads to long stretches of single stranded DNA, and the loss of 
marked nucleosomes associated with this region. This is able to cause a change in the epigenetic 
marks associated with this section of DNA and therefore cause gene expression changes 
(Sarkies et al., 2010, 2012). This phenomenon has been most intensively studied in the BU-1 
locus of DT40 cells specifically using G4-binding ligands, genetic knockouts of enzymes 
involved in processing these structures, and nucleotide pool depletion (Guilbaud et al., 2017; 
Papadopoulou et al., 2015; Sarkies et al., 2012; Schiavone et al., 2014, 2016). However, there 
is no reason to limit the effect to G4 structures and a similar mechanism is proposed for R-loop 
structures in PRIMPOL deficient cells (Šviković et al., 2019). This model should hold for 
anything that uncouples the helicase and polymerase, causing a gap in processive replication, 
and is likely to include lesions in the DNA caused by damage. 
 
All of the work used to generate the model was performed in DT40, a terminally differentiated 
chicken cell line, which may lack the ability to re-establish epigenetic states. Therefore, the 
initial aim of this thesis was to focus on similar mechanisms in a more biologically relevant 
system: differentiation. Since differentiating cells program their epigenome, it may be that they 
are robust to these perturbations. I used differentiation to understand whether impediments to 
DNA replication could alter the efficiency of differentiation with the larger aim of addressing 
whether development could be altered in vivo. The initial hypothesis was that efficiency of 
differentiation to definitive endoderm would be decreased on treatment with DNA damage or 
G4-binding ligands. 
 
7.1.2 Human induced pluripotent stem cells 
The BOBSC hiPS cell line was chosen due to the availability of the genetic knockout cell lines 
created in the Sanger Centre COMSIG project. The human iPSCs allowed the opportunity to 
study how ligands, DNA damaging agents and genetic knockout cell lines could alter the 
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undifferentiated state and the differentiation alone. The differentiation to definitive endoderm 
was chosen, with advice from the Vallier group. The protocol was very efficient, occurred over 
around five cell cycles and there was a good permeabilised flow cytometry read-out to monitor 
the efficiency on a single-cell basis, and a defined end point: the expression of SOX17. The 
gene expression changes in this protocol have been previously studied using microarrays (Teo 
et al., 2011). The differentiation to definitive endoderm was very reliable and was used 
throughout the thesis. 
 
From using the G4 ligand PDC12 in this system, it was clear that DMSO alone was playing a 
role in decreasing the efficiency of differentiation without visibly altering the cell morphology. 
This had been previously noted during differentiation, and specifically during endoderm 
differentiation. One study showed that the differentiation to definitive endoderm could be 
improved by adding 0.5-0.6% DMSO in the early stages (Czysz et al., 2015), which is 50-fold 
higher than used for PhenDC3, PDS and NMM throughout this thesis. A different group showed 
that adding 2% DMSO in differentiation increased the differentiation to all lineages by 
activating Rb and increasing the proportion of cells in G1 phase  (Chetty et al., 2013). Another 
study trialled a range of concentrations of DMSO during definitive endoderm differentiation 
and showed that medium and high doses of DMSO, the equivalent of 10 µM and 100 µM of 
the drugs used in this thesis, downregulated the level of SOX17 and high doses inhibited 
GATA6 expression altogether (Pal et al., 2012). Interestingly for this thesis, DMSO is used in 
PCR reactions to remove DNA secondary structures due to its high polarity and high dielectric 
constant. Therefore, it may be that DMSO is able to remove DNA secondary structures in the 
BOBSC cells, and this may be how it is acting in impacting differentiation. This could imply 
that DNA secondary structures are required during differentiation, but there is no further 
evidence to this conclusion. 
 
The initial hypothesis was that differentiation in the presence of replication impediments would 
decrease the efficiency, monitored by the percentage of cells expressing SOX17 at 72 hours, by 
altering the expression of lineage specifying genes. 
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7.2 The response to DNA damage during definitive endoderm 
differentiation 
7.2.1 Differences in the response to damage in the undifferentiated state compared to 
during differentiation 
One of the first observations was that the undifferentiated and differentiating cells were able to 
tolerate differing quantities of DNA damaging agents. This was shown by increased cell death, 
a block in the cell cycle at G2/M and much greater gene expression changes as monitored using 
RNA sequencing, after treatment with DNA damaging agents during differentiation compared 
to the undifferentiated state. This could be due to differences in the amount of damage 
experienced, different responses to the same amount of damage, or a difference in the kinetics 
of repair. The cells could be experiencing different levels of DNA damage with the same 
concentration of damaging agent due to differences in the chromatin structure (Falk et al., 2008) 
which occur during differentiation. In order to understand whether the two cell states experience 
different numbers of breaks after DNA damage, an alkaline comet assay should be performed, 
and the olive tail moment compared in the undifferentiated state and during differentiation: this 
experiment is being performed as further work. Analysis of the different levels of damage could 
also be performed through monitoring CPDs and 6-4PPs induced by UV damage using 
ChIPseq.  
 
There could also be a difference in response to the damage in each state which may be governed 
by the cell cycle, the expression of repair factors, and differences in the DNA damage response 
which are discussed throughout this thesis. Some of the differences seen between the 
undifferentiated and differentiating states are likely to be due to changes in the cell cycle during 
differentiation. ES cells were thought to have no G1 restriction point to allow the cell cycle to 
complete quickly, and to control the pluripotent state (Pauklin et al., 2011). Due to the lack of 
this restriction point, cells were thought to only respond to damage at the G2/M checkpoint 
(Neganova et al., 2011). The length of the cell cycle increases during differentiation and the 
cells gain this checkpoint, possibly causing the different responses to damage. However, since 
mESCs cultured in LIF and 2i have been shown to have an active G1 checkpoint (ter Huurne et 
al., 2017), this may not be the cause of the differences in response to damage between the states. 
 
In this thesis, undifferentiated cells were shown to express high levels of DNA damage response 
proteins including p53, CHK1 and CHK2, and the levels decreased on differentiation to 
definitive endoderm. These proteins were not phosphorylated, suggesting they were not 
activated by the DNA damage response but were maintained at high levels. It may be that these 
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high levels allow the cells to remain poised for dealing with damage, suggesting why these 
pluripotent cells are better able to process damage. 
 
Using the RNA sequencing data, it was seen that the level of transcripts of proteins implicated 
in DNA repair also changed during differentiation, these included RPA2, PARP1 and 53BP1. 
Interestingly, 53BP1 increases during differentiation which suggests that pathway choice 
occurs at this point between HR and NHEJ. This suggests an increased use of NHEJ during 
differentiation and may contribute to the differences in the cell response to damage. 
 
7.2.2 Phosphorylation of H2A.X during unperturbed differentiation 
In this thesis a major spike of phosphorylation of H2A.X at serine-139 was seen between 40 
and 56 hours in unperturbed endoderm differentiation. This is likely to be at the point of the 
EMT during the differentiation to definitive endoderm. The EMT has been comprehensively 
studied, especially in the context of cancer. Previous work has described ATM phosphorylation 
of H2A.X which is required to induce HMGA2 transcription (Singh et al., 2015). This 
phosphorylation acts to impair H1 from binding, thus destabilising the nucleosome (Li et al., 
2010). The phosphorylation of H2A.X at the EMT is associated with mass transcriptional 
activation caused by transcription factor binding (Singh et al., 2015). Some data has suggested 
that the binding of transcription factors is able to induce a sufficient replication fork blockage 
to induce DNA damage (Xia et al., 2019), however the spike seen in my data is shown mainly 
in G1 and G2, not S phase. In this thesis it is likely that the phosphorylation seen is associated 
with the EMT and large transcriptional changes associated with this transition. However, the 
ATM-/- cell line still showed phosphorylation at this time suggesting that if ATM does 
phosphorylate H2A.X then it is by a redundant mechanism, possibly compensated for by ATR, 
DNA-PK or another protein kinase. This mechanism is likely to be separate from the canonical 
DNA damage response. Ideally, I would follow individual cells to see if all cells which 
phosphorylated H2A.X committed to differentiate, but this would require live cell imaging of 
a phosphor-protein variant which is not currently possible. 
 
Experiments performed in this thesis using inhibitors to attempt to address the question of which 
kinase was phosphorylating H2A.X were inconclusive. Most of the inhibitors induced damage 
and prevented efficient specification to definitive endoderm. While this could suggest that 
phosphorylation is required for differentiation, the knockout mouse model is inconsistent with 
this hypothesis; mice with a genetic knockout of H2AFX are viable but show increased genetic 
instability (Celeste et al., 2002). Further work would include treatment with caffeine, a non-
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specific inhibitor of ATM and ATR, to see whether this prevented the phosphorylation. 
Conditional knockout of ATR and PRKDC in combination with ATM could help to address this 
question but since a single knockout ATR cell line is not viable, this is unlikely to be a practical 
solution. It would also be interesting to follow the dephosphorylation of H2A.X after damage 
as this has been proposed to occur on the nucleosome and not occur as a result of histone 
turnover (Chowdhury et al., 2005; Nazarov et al., 2003; Siino et al., 2002). 
 
It will be important to understand the role of the phosphorylation of H2A.X at the EMT and 
whether it is related with the DNA damage response in any way. Analysis of the ChIP data 
should allow a greater understanding of the regions of DNA these marks are associated with, 
specifically promoters of EMT expressed genes. In order to rule out that this mark is associated 
with DNA damage it is also important to analyse more DDR markers at this point in 
differentiation. Using immunofluorescence would allow analysis of co-localisation of these 
markers, such as 53BP1 and γH2A.X. It is also important to verify this antibody, further work 
analysing the levels of total H2A.X will be required to rule out the possibility that it is the total 
protein changing. 
 
7.2.3 The result of inflicting DNA damage during differentiation 
DNA damaging agents were added during differentiation to induce damage and analyse the 
course of differentiation after treatment. MMS, HU and UV treatment prevented efficient 
differentiation, as measured by SOX17 expression, in a dose dependent manner. All treatment 
induced an increase in cells in G2/M phase of the cell cycle, indicative of DNA damage, likely 
to be due to checkpoint activation. A cell cycle block and increased cell death occurred to a 
much higher level during differentiation than in the undifferentiated state with the same 
treatment. 
 
Treating with MMS did decrease the number of cell cycles gone through during differentiation 
slightly, probably due to the G2/M block slowing the cell cycle. However, this difference was 
not enough to cause the decrease in SOX17 expression because SOX17 protein could be seen 
from around three cell cycles and tended to be present to an extent in wildtype cells from around 
40 hours. This suggested that there was not a trivial reason for this difference in expression and 
this was highlighted by showing that increasing the time of differentiation did not increase the 
proportion of SOX17 expressing cells.  
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An effect was seen when damage was induced at any point during differentiation, but the 
greatest decrease in SOX17 was at around 24 hours. The lower response after 48 hours may be 
due to the cells already becoming specified to endoderm and having turned on SOX17 
expression. 
 
This window of time after specification of differentiation but before expression of SOX17 may 
suggest that more damage was experienced by the cells at around 24 hours, possibly also due 
to changes in chromatin structure during differentiation. This time may correlate with the point 
in which the levels of DDR proteins decrease during differentiation. The resulting upregulation 
of DDR proteins after treatment with DNA damaging agents may prevent further differentiation 
in these cells. This window of time may also correlate with cell fate choice and lineage 
commitment pathway decisions. The outcome could be affected by the position of the cells in 
the cell cycle when damage was induced, as the cell cycle distribution was altered throughout 
differentiation.  
 
Cell synchronisation would allow DNA damaging agents to be added at set points in the cell 
cycle and it would be interesting to see whether the phase that a cell was in would alter the 
differentiation efficiency. 
 
7.2.4 The role of p53 in controlling differentiation 
Previous work has shown that p53 is redundantly required for induction of mesendoderm 
differentiation (Wang et al., 2017), explaining why it is kept at a high level at the onset of 
endoderm differentiation. p53 has also been shown to play a role in the EMT by initiating the 
transition (Chang et al., 2011). In the epithelial state p53 protein levels are high and this is 
required for controlling expression of EMT specific genes: overexpression of p53 in the 
mesenchymal state reverts the phenotype to epithelial. Therefore, p53 is needed to initiate the 
EMT program and is then downregulated by MDM2 to allow completion of this transition 
(Araki et al., 2010). This potentially explains the observations in this thesis that p53 is 
downregulated during differentiation, specifically at the time that H2A.X is phosphorylated, 
further highlighting that this is associated with the EMT. 
 
Differentiation in the TP53-/- cell line occurred in a similarly efficient manner to the wildtype 
cells. This was expected because genetic knockout of Trp53 in mice results in normal 
differentiation most likely because the other family members are able to compensate 
(Donehower et al., 1992). The TP53-/- cell line was used to understand the role played by p53 
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in the presence of DNA damaging agents during differentiation. This cell line showed less cell 
death during unperturbed differentiation than the wildtype cell line, possibly suggesting less 
surveillance of damage in these cells. This could lead to increased problems in embryogenesis 
but as this in vitro system is very different from the in vivo situation this may not have any 
relevance. When DNA damage was induced during differentiation, the TP53-/- cell line 
differentiated efficiently, similarly to untreated cells but unlike wildtype cells. Therefore, it is 
likely that TP53-/- treated cells accumulate damage that may manifest later in the developed 
organism.  
 
However, there was still a large G2/M block in the cell cycle in treated TP53-/- cells. This was 
interesting because it was clearly not the accumulation of cells in G2/M phase that was 
preventing differentiation. The cell cycle phase has been shown to alter the propensity to 
differentiate (Gonzales et al., 2015; Pauklin and Vallier, 2013; Pauklin et al., 2016) but these 
studies were looking at the initiation of differentiation and the escape from pluripotency. 
Therefore, this may not be the case when the DNA damage is induced after commitment has 
occurred. The cell cycle block is likely to be caused by ATM phosphorylating p53, H2A.X and 
CHK2 and inhibiting cdc25, thus preventing activation of CDK1 and movement through the 
cell cycle. This can also occur through the ATR CHK1 pathway. 
 
7.2.5 RNA sequencing analysis of treatment with DNA damaging agents in the 
undifferentiated state and during differentiation 
The RNA sequencing was designed such that each of the triplicates were collected on the same 
day. The caveats of this design are that any confounding variables are not accounted for. 
However, since the efficiency of differentiation was checked by flow cytometry prior to 
performing library preparation, this effect should be minimised. The data was analysed using 
the Cufflinks RNAseq pipeline for comparison to other work performed in the group but prior 
to publishing it will be interesting to also analyse this data using the DESeq2 pipeline. In order 
to rule out any variables the triplicates should ideally be collected on different days to factor in 
different batches of media, different times of the incubator being open and difference in seeding 
density. There are a number of biases to be aware of when analysing sequencing data because 
they can lead to very significant p-values in data enrichment analyses without any biological 
significance. Technical biases can arise due to base bias derived from different polymerases 
used in the PCR reaction. This bias occurs as some polymerases preferentially catalyse 
elongation over A/T-rich or G/C-rich regions, this is important when using the G4 ligands in 
the next section. A high GC bias can manifest itself as the GO term ‘DNA-Templated 
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Transcription’ p=2x10-20 in terms of the significant genes, whereas a low GC bias can lead to 
‘GPCR Signalling’ p=4x10-12 (unpublished, Babraham Bioinformatics Department, 
Cambridge). There are also statistical biases including the length of a gene; it is harder to see 
changes in shorter genes. This can again, lead to a highly significant GO analysis: ‘synapse’ 
p=2x10-30 (Ibid). There are also some gene sets that have common hits for non-specific reasons: 
ribosomal, cytoskeleton, extracellular, secreted, translation. These biases are important to 
consider when analysing data of this nature. 
 
Treatment with MMS in the undifferentiated state induced more changes in wildtype cells 
compared to TP53-/-, as expected, but there were very few changes in either. This was in stark 
contrast to treatment during differentiation. Comparing the wildtype and TP53-/- cells treated 
with damage, it was clear that the deregulated pathways were involved in apoptosis, DNA 
damage, and checkpoint activation, as expected, further suggesting that without p53 the cells 
cannot respond to damage in the same manner. 
 
During differentiation, it was clear that adding MMS to wildtype cells altered differentiation as 
the most significant GO term enrichment was pathways involved in morphogenesis and 
development. However, this was not the case in TP53-/- cells, again suggesting that inducing 
damage did not cause changes to differentiation in these cells. This was further seen by the 
number of deregulated TP53-/- transcripts decreasing from 48 to 72 hours, after the damage. In 
the wildtype cells the magnitude of deregulated genes was much greater and increased during 
differentiation, suggesting that the cells were differentiating down a different pathway. This 
enhanced the view of the flow cytometry experiments, but further analysis of this sequencing 
data will allow a much more detailed understanding of this process. Further analysis of the 
expression of genes expressed in each lineage will allow an understanding of whether treatment 
simply prevents differentiation or directs differentiation towards a different lineage such as 
mesoderm. 
 
7.2.6 Further work to understand the mechanism of the DDR in differentiation 
A lot of information has been gained from the BOBSC knockout Sanger Centre COMSIG cells, 
including the REV1-/- and TP53-/- cells. Using CHEK2-/- and H2AFX-/- would be informative as 
to the method of differentiation inhibition, the EMT and cell cycle inhibition. The MDM2-/- 
cells would also allow understanding of whether preventing downregulation of p53 is able to 
inhibit differentiation. 
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Although the BOBSC cell line has been helpful in this project, it contains a translocation which 
may alter the generality of these findings. Therefore, it will be important to confirm these 
findings in the untranslocated BOBSC cell line, and other iPSCs. Repeating the work in the H9 
and other hESC lines will be very helpful. However, there are likely to be some changes due to 
the differences in these cell lines and their different genetic backgrounds. 
 
7.3 The ability of the G4 secondary structure to alter differentiation 
7.3.1 G4-binding ligands alter the fate of differentiation 
Both PDS and PhenDC3 treatment were decreasing the expression of SOX17 significantly at 
48 and 72 hours but not the initial expression of EOMES at 24 hours. The changes to SOX17 
showed that definitive endoderm differentiation was perturbed. As with DNA damage, the 
ligands needed to be present during differentiation and not added after, in which case no 
decrease in SOX17 expression was observed. This further suggests that endoderm specification 
must be perturbed before commitment, but after 72 hours this can no longer be altered. 
However, the action of PDS could be prevented by using the genetic knockout TP53-/- cell line 
and therefore the effect of DNA damage outweighed any G4-specific replication changes. The 
reason behind PhenDC3 not triggering DNA damage or a DDR in the cell is not yet known but 
is likely to be due to the method of binding to the G4 and the kinetics of release. 
 
Altering the point of PhenDC3 treatment suggested that addition for the first 24 hours caused 
the greatest effect on the expression of SOX17. This implied that PhenDC3 was likely to be 
causing gene expression changes early on which then propagate to greater changes at the end 
of differentiation. Preliminary media switching experiments in PhenDC3 treated cells showed 
that secreted factors produced in the mock-treated medium in the first six hours could at least 
partially compensate for the addition of PhenDC3.  
 
If this outcome was due to a G4 being stabilised by PhenDC3 and inducing a replication 
impediment, then this should occur stochastically with each cell cycle. Therefore, it is assumed 
that the longer the cells are cultured in the presence of ligand, the greater the change. If the 
ligand were interfering with a transcription factor binding site then this would cause dose-
dependent changes to the equilibrium. However, during development there are key windows 
where small changes in gene expression will affect the outcome overall. This data does not 
show whether this is a replication dependent epigenetic change or whether the ligand interferes 
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with transcription factor binding patterns, or other methods of regulation, but it is likely to 
happen early in differentiation. 
 
Checking lineage specific markers of mesoderm, it was clear that both PDS, especially at early 
timepoints, and PhenDC3 treated cells were expressing markers of mesoderm differentiation. 
This suggested that the drugs were not preventing initial differentiation to mesendodermal fate, 
but the cells were not committing to an endodermal fate. Surprisingly, this increase in 
mesoderm specification genes was shared with MMS treated wildtype cells. This fate choice 
suggests that when differentiation is perturbed the cells choose mesodermal fate in preference 
to endodermal, in this system. 
 
Due to the fact that both G4 ligands were not inducing identical changes, it is hard to suggest a 
mechanism to cause these changes specific to this secondary structure. The PDS was inducing 
DNA damage and acted in part similarly to MMS. However, PhenDC3 was not inducing DNA 
damage and the expression profile was different to the PDS treatment. 
 
7.3.2 REV1 knockout cells show altered definitive endoderm differentiation 
REV1-/- cells showed very different gene expression compared to wildtype cells using RNAseq. 
This was interesting because in the initial experiments the differentiation efficiency had been 
as high as in the wildtype cells. However, observations showed that there were increased 
numbers of cells losing adherence, and less rounded colonies in the REV1-/- cells in the 
undifferentiated state and this was exacerbated the longer the cells were kept in culture. The 
decrease in the ability to differentiate also seemed to occur with an increase in passage number. 
This could be of significance because it may be consistent with long term culture leading to 
epigenetic alterations and changes in the transcriptome over time, similar to the observations 
made in REV1-/- DT40 cells. 
 
7.3.3 Similarities between the REV1 knockout cell line and G4 ligand treatment during 
definitive endoderm differentiation 
There was a high level of overlap in the genes deregulated on ligand treatment and the REV1-/- 
cell line at 72 hours of endoderm differentiation. The enrichment analysis for this list showed 
GO terms associated with differentiation and developmental processes with significant p-
values. Further work suggested that combining the REV1-/- cell line with the G4 ligands further 
decreased the efficiency of differentiation, suggesting that this could exacerbate the phenotype 
further. The mechanism may be that the drugs are increasing the number of G4s further than 
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biologically relevant, and REV1-/- cells struggle further to process them. This suggests that G4s 
may be able to alter differentiation specifically, and further analysis of the enrichment of 
predicted G4 structures is being performed. 
 
7.3.4 Further sequencing data analysis 
While a general analysis of all of the sequencing data in more detail will provide greater insight 
into the pathway perturbations and the differences between the ligands and the DNA damaging 
agents, there will also be more specific analysis required to understand whether these PhenDC3 
and REV1-/- induced changes are G4-specific. A greater metanalysis of G4 or G-rich regions 
and their proximity to introns, TSSs, transcription factor binding sites and other features would 
be informative to show if there is an association, as previously performed by other groups (Eddy 
et al., 2011; Tang et al., 2016). It would also be interesting to attempt to find a general consensus 
for the different types of G4 bound by each drug, if either had a preference for binding to a 
given structure. 
 
The initial idea proposed was to try to narrow down a subset of genes that PhenDC3 acts on, 
but having analysed the data, this looks to be an unrealistic goal. However, more recombinant 
protein experiments, such as GSC addition, may help to find some factors. Further RNAseq on 
very early timepoints on PhenDC3 treatment may help to elucidate the earlier expression 
changes that may alter further pathways. Single-cell RNAseq may also allow an understanding 
of whether these processes are stochastic, and therefore whether they are likely to act in a similar 
manner to BU1 loss in DT40. The final aim still remains to narrow down a list of G4s that may 
be mechanistically responsible for these changes. 
 
The thesis is missing any knowledge of the underlying chromatin, and changes to this with the 
treatments and during differentiation. Therefore, it would be interesting to perform ATACseq 
and ChIPseq using the ligands, knockouts and damaged cells to understand how treatment are 
able to alter the epigenetic state at loci associated with changes during this differentiation. 
 
7.4 Conclusions 
I set out to address the question ‘is differentiation robust to replication impediments’ but this 
work has uncovered two separate issues: the effect of the DDR on differentiation and the 
possible direct effect of G4s on differentiation. 
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In conclusion, this thesis has shown that there are vast changes between cells cultured in the 
pluripotent state and those undergoing differentiation. This occurs at the level of the 
transcriptome, cell cycle and response to DNA damage. While much work has been done on 
comparing undifferentiated cells and differentiated cells, far less has been performed on the 
comparison to differentiating cells, in these early lineages. 
 
I propose that G4 ligands are able to alter the course of definitive endoderm differentiation via 
two separate means. PDS prevents endoderm specification through the DDR whereas PhenDC3 
induces gene expression changes, altering a vast array of pathways, and this stops movement 
through the EMT without a significant activation of the DDR. Further work will allow a more 
in-depth analysis of the possible G4s responsible for these changes.  Interestingly, change in 
the expression of SOX17 during differentiation is stochastic in PhenDC3 treated cells, 
potentially supporting a replication-dependent phenomenon.  
 
I suggest that during differentiation, levels of DDR proteins decrease, controlled either at the 
level of the RNA or protein depending on the factor. This alters the response to DNA damaging 
agents, as well as G4 ligands, and can induce increased levels of cell death. During 
differentiation, H2A.X is phosphorylated at the EMT, most likely by ATM but this may be 
redundant, and all other proteins phosphorylated by ATM have low expression at this time so 
that they are not phosphorylated by ATM and do not induce the canonical DDR. However, 
when damage is induced, these proteins are upregulated and become phosphorylated by ATM, 
inducing the DDR and preventing differentiation, I have termed this a ‘differentiation 
checkpoint’ (Figure 115). When p53 is not present this checkpoint does not occur and 
differentiation continues in the face of damage, possibly leading to increased damage in the 
cell. This checkpoint may be a direct transcriptional effect of p53 turning on mesoderm 
specifying genes or acting via the canonical DDR but this remains to be elucidated. 
 
Despite vast amounts of work studying the way a cell responds to damage in differentiated cells, 
the response during differentiation has barely been touched on. Changes in the DNA damage 
response during differentiation are very important to understand the reaction to endogenous and 
exogenous damage during differentiation. This fundamental understanding is interesting and 
has rarely been studied. 
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Figure 115. A model to suggest how DNA damage induces a ‘differentiation checkpoint’. The expression of DDR 
factors decreases during differentiation and H2A.X is phosphorylated at 48 hours by ATM. However, when 
damage is induced, p53 and possibly other DDR proteins are upregulated and ATM is also able to phosphorylate 
these proteins. The phosphorylation of p53 causes this differentiation checkpoint to become active and prevent 
endoderm specification. 
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